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Zusammenfassung 
 
Glycogensynthasekinase-3 (GSK-3), eine Serin/Threonin-Kinase mit Docking-
Eigenschaften, reguliert zahlreiche zelluläre Prozesse. Zwei Isoformen, GSK-3α und 
GSK-3β, wurden beschrieben. GSK-3β stellt die Hauptform in vivo dar, sie spielt eine 
Schlüsselrolle bei der Regulation von Transkriptionsfaktoren inklusive der Steroidrezeptoren. 
Ziel der vorliegenden Arbeit war, die Rolle der GSK-3 bezüglich der Funktion von 
Estrogenrezeptor-α (ERα) in Brustkrebszellen zu entschlüsseln. Als experimentelles Modell 
wurden hauptsächlich MCF-7 Zellen, eine ERα-positive menschliche Brustkrebszelllinie, 
verwendet. 
Silencing von GSK-3α und/oder GSK-3β durch Transfektion spezifischer siRNA-
Sequenzen führte zur Degradation von ERα durch das Proteasom. Durch Verwendung des 
Proteasomeninhibitors MG132 konnten die ERα - Proteinspiegel in GSK-3 siRNA-
 transfizierten Zellen wiederhergestellt werden. Dies zeigt, dass GSK-3 den ERα stabilisiert 
und vor proteasomaler Degradation schützt. In einem weiteren experimentellen Ansatz wurde 
endogene GSK-3β durch Transfektion der Zellen mit microRNA - Konstrukten spezifisch 
ausgeschaltet; auch hier wurde das Silencing der GSK-3β von einer Reduktion des ERα-
Proteinspiegels begleitet. In diesen Zellen konnten die ERα - Proteinspiegel durch 
Überexpression von Wildtyp- oder Kinase - inaktiver Xenopus-GSK-3β wiederhergestellt 
werden. Daraus ist zu schließen, dass die Docking-Eigenschaften der GSK-3 und nicht deren 
Kinaseaktivität für die ERα - Stabilisierung wichtig sind.  
Behandlung von Zellen mit 17β-Estradiol führte zu rascher Phosphorylierung und 
Inaktivierung zytoplasmatischer GSK-3. Diese Phosphorylierung an GSK-3 führte zur 
Freisetzung von ERα aus dem GSK-3/ERα - Komplex und seine Translokation in den 
Zellkern. Dort wurde ERα durch aktive kernständige GSK-3β an Ser-118 phosphoryliert; 
diese Phosphorylierung ist essentiell für die volle Aktivierung von ERα. Behandlung der 
Zellen mit dem GSK-3 Inhibitor LiCl führte zur Hemmung der E2-induzierten 
Phosphorylierung an Ser-118, denselben Effekt zeigte die Reduktion des GSK-3 Spiegels im 
Zellkern nach GSK-3 Silencing. Diese Ergebnisse belegen, dass ein nukleärer Pool aktiver 
GSK-3, welcher durch Behandlung der Zellen mit E2 nicht phosphoryliert und inaktiviert 
wird, für die E2-induzierte Ser-118 Phosphorylierung von ERα nötig ist. Als Konsequenz der 
verminderten Ser-118 Phosphorylierung in GSK-3 siRNA - transfizierten Zellen wurde eine 
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signifikante Reduktion der transkriptionalen Aktivität des ERα beobachtet. Diese 
Aktivitätsminderung wurde sowohl durch ERE-abhängige Luziferase Reporter-Assays als 
auch durch Messen der Transkription der ERα - abhängigen endogenen Gene pS2 und 
Progesteronrezeptor durch quantitative Real-Time PCR nach E2-Behandlung in GSK-3 
siRNA - transfizierten Zellen nachgewiesen. Weder die Ser-118 Phosphorylierung an ERα 
noch die ERα-Aktivität konnte durch Inkubation von GSK-3 siRNA - transfizierten Zellen 
mit MG132 wiederhergestellt werden, was die Bedeutung der nukleären GSK-3 für diese 
Prozesse unterstreicht. Weiterhin konnte durch Überexpression humaner GSK-3β in stabil mit 
einem ERE-kontrollierten Luziferase Reportergen transfizierten MCF-7 Zellen die Funktion 
der GSK-3 bei der E2-induzierten Aktivierung von ERα bestätigt werden. Durch Expression 
von GSK-3β - Mutanten, welche gegenüber geprimten GSK-3 - Substraten inaktiv sind, 
wurde gezeigt, dass ERα ein nicht-geprimtes Substrat für GSK-3 darstellt.  
Der in dieser Arbeit neu beschriebene GSK-3 / ERα – Signalweg zeigt, dass GSK-3 
einen dualen Effekt auf die Funktion des ERα ausübt. In nicht-stimulierten Zellen wird ERα 
im Zytoplasma durch GSK-3 stabilisiert. Nach Stimulation mit E2 transloziert ERα in den 
Zellkern, wo er durch eine kernständige aktive GSK-3 phosphoryliert und aktiviert wird. Die 
Befunde erlauben die Schlussfolgerung, dass GSK-3 ein Bindeglied zwischen den schnellen 
nicht-genomischen, im Zytoplasma ablaufenden Prozessen und den im Zellkern ablaufenden 
genomischen Reaktionen des Liganden-aktivierten ERα darstellt.   
Der ERα-Signalweg spielt eine kritische Rolle bei der Initiation und Progression von 
Brustkrebs. Deshalb stellt sich die Frage nach der Regulation von Funktion und Aktivität des 
ERα durch GSK-3 bei diesen Prozessen. Erste vorläufige Ergebnisse aus immunhisto-
chemischen GSK-3β – Färbungen an Formalin-fixierten Gewebeschnitten menschlicher 
Mammakarzinome sprechen für eine vermehrte GSK-3β Expression in niedrig differenzierten 
(Grad 3) Tumoren im Vergleich zu gut bzw. mäßig differenzierten (Grad 1/2) Tumoren.   
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I - Summary 
 
Glycogen synthase kinase-3 (GSK-3), a serine/threonine kinase with docking 
properties, regulates numerous cellular processes. Two isoforms, GSK-3α and GSK-3β have 
been described. In vivo, GSK-3β is the major isoform and plays a key role in the regulation of 
transcription factors including steroid receptors. The aim of the present work, mainly 
performed on the estrogen receptor-α (ERα)-positive MCF-7 human breast cancer cell line, 
was to unravel the role of GSK-3 regarding ERα function. 
After silencing of GSK-3α and/or GSK-3β isoforms using specific siRNA sequences, 
increased proteasomal degradation of ERα was observed. The use of the proteasome inhibitor 
MG132 restored ERα protein levels in GSK-3 silenced cells, showing that GSK-3 stabilizes 
ERα and protects it from proteasomal degradation. In another approach, specific silencing of 
the endogenous GSK-3β of MCF-7 cells using microRNA constructs was accompanied by 
down-regulation of ERα protein content. In these cells, ERα protein was rescued after 
overexpression of wild-type or kinase-inactive xenopus GSK-3β, which suggests that the 
docking properties of GSK-3 and not the kinase activity are important for ERα stabilization. 
Then, we found that 17β-estradiol (E2) -treatment resulted in rapid phosphorylation and 
consequent inactivation of cytoplasmic GSK-3. This GSK-3 phosphorylation may lead to 
ERα release from the GSK-3/ERα complex and ERα translocation into the nucleus, where it 
is phosphorylated at Ser-118 leading to its full activation. Upon E2 stimulation, treatment of 
the cells with the GSK-3 inhibitor LiCl resulted in a decrease of ERα phosphorylation at 
Ser-118. This decrease was confirmed upon silencing of GSK-3 in the nucleus and show that 
a nuclear active pool of GSK-3 is required for E2-induced phosphorylation of ERα at 
Ser-118. As a consequence, in GSK-3 silenced cells, E2-induced ERα transcriptional activity, 
studied by ERE-dependent luciferase reporter assays and by measuring transcription of the 
ERα-dependent target genes, pS2 and progesterone receptor, by quantitative real-time PCR, 
was significantly reduced. In GSK-3 silenced cells, neither Ser-118 phosphorylation nor 
luciferase activity was restored by use of MG132. Furthermore, overexpression of human 
GSK-3β wild-type and mutants inactive towards primed substrate of the kinase in MCF-7 
cells stably transfected with an ERE-controlled luciferase reporter confirmed that GSK-3 
triggers E2-induced ERα activation and suggests that ERα is a non-primed substrate of 
GSK-3 kinase. Taken together, this newly signalling pathway depicted a dual function of 
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GSK-3 regarding ERα, GSK-3 stabilises ERα in the cytoplasm of unstimulated cells and 
phosphorylates/activates the receptor in the nucleus upon E2 treatment. This permits the 
conclusion that GSK-3 represents a link between the rapid cytoplasmic non-genomic and the 
nuclear genomic actions of E2-liganded ERα. 
Finally, ERα signalling pathway plays a crucial role in breast cancer initiation and 
progression. Therefore, the regulation of ERα function and activity by GSK-3 may have an 
impact on breast cancer progression. Preliminary data from GSK-3β immunostaining of 
formalin-fixed human tissue sections suggests a tendency toward an increase of GSK-3β 
expression in grade 3 tumors in comparison with grade 1/2 tumors. 
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II - Introduction 
 
II - 1) Cancer overview 
 
Cancer is one of the most frequent diseases and subject of extensive studies 
worldwide. Recently, some factors such as improvement of tumor diagnosis and longer 
human lifespan have increased the number of patients suffering from cancer. An early 
detection of cancer enhances the possible cure of the patient but the panel of therapies to heal 
cancer is not efficient enough. The aim of current cancer research is to better understand the 
aetiology and the progression of the tumor to find a strategy able to prevent, reduce, abolish 
and maybe eradicate cancer.  
The growth of the different types of cells constituting each tissue of the human body is 
tightly regulated. In cancer, the homeostasis is disrupted. In other words, the rates of cellular 
proliferation and apoptosis are not anymore in balance. This un-controlled growth leads to the 
formation of a neoplasm or tumor. Benign tumors grow locally and can neither invade healthy 
surrounding tissues, nor metastasize in distant organs. On the contrary, malignant tumors can 
spread by invasion and metastasis. The term “cancer” applies only for malignant tumors. 
Uncontrolled growth that progresses toward limitless expansion is the hallmark characteristic 
shared by all the types of cancer (definition of the National Cancer Institute, 
http://www.cancer.gov). 
Cancer classification was established according to the nature of the tissue from which 
the tumor has originated. Sarcomas are cancers arising from connective or supportive tissues 
of the body that are derived from mesenchymal cells such as bone, fat and muscle. Secondly, 
leukemias and lymphomas are cancers arising from hematopoietic cells of the bone marrow 
and from tissues of the body’s immune system, respectively. Finally, 90% of cancers are 
carcinomas, which arise from epithelial cells of the bladder, breast, colon, lung, prostate and 
skin. Among men, the most lethal cancer types in order of death numbers worldwide are lung, 
stomach, liver, colorectal, oesophagus and prostate carcinomas. Among women, the most 
lethal cancer types in order of death numbers worldwide are breast, lung, stomach, colorectal 
and cervical carcinomas (World Health Organisation, 2006, www.who.int). This dissertation 
will focus on breast cancer and it will describe and analyse biological mechanisms playing a 
crucial role in the initiation and progression of this harmful carcinoma. 
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II - 2) Breast cancer 
 
To understand breast cancer and more accurately the different types of breast cancer 
the structure and function of the breast was studied. Depending on the diagnosis, the stage of 
development and progression at the time point of detection and cellular origin, the breast 
cancer types will have different prognosis and the treatment strategy will be adapted to 
optimize the clinical outcome for the patient. 
 
II - 2.1) Anatomy of the breast  
The breasts contain lobules and ducts, surrounded by fat tissue, which are responsive 
to many of the female hormones, such as estrogen and progesterone (Fig. II - 1). The lobules 
consist of tiny bulbs or glands (alveoli) that proliferate during pregnancy and are responsible 
for producing milk after delivery. The milk is then secreted into the ducts. These thin tubes 
start from the lobes (groups of lobules) and carry the milk to the nipple. Blood and lymph 
vessels drain the breast tissue. The lymph vessels lead to small, bean-shaped organs called 
lymph nodes. Groups of lymph nodes are located near the breast and in the axilla, or armpit. 
Some muscles that are important for the arms movements as well as for breathing are also 
found over the ribs under each breast.  
 
Figure II - 1: Structure of normal and malignant breast tissue. a) Anatomy of the human 
mammary gland. Each mammary gland contains 15-20 lobes, each lobe containing a series of 
branched ducts that drain into the nipple. b) The branches of the duct open into the alveoli that are 
formed of two cell layers, the luminal epithelial cells and the myoepithelial cells. The luminal cells are 
responsible for the milk production. The glandular ducts are embedded in stroma. c) This 
mesenchymal structure breaks down in breast cancer, resulting in an epithelial cell mass. b and c are 
immunostained using antibodies to the estrogen receptor α (ERα; brown stained nuclei), showing that 
only a small proportion of epithelial cells are ERα positive in the normal breast. The percentage of 
ERα-positive cells in breast cancer is highly variable and can cover less than 10 % to more than 70 % 
of the cancer cells (Ali and Coombes, 2002). 
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II - 2.2) Types of breast cancer 
Breast cancers may originate from either the lobules or the ducts and they are called 
lobular carcinoma and ductal carcinoma, respectively. “In situ” carcinomas are cancers that 
have not crossed beyond the lobular or ductal cell layers. They are opposed to invasive 
cancers that extend beyond the cell layer and basal membrane and metastasizing breast 
cancers, which spread outside the breast.  
Ductal carcinomas are the most common type of breast cancer. Invasive ductal 
carcinoma (IDC) accounts for 85 % to 90 % of breast cancers (Ray and Mitra, 2003). This 
begins in the milk duct and it invades the surrounding fatty and connective tissues. It also has 
the possibility to metastasize. Unlike IDC, ductal carcinoma in situ (DCIS) is a non-invasive 
type of cancer located inside the milk ducts.  
Lobular carcinomas are less common. They are also divided into LCIS (lobular 
carcinoma in situ) and ILC (invasive lobular carcinoma). LCIS are pre-cancerous neoplasias 
located in the lobules. ILC have the potential to invade surrounding tissue and to metastasize. 
They account for about 10 to 15% of breast cancer. 
More rare type of breast cancers are sometimes diagnosed such as inflammatory breast 
cancer, medullary carcinoma, mucinous carcinoma, Paget’s disease of the nipple and 
phyllodes tumors. 
 
II - 2.3) Epidemiology and aetiology 
Breast cancer is the most common cancer among women in Western countries. The 
American Cancer Society estimated that, in 2007, more 178480 new invasive cases were 
diagnosed among women in the United States. At this time, slightly over 2 million women 
living in the United States have been diagnosed with and treated for breast cancer. One 
woman in eight either has or will develop invasive breast cancer in her lifetime. This 
represents the highest rate of breast cancer among women in the world. Each year in the 
United States, about 40460 women and 450 men die due to breast cancer (American Cancer 
Society, 2007, http://www.cancer.org). In comparison, 47500 women were diagnosed among 
women in 2003 in Germany and 17173 women died from breast cancer (Robert Koch 
Institute, http://www.rki.de). 
Concerning the aetiology of breast cancer, some risk factors are out of woman’s 
control, such as her age or family history. Indeed, the older a woman is, the greater is her risk 
to get breast cancer. Genetics and familial factors will increase even more the probability of 
cancer development. At the opposite, some risk factors are under a woman’s control and 
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concern her lifestyle. For example, drinking alcohol and smoking increase the rate of breast 
cancer. Some non-classified risks such as obesity, early menarche onset, late menopause and 
delayed first pregnancy or absence of pregnancy may also increase the incidence of breast 
cancer. Finally, breast cancer development and breast tissue homeostasis are under the 
influence of endogenous and exogenous hormonal agents. The number of mammary 
carcinoma cases rises dramatically for over-fifty years old women and corresponds to 
physiological hormonal modifications of estrogen and progesterone ratios due to the 
menopause. In addition, hormone replacement therapy (HRT) used as an exogenous 
postmenopausal treatment has been controversially shown by some epidemiological studies to 
increase breast cancer occurrence (National Cancer Institute, http://www.cancer.gov; 
Medlineplus, http://www.nlm.nih.gov/medlineplus).  
 
II - 2.4) Detection and diagnosis 
Breast cancer cases are mostly discovered either by self-examination or by 
mammography imaging. The aim is to detect the cancer as early as possible to have better 
chance of recovery and disease-free survival.  
Self-exam is the first recommended method to detect cancer. A woman should check 
her breasts monthly for possible changes. If a lump can be felt in the breast, the advice is to 
perform a clinical breast exam. Over the age of 40, this exam is recommended yearly since 
mammographs seem to be the most reliable method to detect breast cancer. This technique 
uses X-ray to detect alterations in woman’s breasts. Deposits of calcium can also be detected. 
They are mostly benign, but a cluster of them may be an early sign of breast cancer. “False 
negative” and “false positive” findings can disturb the diagnosis. Therefore, biopsies can be 
performed for histopathological classification of the findings. These studies of fluid or tissue 
removed from the suspicious area will improve the diagnosis.  
When breast cancer has been detected, further tests must help to identify the possible 
presence of metastasis. Radiological tests including bone scan and different computerized 
axial tomography (CAT) scans are performed to check whether the cancer has spread outside 
the breast, especially in the axillary lymph nodes.  
 
II - 2.5) Staging 
The diagnosis of a cancer includes the classification of this cancer into a well defined 
stage to follow tumorigenesis and tumor progression more precisely and to find the best 
treatment strategy. The ‘TNM’ classification system is a standard system used to describe the 
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growth and the spreading rates of tumors (Table II - 1). ‘TNM’ stands for ‘Tumor-Nodes-
Metastasis’ and respectively indicates the tumor’s size (T), whether lymph nodes (N) in the 
area of the original tumor have become infiltrated by cancer cells and whether the cancer has 
spread to other organs (M or metastasis). Then, according to information from the ‘TNM’ 
classification, a patient’s overall disease stage is determined.  
 
Size of the  
Primary Tumor (T) Definition 
TX Primary tumor cannot be assessed. 
T0 No evidence of primary tumor. 
Tis Pure carcinoma in situ: LCIS, DCIS or Paget disease of the nipple with no associated tumor mass. 
T1 Tumor 2 cm or less in greatest dimension. 
T2 Tumor more than 2 cm but not more than 5 cm in greatest dimension. 
T3 Tumor more than 5 cm in greatest dimension. 
T4 Tumor of any size growing into the chest wall or skin. 
Lymph Nodes (N) Definition 
NX Regional lymph nodes cannot be assessed. 
N0 Cancer has not spread to regional lymph nodes. 
N1 Cancer has spread to 1 to 3 lymph node(s) in the axilla 
N2 Cancer has spread to 4 to 9 lymph nodes in the axilla. 
N3 Cancer has spread to 10 or more lymph nodes in the axilla or also involves lymph nodes in other areas around the breast. 
Metastasis (M) Definition 
MX Presence of distant spread (metastasis) cannot be assessed. 
M0 No distant spread. 
M1 Spread to distant organs is present. 
 
Table II - 1: TNM classification of breast cancer (Singletary et al., 2002). 
 
Breast cancer stages are usually expressed with Roman numbers from 0 to IV. A low 
number indicates an early stage of cancer. Stage 0 (Tis, N0, M0) is sometimes called non-
invasive carcinoma or carcinoma in situ. Cells that look like cancer are located in either a 
breast lobule (LCIS) or a breast duct (DCIS) and these cells did not cross beyond the 
basement membrane to invade the surrounding tissues.  
Stages I and II are considered early stages of breast cancer. In the stage I (T1, N0, 
M0), breast carcinoma become invasive and can be considered now onward as a cancer. The 
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primary tumor measures no more than 2 cm and has not spread outside of the breast. In the 
stage II, different types of breast cancer are classified. In stage IIa, the primary tumor can 
measure less than 2 cm and has spread nearby to the lymph nodes in the axilla (T0, N1, M0 or 
T1, N1, M0) or the primary tumor can also be bigger (2-5 cm in size) and may or may not 
have spread to the lymph nodes under the arm (T2, N0, M0). In stage IIb, the primary tumor 
is larger than 5 cm and has not spread outside the breast (T2, N1, M0 or T3, N0, M0).  
Stages III and IV are considered advanced stages of breast cancer. In the stage IIIa 
(T0-2, N2, M0), the cancer has really taken hold in the lymph nodes. In stage IIIb (T4, N0-2, 
M0), the primary tumor has grown into the chest wall and/or skin. In stage IIIc (T0-4, N3, 
M0), tissues around the breast such as skin or chest wall may be invaded by tumor cells with 
spreading to 10 or more lymph nodes in the axilla; or to 1 or several lymph nodes under the 
clavicle (infraclavicular) or above the clavicle (supraclavicular); all these on the same side as 
the breast primary tumor. Stage IV (T0-4, N0-3, M1) represents metastatic stages of cancer. 
The cancer has spread beyond the breast, leading to secondary tumors in the bones, the lungs, 
the liver, the brain or elsewhere.  
 The percentage of patients who live at least 5 years after their cancer is diagnosed 
(also called 5-year survival rate) decline according to the breast cancer stages. This 5-year 
survival rate is 100 %, 100 %, 92 %, 81 %, 67 %, 54 % and 20 % for the stage 0, stage I, stage 
IIa, stage IIb, stage IIIa, stage IIIb and stage IV, respectively (American College of Surgeons 
National Cancer Data Base, http://www.facs.org/cancer/ncdb, 1998). The stage IIIc was not 
estimated since it was only recently described (system revised in 2002). Moreover, the 
survival rates should be better now with the improvement of treatment strategies. 
 
II - 2.6) Grading 
Histological grades of patient’s cancerous breast tumors are determined by 
pathologists to identify the type of tumor present, including cellular structure and function. 
The histological grading of breast cancer helps to determine prognosis for the patient and to 
orientate the medical treatment. The most common grading system used today is the Scarff-
Bloom-Richardson (SBR) system (Scarff and Torloni, 1968; Bloom and Richardson, 1957). 
After breast biopsy, lumpectomy or mastectomy, a sample of breast tissue is examined under 
the microscope. To determine the cancer’s grade (Table II - 2), three features are closely 
observed: the frequency of cell mitosis (rate of cell division), tubule formation (percentage of 
carcinoma composed of tubular structures) and nuclear polymorphism (change in size and 
uniformity of nuclei). To each of these features, a score ranging from 1 to 3 is assigned and 
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the final sum will range the breast cancer between 3 and 9. Grade 1 tumors are well 
differentiated with a sum of 3, 4 or 5. Grade 2 tumors, moderately differentiated, have a score 
of 6 or 7. Grade 3 tumors are poorly differentiated and reach 8 to 9. Some other features such 
as necrosis are also reported by pathologists when determining the tumor’s grade. 
 
Grade Description Score 5 years survival 
7 years 
survival 
Grade 1  
(slower cell growth) 
Well differentiated breast cells; cells 
generally appear normal and are not 
growing rapidly; cancer arranged in 
small tubules. 
3, 4, 5 95 % 90 % 
Grade 2 
Moderately differentiated breast 
cells; have characteristics between 
Grade 1 and Grade 3. 
6, 7 75 % 63 % 
Grade 3  
(faster cell growth) 
Poorly differentiated breast cells; 
cells do not appear normal and tend 
to grow and spread more 
aggressively. 
8, 9 50 % 45 % 
 
Table II - 2: Scarff-Bloom-Richardson (SBR) grade system and survival prognosis   
(Scarff and Torloni, 1968; Bloom and Richardson, 1957). 
 
II - 2.7) Treatment strategies 
Death rates from breast cancer have been declining due to earlier detection and 
improved treatment. The fewer tumor cells are present before the treatment, the higher is the 
probability of healing the cancer. According to the stage of breast cancer and for every 
patient, the most appropriate combination of the strategies described below must be chosen to 
reach the best efficiency of treatment and to minimise the side effects. 
Most breast cancers are taken out surgically. The aim of a lumpectomy is to remove 
the cancerous lump completely and to perform biopsies of some axillary lymph nodes to 
check for possible spreading. Mastectomy can also be performed. This technique is a total or 
partial removal of the breast, along with most of the lymph nodes in the axilla. Surgery alone 
is only efficient if the cancer has been detected at an early stage, when it has not spread 
elsewhere in the body. To prevent recurrence of a cancer, the surgeon may recommend some 
therapies in addition, including radiation therapy, hormonal therapy and chemotherapy. 
Radiation therapy is often used after surgery to destroy any remaining cancer cells. The use of 
high-energy rays (X-rays) to kill cancer cells also causes severe DNA damages to the healthy 
cells.  
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Chemotherapy is mostly used to treat cancer that has spread to other organs of the 
body or to prevent cancer from spreading outside the breast. Chemotherapy consists of a 
combination of drugs given orally or by injection to kill cancer cells. The drugs can block cell 
proliferation, disrupt the cell cycle or induce cell apoptosis. The treatment efficiency and the 
side effects of the drug are proportional to the concentration of drug reaching the tumor and to 
the duration of the treatment.  
Breast cancer is a typical hormone-dependent neoplasm. Estrogen is the key hormone 
involved in the development and progression of almost all mammary tumors. The estrogen 
receptors are the mediators of estrogenic actions in breast cancer. About 70 % of breast 
cancers are positive for estrogen receptors (Johnston and Dowsett, 2003). Hormone therapy is 
therefore based on either blocking the activation of estrogen receptor by estrogen or 
preventing estrogen synthesis (Fig. II - 2). Antiestrogens including selective estrogen receptor 
modulators (SERM), selective estrogen receptor destabilisators (SERD), aromatases inhibitors 
and releasing hormone analogs have been used after breast tumor removal by surgery. 
Tamoxifen was the first SERM discovered in 1967 by Harper and Walpole and inhibits the 
activation of estrogen receptor in a tissue selective manner. Tamoxifen is widely used today 
and is considered as the SERM of reference. However, critical side effects have been reported 
and recently, other SERMs such as raloxifene have reached clinical trial. Fulvestrant 
(faslodex) is a newly approved SERD, which eliminates estrogen receptor. Then, aromatase 
inhibitors (letrozole, anastrozole, exemestane) represent a promising way to treat breast 
cancer. Indeed, the aromatase enzyme converts androgens (androstenedione) to estrogen 
(estrone) and is the ultimate source of estrogen. Aromatase inhibitors are only efficient for 
postmenopausal women, whose estrogen production is in small amounts. Lowering the level 
of estrogen can be achieved for premenopausal women by ovarian ablation. Some luteinising 
hormone-releasing hormone (LHRH) or gonadotropin releasing hormone (GnRH) analogs 
such as goserelin or leuprolide can also be given to block ovaries making estrogen.  
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Figure II - 2: Mechanism of action of therapeutic agents used in endocrine therapy. Ovarian 
estrogen synthesis is regulated by the pituitary, which releases luteinising hormone-releasing hormone 
(LHRH). This, in turn, regulates the release of luteinising hormone (LH) and follicle-stimulating 
hormone (FSH) from the pituitary. In the ovary, both LH and FSH increase intracellular levels of 
cyclic AMP (cAMP). This activates the transcription factor cAMP-response-element-binding protein 
(CREB) and increases the expression of aromatase, which catalyses the conversion of ovarian 
androgens to estrogens. LHRH agonists first cause a release of stored LH and FSH and a subsequent 
LHRH-receptor downregulation that inhibits further LH and FSH release. In the normal breast, 
adipose tissue is a local source of estrogen synthesis. Factors that regulate aromatase expression, 
resulting in local estrogen synthesis, include interleukin-6 (IL-6), oncostatin M (OSM) and tumour 
necrosis factor-α (TNF-α). In breast cancer, the cancer cells themselves synthesize estrogens, and 
aromatase inhibitors are used to suppress local production of estrogens from adrenal steroids, as well 
as reducing ovarian estrogen synthesis. Moreover, locally produced prostaglandin E2 (PGE2) seems to 
be an important regulator of aromatase activity. PGE2 can activate prostaglandin E receptors on breast 
cancer cells, which increase cAMP levels and activate aromatase expression. Cyclooxygenase-2 
(COX-2) antagonists, by blocking prostaglandin production, might inhibit this pathway. Finally, anti-
estrogens inhibit estrogen action directly by binding to the estrogen receptor (ER). AC, adenylyl 
cyclase (Ali and Coombes, 2002). 
 
In addition, progesterone receptors described in some breast cancer (Johnston and 
Dowsett, 2003) may be used as a potential target to treat this disease. However, progesterone 
receptor antagonists are still under pharmaceutical investigations for the treatment of breast 
cancer (Hoffmann and Sommer, 2005).    
Finally, growth factors and growth factor receptors promoting tumor progression are 
potential therapeutic targets. In some breast cancer, the epidermal growth factor receptor 
ErbB2 (or HER2/neu) is overexpressed in the cancer cells and this correlates with reduced 
patient survival (Baselga, 2006). Monoclonal antibodies have been developed to decrease 
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proliferation of cancer cells overexpressing such growth stimulating receptors. Trastuzumab is 
the only validated example so far of humanised monoclonal antibodies. This antibody targets 
the extracellular region of the ErbB2 receptor and selectively inhibits the growth of cancer 
cells overexpressing this receptor. However, the impact of this monoclonal antibody treatment 
is limited since amplification of ErbB2 occurs in 25-30% of early-stage breast cancer (Bange 
et al., 2001) and resistance to the treatment rapidly arises.       
 
 
II - 3) Estrogen signalling and breast cancer 
 
Hormones can be defined as chemical signals secreted by glands into the blood stream 
that act on distant tissues, usually in a regulatory fashion (Larsen et al., 2002). Hormones act 
on cells either via binding to extracellular receptors and second messenger activation or via 
intracellular receptors. Steroid hormones are lipophilic ligands that can diffuse freely trough 
the cytoplasmic membrane of the target cells and bind to intracellular receptors know as 
nuclear receptors. Indeed, hormone binding will phenotypically change the conformation of 
these receptors and allow them to cross the nuclear membrane and to enter the nucleus. In this 
cell compartment, the hormone-receptor complex will selectively bind to hormone response 
elements and promote the transcription of appropriate target genes. 
Breast development and function are under the influence of hormones. Unsurprisingly, 
breast cancer is therefore a classical hormone-dependent neoplasm. The two hormones 
essential for mammary gland growth and development are estrogen and progesterone. The 
roles of these steroidal hormones and their nuclear receptors in breast tumorigenesis must be 
clarified but estradiol has an obligate role in the development of breast cancer (Anderson and 
Clarke, 2004). In particular, about 70 % of primary breast cancers in women are ERα positive 
and show estrogen-dependent growth. In the following, the synthesis, the mechanisms of 
action and the effects of estrogen will be especially described to further analyse its 
involvement in breast cancer.  
 
II - 3.1) Estrogen biosynthesis and function  
Steroid hormones are derived from the cholesterol (Fig. II - 3). Tissues involved in 
steroid transformation receive cholesterol from the blood and can also synthesise this 
compound in situ. In these tissues, hydroxylases transform cholesterol into pregnenolone. The 
following step depends on the enzymatic endowment of each tissue and the steroids 
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synthesised are consequently different. In the adrenal glands, either C21 steroids (aldosterone 
and cortisol) or C19 steroids (dehydroepiandrosterone or DHEA) are produced. The ovaries 
and the placenta are enzymatically equipped with aromatases (a cytochrome P450 enzyme 
complex) and C18 steroids (estrogens) can be additionally synthesised.  
The naturally occurring estrogens are the estrone, the estriol and the estradiol. The 
most abundant and biologically most active circulating form of estrogen in the human body is 
the 17β-estradiol (E2). E2 was first discovered by Allen and Doisy in 1923. E2 is synthesised 
primarily in the ovaries. Ovarian synthesis of estrogen ceases after the menopause, but non-
ovarian estrogen is still produced in the breast and adipose tissue for example (Ali and 
Coombes, 2002). To regulate their various biological functions, estrogens (i.e. E2) bind to 
estrogen receptors in the same cells where estrogen is produced (autocrine activation), in 
neighbouring cells (paracrine activation) or in cells of distant organs (endocrine activation). 
 
Estriol
Estrone
Estradiol
Cholesterol
Pregnenolone
ProgesteroneDehydroepiandrosterone
(DHEA)
Testosterone
 
Figure II - 3: Biosynthesis of estrogens from cholesterol. The cholesterol comes from the 
triglycerides in diet and is transformed via enzymatic reactions into hormone precursors and finally 
active hormones such as the estrogens. Estradiol, estrone and estriol represent respectively 10%, 10% 
and 80% of the female estrogens within the whole human body.  
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II - 3.2) Mechanism of estrogen receptors function and activity 
 
II - 3.2.1) Structure and tissue expression of estrogen receptors 
Estrogen receptor was first discovered in 1962 by Jensen and Jacobson. Estrogen 
receptors (ER) are categorised into the class I of nuclear hormone receptor superfamily of 
proteins and function as transcription factors. Estrogen receptor alpha (ERα) and estrogen 
receptor beta (ERβ) have been identified. These two proteins come from distinct genes 
located on separated chromosomes (6q 25.1 and 14q 22-24, respectively; Menasce et al., 
1993; Enmark et al., 1997). However, their structures are similar (Fig. II - 4). They consist of 
a variable amino-terminal A/B domain, which contains a ligand-independent activation 
function (AF-1); a C domain composed of two zinc fingers, which is required for DNA 
binding; a D domain or hinge region, which contains the nuclear localisation signal; an 
E domain, which contains a ligand-dependent activation function (AF-2); and a C-terminal or 
F domain with so far unclear function (Henry and Norman, 2003). AF-2 requires the binding 
of estrogen to be activated, whereas AF-1 activity is regulated by phosphorylation. These 
activation domains act independently and/or synergistically to regulate the transcriptional 
activity of target genes (Ali and Coombes, 2002). 
 
 
hERα       A/B C D E F N C 
1 180 263 302 549 595
hERβ       17% 97% 30% 60% 18% C N 
1 144 224 254 504 530 
AF-1 DBD LBD 
AF-2 
Figure II - 4: Domain structure representation of human ERα and ERβ subtypes. Domains 
(labelled A-F), amino acid sequence numbering, two activation functions (AF-1 and AF-2), and 
percentage of homology between the two receptor subtypes in different regions, including the DNA-
binding domain (DBD) and ligand binding domain (LBD) are shown (adapted from Kong et al., 2003; 
Moggs and Orphanides, 2001). 
 
The two subtypes of ER have a high degree of homology regarding their C domain. 
They differ essentially at their extremities in the A/B domain and in the F domain. Moreover, 
they show different patterns of tissue expression (Katzenellenbogen et al., 2000). Tissue 
responsiveness to estrogenic compounds is believed to depend on the expression patterns of 
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ER subtypes and their coregulators (Moggs and Orphanides, 2001). ERβ exhibits the most 
limited expression pattern and is primarily detected in the ovary, prostate, testis, spleen, lung, 
hypothalamus and thymus (Couse et al., 1997). At the opposite, ERα can be detected in 
almost all tissues. ERα is the predominant subtype expressed in the breast, uterus, cervix and 
vagina (Hall et al., 2001).  
 
II - 3.2.2) Cell signalling of estrogen receptors 
Four signalling pathways were reported to mediate biological effects of estrogen 
receptors (Fig. II - 5). Three of these pathways include genomic effects of ER and the fourth 
pathway leads to non-genomic estrogenic activity (Hall et al., 2001).  
The first classical mechanism is a ligand-dependent activation of ER. Upon E2 
stimulation, conformational modifications of estrogen receptors lead to increased 
phosphorylation of the receptors (Lannigan et al., 2003; Likhite et al., 2006). Regarding the 
ERα subtype, phosphorylation at serine residues was observed in a number of different cell 
types (Le Goff et al., 1994). The protein kinases involved in these phosphorylations will be 
described in the part II - 4.3 of this introduction. Concerning ERβ, phosphorylation sites are 
still unclear. Nevertheless, phosphorylation seems to be a crucial step in the activation of ER 
signalling pathway for both receptor subtypes. It may lead to ER dimerization and help to the 
recruitment of co-activators (Likhite et al., 2006). Homodimerization (α/α or β/β) or 
heterodimerization (α/β) can occur, but the respective contribution of each dimer is not well 
clarified so far. Overall, the dimers are able to recruit specific coactivators to become 
functionally active and to bind estrogen response elements (ERE) located in the promoter 
region of target genes. The consensus ERE is a 13 base pair (bp) palindromic sequence 
(GGTCAnnnTGACC) consisting of two 5-bp inverted repeats with a 3-bp spacer (Henry and 
Norman, 2003). Each ER molecule of the dimer will bind to a 5-bp repeat and together, they 
will regulate transcription of target genes. 
Second, growth factors such as the epidermal growth factor (EGF) or insulin-like 
growth factor-1 (IGF-1) can activate ERα in a ligand-independent manner. Modification of 
the phosphorylation state of the ERα seems to be also an important mechanism in the 
activation of this second pathway. The mechanisms are not entirely clear but phosphorylation 
of ERα may be sufficient to activate dimerization of the receptor and to regulate the 
transcriptional activity of ERE-dependent target genes. The ligand-dependent and ligand-
independent ERα signalling cascades are relatively similar but the panel of genes regulated by 
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these two pathways may be different. Even more, each growth factor implicated may have 
different effects on the regulation of gene expression.  
Third, an ERE-independent genomic action of estrogen can take place. After E2 
stimulation, the complex agonist/ERα can lead to gene regulation in the absence of direct 
DNA binding. Indeed, this complex may interact with other transcription factors such as 
specificity protein 1 (Sp-1) and activator protein-1 (AP-1) and activate their responsive 
elements.  
Another mechanism of ERα activation includes non-genomic effects of estrogens. 
Cell-surface bound ERα seems to be directly linked to intracellular signal transduction 
proteins and several protein kinases may especially be implicated. However, the functional 
relevance of this E2 signalling pathway is still under debate. 
 
 
Figure II - 5: The multifaceted mechanisms of estradiol and estrogen receptor signalling. The 
biological effects of ER are mediated trough at least four signalling pathways. 1) classical ligand-
dependent, E2-ER complexes bind to ERE in target gene promoters leading to an up- or down- 
regulation of gene transcription and subsequent tissue responses. 2) ligand-independent, growth 
factors (GF) or cyclic adenosine monophosphate (not shown) activate intracellular protein kinase 
pathways, leading to phosphorylation (P) of ER, receptor dimerization and binding to ERE-containing 
promoters of target genes. 3) ERE-independent, E2-ER complexes alter transcription of genes 
containing alternative response elements such as AP-1 binding sites through association with other 
DNA-bound transcription factors (Fos/Jun), which tether the activated ER to DNA, resulting in an up- 
or down-regulation of gene expression. 4) Cell-surface (non-genomic) signalling, E2 activates a 
putative membrane-associated binding site, possibly a form of ER linked to intracellular signal 
transduction pathways that generate rapid tissue responses (Hall et al., 2001). 
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I - 3.2.3) Biological function of estrogen receptors 
According to the expression patterns of ER subtypes within a tissue and to the ER 
signalling pathways activated, estrogen receptors have multiple actions in reproductive tissues 
(such as breast, uterus and ovary) and in many non-reproductive tissues including bone, the 
central nervous system (CNS) and the cardiovascular system (Stossi et al., 2004). The 
different phenotypes observed for ERα, ERβ and double ER null mice gave us valuable 
information on the impact of these receptors for the development and functionality of 
different tissues (Couse and Korach, 1999; Table II - 3) and notably showed that ERα was 
the main receptor responsible for these phenotypes. As an example, the mammary gland was 
immature and insensitive to estradiol in ERα null mice and no further alterations were 
observed in the double ER null mice. 
 
 
Table II - 3: Phenotypes of ER knockout mouse models (Henry and Norman, 2003). 
 
II - 3.3) Estrogenic activity and breast tumorigenesis 
Estrogen regulates genes involved in the differentiation and proliferation of normal 
breast epithelial cells. Unsurprisingly, most breast cancers (about 95 %) are initially hormone-
dependent, where the hormone estradiol plays a crucial role in their development (Pasqualini, 
2004). Cumulative exposure of the breast epithelium to estrogen was particularly depicted as 
a risk factor associated with initiation and/or promotion of breast cancer. Two current 
hypotheses may explain the involvement of estrogen in breast cancer. In the first, binding of 
estrogen to its cellular receptor stimulates proliferation of mammary cells, increasing cell 
division and enhancing replication errors. In the second, estrogen metabolism leads to the 
production of genotoxic by-products that could directly damage DNA. Both of these 
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hypotheses may imply that estrogen induces mutations leading to the disruption of normal 
cellular processes such as cellular proliferation, apoptosis and DNA repair (Deroo and 
Korach, 2006). Breast cancer is therefore considered as the outcome of a complex and not 
fully understood interplay amongst genetic and hormonal factors (Ray and Mitra, 2003). 
As described previously for the development of the mammary gland, ERα subtype is 
also the primary mediator of estrogenic actions in breast cancer. The estrogenic regulation of 
gene expression is under the influence of this receptor subtype. Moreover, several sequence 
variations or single-nucleotide polymorphisms (SNPs) in the ERα have been identified and 
associated with either increased or decreased risk of breast cancer. However, the hereditary 
contribution of SNPs for the development of breast cancer must be further investigated. 
Finally, alteration of the receptor expression was suggested to be the major cause of cancer 
progression and hormone-therapy resistance (Deroo and Korach, 2006).   
    
II - 3.3.1) Regulation of gene expression upon estrogen stimulation 
In 2003, Frasor et al. performed gene expression profiling studies in estrogen receptor 
positive MCF-7 human breast cancer cells after E2 treatment for different time courses. For 
the genes regulated by estradiol, they observed that the majority of them (70 %) were 
downregulated. These include transcriptional repressors as well as anti-proliferative and 
proapoptotic genes. At the opposite, up-regulation was observed for positive proliferation 
regulator genes, for genes involved in cell cycle progression and for genes leading to the 
production of proteases playing a role in tumor invasiveness. In 2004, Terasaka et al. 
confirmed that estrogen target genes include primarily growth-associated genes and tumor-
associated genes. They also showed that other genes such as ion-associated genes or genes 
coding for structural proteins may be regulated by E2.  
Overall, estrogen mainly regulates genes resulting in growth and proliferation of breast 
cancer cells. Therefore, estrogens are considered as powerful enhancers of tumor progression.  
 
II - 3.3.2) Estrogen receptor status in breast cancer  
The clinical outcome of breast cancer depends on ER and especially ERα status of the 
tumor. Allred et al. (2004) correlated the levels of ERα expression of invasive breast cancer 
assessed by immunohistochemistry with the clinical outcome of the patients (Fig. II - 6). 
They concluded that even if ERα was expressed in only few cells of the tumor, the clinical 
response to hormonal therapy was far better than in ERα negative tumors. Overall, estrogen-
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dependent tumors have the tendency to grow faster than estrogen-independent tumors but the 
improvement of hormonal therapy may consider estrogen-dependent tumor easier to eradicate. 
Moreover, Allred et al. (2004) also showed that only a slight gradient of hormonal therapy 
efficiency was observed with better hormonal therapy response for tumors with high number 
of cells expressing ERα.  
 
 
Figure II - 6: Kaplan-Meyer curves illustrating relationship between ERα (ER) status 
(immunohistochemistry [IHC] scores) and clinical outcome (disease-free survival [DFS]). 
Invasive breast cancer of patients (n=777) treated with adjuvant tamoxifen therapy were stained by 
IHC. IHC score equal to 0 and 2 corresponds to none and < 1 % ERα-positive (ER+) cells, 
respectively and were considered as ERα-negative (ER-) tumors. An IHC score of 3 represents tumors 
with 1-10 % of ER-positive cells and tumors with IHC score from 4 to 8 proportionally corresponds to 
> 10 % to 100 % ER-positive cells (Allred et al., 2004). 
 
 
II - 4) Estrogen signalling-related protein kinases as key players of breast tumorigenesis  
 
The protein kinase superfamily is one of the largest families in the human genome and 
regroups more than 518 members (Johnson and Hunter, 2005). Protein phosphorylation 
regulates important intracellular mechanisms and especially modification of proteins involved 
in the transmission of signals within the cell (signal transduction) such as ion transport, 
cellular proliferation and hormone responses. Therefore, protein kinases are very attractive 
targets for therapeutic interventions in many diseases such as cancer, diabetes, inflammation 
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and arthritis. In this regard, protein kinases represent as much as 30 % of all protein targets 
under investigation by pharmaceutical companies (Cohen, 2002).  
As previously described, the regulation of estrogen signalling via ERα is under the 
influence of protein kinases and this signalling pathway is of major importance in breast 
cancer. Therefore, research investigation currently focuses on the specific protein kinases 
involved in this signalling cascade. The aim is to find target protein kinases of interest for the 
future development of protein kinase inhibitors to treat this hormone-dependent cancer. 
 
II - 4.1) The protein kinase superfamily 
Protein kinases belong to a huge superfamily. In 1991, from catalytic domain 
alignment, Hanks and Quinn provided a general classification of protein kinases. This 
classification is still used. The protein kinases superfamily was divided into five protein 
kinase groups: AGC, CaMK, GMCC, PTK and OPK. Their names come from the proteins 
that belong to each of them. The AGC group includes protein kinases A, G and C, 
respectively regulated by cAMP, cGMP and diacylglycerol (DAG). The CaMK group 
corresponds to protein kinases regulated by calcium/calmodulin (CaM). The GMCC group 
includes glycogen synthase kinases (GSK) and especially glycogen synthase kinase-3β, 
mitogen-activated protein kinases (MAPK), cyclin-dependent kinases (Cdk) and the carboxy-
terminal domain (CTD) kinases. The PTK group is composed of protein tyrosine kinases 
(PTK). The OPK or other protein kinases summarize some protein kinases such as 
MAPK/ERK kinase (MEK) and c-Jun N-terminal kinase (JNK) (Henry and Norman, 2003). 
Protein kinases modify other proteins by chemically adding phosphate groups to them. 
A protein kinase transfers the γ-phosphate group from adenosine triphosphate (ATP) 
covalently to a hydroxyl group of a protein substrate (Henry and Norman, 2003). Most protein 
kinases act on both serine and threonine residues. Others act on tyrosine residues and some 
called dual specificity protein kinases act on all three. Therefore, protein kinases can be 
classified more easily according to the nature of the residue they prefer to phosphorylate. The 
serine/threonine protein kinase family include the AGC, CaMK and GMCC groups and some 
protein kinases from the OPK group. PTK constitute a separate family and the last family is 
composed of dual-specificity protein kinases. 
The transfer of the phosphate group may functionally alter the target protein by 
changing its enzymatic activity, its cellular location or its association with other proteins. 
Protein kinases regulate the majority of cellular pathways such as cell growth, cell motility 
and cell death among others. Therefore, their activities are tightly regulated. Regarding the 
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protein kinase of interest, its regulation can be achieved through phosphorylation by other 
protein kinases (protein kinase cascade), by autophosphorylation, by binding of activators or 
inhibitors, or by controlling its location in the cell relatively to its substrates.  
 
II - 4.2) Protein kinases related to breast cancer 
Thirty-two known cytoplasmic PTK have been determined so far and about half of 
them have been implicated convincingly in human cancer (Blume-Jensen and Tony Hunter, 
2001). These PTK are involved in the signal transduction of receptor tyrosine protein kinases 
(RTK) playing a role in tumorigenesis, such as epidermal growth factor receptor (EGFR), 
insulin-like growth factor receptor (IGFR), platelet-derived growth factor receptor (PDGFR), 
vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor 
(FGFR). In particular, for mammary carcinomas, overexpression of RTK including the ErbB2 
member of the EGFR family and the FGFR4 have been reported (Koziczak and Hynes, 2004). 
This implies hyperactivation of the related PTK in these breast cancers.  
Downstream of RTK are numerous cytoplasmic protein-serine/threonine kinases that 
have been linked to cancer. For example, MAPK signalling pathway has been involved in cell 
proliferation and cancer progression but no frequent recurring mutations have been identified 
in human mammary malignancies. In contrast, mutations of the PI3K/Akt and the mTOR/S6 
kinase signalling pathways are involved in mammary tumorigenesis (Blume-Jensen and Tony 
Hunter, 2001). The most common genetic aberration in breast cancer is somatic mutation of 
the PIK3CA gene encoding for the p110α catalytic subunit of phosphatidylinositol 3-kinase 
(PI3K). 26 % of primary breast tumors and 28 % of breast cancer cell lines displayed 
mutations in the PIK3CA gene (Bachman et al., 2004, Saal et al., 2005). Mutations in the 
p110α catalytic subunit of PI3K may result in activation of the PI3K signalling pathway and 
may contribute to mammary tumor progression (Dillon et al., 2007). Indeed, the PI3K 
pathway activates processes that fulfil hallmarks of cancer such as evading apoptosis, 
limitless replicative potential, insensitivity to anti-growth signals, sustained angiogenesis and 
tissue invasion and metastasis (Dillon et al., 2007). In addition, PKB/Akt, a downstream 
effector of PI3K, plays a role in breast cancer cell growth via the activation of mTOR 
signalling pathway (Li et al., 2004). Therefore, some of the transforming cell-growth and cell-
cycle-promoting effects of PI3K are mediated through the mTOR pathway. 
However, the overwhelming majority of protein kinases remain largely 
uncharacterized. Their relevance concerning breast cancer is under investigation and their role 
in the estrogen receptor signalling pathway must be specified.     
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II - 4.3) Phosphorylation sites and protein kinases involved in ERα signal 
transduction 
Lannigan et al. (2003) suggest that ERα becomes predominantly phosphorylated at 
Ser-118 and to a lesser extent at Ser-104 and Ser-106 in response to estradiol (Fig. II - 7a). 
Upon E2 stimulation, phosphorylation at Ser residues and particularly at Ser-118 in the 
AF1 domain appears to influence the recruitment of coactivators, resulting in enhanced ERα-
mediated transcription (Likhite et al., 2006). Indeed, ERα mutated to Ala at Ser-104, Ser-106 
and Ser-118 showed decreased estrogen-induced transcriptional activity in comparison with 
wild type ERα (Lannigan et al., 2003). However, the results were controversial with respect 
to the amino acid the Ser-118 residue was mutated to. ERα in which Ser-118 was mutated to 
Ala showed diminished transcriptional activity in response to E2 whereas ERα mutation at 
Ser-118 by an acidic residue could enhance the transcriptional response (Valley et al., 2005). 
While these phosphorylations are well established, the protein kinases involved are 
controversial. The protein kinases responsible for Ser-104/Ser-106 phosphorylation may be 
different from the one that phosphorylates Ser-118. Additionally, more than one protein 
kinase may phosphorylate a certain serine residue. In response to estradiol, cyclin A-cyclin 
dependent kinase 2 (Cdk2) complex phosphorylated Ser-104 and Ser-106, but it did not affect 
Ser-118 (Rogatsky et al., 1999). According to Chen et al. (2000), Ser-118 may be 
phosphorylated by TFIIH cyclin-dependent kinase in response to estradiol. Additionally, 
activated MAPK also phosphorylated Ser-118, but not after E2 treatment (Joel et al., 1998).  
Some other ERα serine residues such as Ser-167 and Ser-236 may also be 
phosphorylated by protein kinases (Fig. II - 7b). In particular, Ser-167 was described as a 
major site of phosphorylation in response to estradiol binding according to Arnold et al. 
(1994) but this observation was not confirmed by Le Goff et al. (1994) and Clark et al. 
(2001). Moreover, protein kinases such as Akt and ribosomal S6 kinase (Rsk) have been 
shown to phosphorylate Ser-167 residue in vitro and in vivo (Lannigan et al., 2003). However, 
phosphorylation at Ser-167 by these protein kinases has not been reported in response to E2 
suggesting that Ser-167 phosphorylation may have a role in ligand-independent ERα 
activation. Similarly, Ser-236 phosphorylation, hypothetically by PKA, may lead to ligand-
independent dimerization of the receptor.  
Finally, Tyr-537 phosphorylation of ERα may also occur and may be involved in the 
regulation of ERα sensitivity to E2 (Ali and Coombes, 2002). The protein kinases involved in 
this phosphorylation are unknown so far. 
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Figure II - 7: ERα serine phosphorylation sites. Phosphorylation of ERα at Ser residues is 
enhanced (a) in response to estradiol binding and (b) in response to second messengers leading to 
ligand-independent activation of the receptor. The serine phosphorylation sites and the protein kinases 
suggested to be responsible for these phosphorylations are shown (Lannigan et al., 2003). 
 
Moreover, rapid biological effects of E2 have been observed in the bone, breast, 
vasculature, and nervous system (Hall et al., 2001). These nongenomic effects of estrogens 
may be mediated through cell-surface associated ERα and downstream activation of 
intracellular signal transduction proteins such as protein kinases. ERα localisation at the 
membrane is still controversial but Song et al. (2004) suggested that Shc and IGFR serve as 
key elements in the translocation of ERα to the cell membrane and in the facilitation of ERα-
mediated rapid E2 action. In human MCF-7 breast cancer cells, estrogens via binding to the 
membrane-bound ER may rapidly activate several protein kinases, i.e., MAPK, PI3K, PKA 
and PKC. This rapid signal transduction cascades may be relevant for breast cancer cell 
proliferation in response to E2 (Vasudevan and Pfaff, 2007).  
 
II - 4.4) A putative role for the glycogen synthase kinase-3β (GSK-3β) 
Recently, the serine/threonine protein kinase glycogen synthase kinase 3 (GSK-3) was 
described as a key regulator of many transcription factors. Some findings also postulate a 
possible effect of GSK-3 on the activity of steroid hormone receptors including ERα. The 
next parts will focus on GSK-3 kinase function and activity with emphasis on the possible 
role of GSK-3 kinase regarding the ERα signalling pathway. 
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Two highly homologous forms of mammalian GSK-3, GSK-3α and GSK-3β, have 
been described (Woodgett, 1990). The two isoforms are encoded by different genes and share 
nearly identical sequences (97% sequence similarity) in their protein kinase domain (Jopes 
and Johnson, 2004), while these isoforms have significant sequence differences outside from 
this region. The isoforms show similar substrate specificity but the isoform-specific functions 
are still unclear. The disruption of the GSK-3β gene in mice results in embryonic lethality, 
indicating that GSK-3α cannot completely compensate the loss of GSK-3β, whereas GSK-3β 
can overcome the loss of GSK-3α (Hoeflich et al., 2000).  Therefore, GSK-3β seems to be 
more essential. GSK-3β phosphorylates and thereby regulates the functions of many 
metabolic, signalling and structural proteins (Grimes and Jope, 2001).  
 
II - 4.4.1) GSK-3β substrates  
GSK-3β has unique substrate specificity. Most GSK-3β substrates require a priming 
phosphate at n + 4 (where n is the site of phosphorylation) to be in turn phosphorylated by 
GSK-3β. For example, glycogen synthase (GS) must be phosphorylated at Ser-656 by casein 
kinase 2 (CK2) to allow GSK-3β phosphorylation at Ser-652, which in turn allows 
phosphorylation at Ser-648 and so on until five serine residues have become phosphorylated. 
Similarly, eukaryotic initiation factor-2B (eIF2B) might be phosphorylated by dual-specificity 
tyrosine-phosphorylated and regulated kinase (DYRK) at Ser-539 prior to GSK-3β 
phosphorylation at Ser-535 (Fig. II - 8).  
 
 
 
Figure II - 8: The unique substrate specificity of GSK-3β. Most substrates of GSK-3β must be 
phosphorylated by another protein kinase at a serine or a threonine residue located four residues 
carboxy-terminal to the site of GSK-3β phosphorylation. Schematic demonstration of the 
phosphorylation schedule of glycogen synthase and eukaryotic initiation factor-2B (eIF2B) proteins 
(adapted from Cohen and Frame, 2001). 
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However, other proteins such as axin and β-catenin, which are part of the Wnt 
pathway (Cohen and Frame, 2001), seem to be unprimed substrates of GSK-3β. Axin might 
bind to a distinct site of GSK-3β. Then, axin phosphorylation site might be directed to the 
active protein kinase site of GSK-3β, where axin is phosphorylated without primed 
phosphorylation by another kinase. A similar mechanism might also trigger the recruitment 
and phosphorylation of β-catenin without any priming phosphate (Fig. II - 9). GSK-3 
inhibitors developed so far were ATP-competitive and did affect every substrates of GSK-3 
regardless of their ‘primed’ or ‘unprimed’ properties. The difference between primed and 
unprimed substrates may help to develop compounds that target specifically the site that binds 
the ‘priming phosphate’ of substrates. Therefore, phosphorylation and activation of proteins 
that mediates insulin signalling (GS, eIF2B) may be inhibited without affecting ‘unprimed’ 
proteins such as members of the Wnt signalling pathway which are known for their 
involvement in oncogenesis (Cohen and Frame, 2001).    
 
 
Figure II - 9: GSK-3β substrates and their relevance for drug development. Drugs that bind to the 
‘priming phosphorylation site’ might mimic insulin signalling without triggering the Wnt signalling 
pathway (Cohen and Frame, 2001). 
 
In conclusion, GSK-3β phosphorylates diverse substrates including metabolic and 
signalling proteins, structural proteins and transcription factors (Table II - 4). According to 
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Grimes and Jope (2001), one of the most important roles of GSK-3β is the regulation by 
phosphorylation of numerous transcription factors and thereby the control of the expression of 
the respective target genes. These transcription factors regulate genes involved in cell growth, 
cell proliferation and cell death such as AP-1. Others such as Myc and CCAAT/enhancer 
binding protein α (C/EBPα) contribute to the regulation of cellular differentiation. Some 
including nuclear factor kappa B (NFκB), nuclear factor of activating T cells (NFAT) and 
heat shock factor-1 (HSF-1) are involved in the immune system. Finally, CREB seems to be 
regulated by GSK-3β. This transcription factor plays a critical role in formation of long-term 
memory, maintenance of synaptic plasticity and apoptosis.    
 
Metabolic and signalling 
proteins Structural proteins Transcription factors 
 
- AcetylCoA carboxylase 
 
- Amyloid precursor protein 
(APP) 
 
- Adenomatous polyposis 
coli (APC) 
 
- ATP-citrate lyase 
 
- Axin 
 
- cAMP-dependent protein 
kinase 
 
- Cyclin D1 
 
- Cyclin E 
 
- Eukaryotic initiation  
factor-2B (eIF2B) 
 
- Glycogen synthase (GS) 
 
- Insulin receptor substrate-1 
(IRS-1) 
 
- Myelin basic protein 
 
- Nerve growth factor (NGF) 
receptor 
 
- Protein phosphatase 1 
 
- Protein phosphatase 
inhibitor-2 
 
- Pyruvate dehydrogenase 
 
 
- Dynamin-like protein 
 
- Microtubule associated 
protein 1B (MAP1B) 
 
- Microtubule associated 
protein 2 (MAP2) 
 
- Neural cell-adhesion 
protein (NCAM) 
 
- Neurofilaments 
 
- Ninein 
 
- Tau 
 
- Telokin 
 
- Activator protein-1 (AP-1)  
 
- β-catenin 
 
- CCAAT/enhancer binding 
protein (C/EBPα) 
 
- Cyclic AMP response 
element binding protein 
(CREB) 
 
- Glucocorticoid receptor 
(rat) 
 
- Heat shock factor-1    
(HSF-1) 
 
- Myc 
 
- Nuclear factor of activated 
T cells (NFAT) 
 
- Nuclear factor kappa B 
(NFκB) 
 
- Notch 
 
- p53 
 
- T-cell factor (TCF) 
 
- Androgen Receptor 
 
- ERα 
 
Table II - 4: Mammalian protein putatively phosphorylated by GSK-3β (updated from Grimes 
and Jope, 2001; Jope and Johnson, 2004). 
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II - 4.4.2) GSK-3β regulation in a variety of intracellular pathways  
Since GSK-3β has a predominant role in the control of several intracellular pathways, 
its activity needs to be carefully regulated. GSK-3β is one of the few protein kinases, which is 
inactivated by phosphorylation. In fact, serine phosphorylation inhibits GSK-3β activity, 
whereas tyrosine phosphorylation stimulates and increases its activity. Additionally, protein 
complex formation and intracellular localisation are other ways to regulate this enzyme.  
Originally, GSK-3β was named for its ability to phosphorylate and thereby to 
inactivate the glycogen synthase (GS), which is a key regulator of glycogen metabolism 
(Grimes and Jope, 2001). Glycogen and glucose metabolism are regulated by insulin and the 
role of insulin is to decrease the level of blood glucose. Insulin binding to its cellular receptor 
triggers the activation of protein kinase B, which phosphorylates GSK-3β at Ser-9 residue and 
inhibits the activity of this enzyme (Cross et al., 1995; Fig. II - 10). Indeed, the inactivation 
of GSK-3β promotes dephosphorylation of glycogen synthase at the sites phosphorylated by 
GSK-3β and contributes to the stimulation of glycogen synthesis (Frame and Cohen, 2001). 
By this way, insulin also stimulates the dephosphorylation and activation of eukaryotic 
initiation factor 2B (eIF2B), which is phosphorylated and inhibited by GSK-3β (Wang et al., 
2002).  
 
Insulin, IGF-I EGF Wnt 
PKC Akt p90Rsk 
 
 
Figure II - 10: Phosphorylation-dependent regulation of GSK-3β. Some of the signals proposed to 
mediate activation of GSK-3β via phosphorylation of Tyr-216 (p-Tyr-216) and the inhibition of 
GSK-3β via phosphorylation of Ser-9 (p-Ser-9) are depicted (adapted from Grimes and Jopes, 2001). 
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Moreover, other proteins such as MAPKAP kinase-1 (p90Rsk), mammalian target of 
rapamycin (mTOR), PKA and PKC phosphorylate GSK-3β at Ser-9 residue (Fig. II - 10). 
These enzymes belong to growth factor and hormone-stimulated signal transduction pathways 
and stringently control GSK-3β.  
Phosphorylation of GSK-3β at Tyr-216 increases the enzyme’s activity. In 1994, 
Wang et al. suggested an autophosphorylation of this site. More recently, Kim et al. (1999) 
reported that ZAK1 kinase may increase GSK-3β activity via Tyr-216 phosphorylation in 
Dictyostelium. Lesort et al. (1999) suggest that Fyn, a member of the Src tyrosine protein 
kinase family, may also directly phosphorylate Tyr-216 and thereby activate GSK-3β. 
Additionally, increase of intracellular calcium and several proapoptotic stimuli were described 
to induce Tyr-216 phosphorylation and increase GSK-3β activity, but the protein kinases 
involved have not yet been identified.    
GSK-3β activity can also be regulated by protein complex formation in the Wnt 
signalling pathway (Fig. II - 11). This mechanism was first described in xenopus and then 
extended to drosophila and mammals. In all these organisms, this pathway specifies cell fate, 
cell proliferation and cell differentiation (Frame and Cohen, 2001). Similar complex 
formation is observed in the Wnt signalling pathway between these organisms. The 
differences concern only the names of the proteins involved in this complex. Protein 
nomenclature in mammals will be used for the following description of the different 
components of this complex. In the absence of secreted glycoproteins known as Wnt, GSK-3β 
is active in the complex and phosphorylates adenomatous polyposis coli (APC), axin and 
β-catenin. The aim of APC phosphorylation is unclear, but it may enhance interaction 
between GSK-3β and β-catenin. Axin is stabilised by phosphorylation and β-catenin 
phosphorylation targets it for ubiquitination and subsequent proteolytic destruction. After the 
binding of Wnt to their receptors, the proteins dishevelled (DVL) together with frequently 
rearranged in advanced T-cell lymphomas (FRAT) bind to GSK-3β and inhibit its activity. 
Therefore, APC, axin and β-catenin will be dephosphorylated and released from the complex. 
Then, β-catenin translocates and accumulates in the nucleus, where it binds to members of the 
T-cell factor (TCF) family of transcription factors (also called LEF or lymphoid-enhancer 
factor). This stimulates the transcription of genes required for embryogenesis during 
developmental stage and the transcription of genes especially involved in tissue proliferation 
such as mammary development during lactation in the adult stage (Hatsell et al., 2003; Hens 
and Wysolmerski, 2005).  
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Figure II - 11: Outline of the mechanism by which Wnt signalling might lead to the inhibition of 
GSK-3, accumulation of β-catenin and the activation of gene transcription. This signal 
transduction pathway has still to be fully elucidated and some of the details depicted are not generally 
accepted. The Wnt signalling is not only of importance during embryogenesis, but this pathway is also 
involved in gene regulation in adult organisms, and mutations in some components of the pathway, 
such as APC and β-catenin, can cause cancer (adapted from Cohen and Goedert, 2004).  
 
Aberrant activation of the canonical Wnt/β-catenin pathway is one of the most 
frequent signalling abnormalities known in human cancer (Polakis, 2000; Brennan and 
Brown, 2004). Wnt-1 was the first oncogene identified after infection of mice with the mouse 
mammary tumor virus (MMTV) and transgenic expression of Wnt-1 in mice induces ER+ 
mammary tumors (Zhang et al., 2005).  Aberrant Wnt signalling is also associated with breast 
tumorigenesis although mutations of β-catenin or other Wnt pathway components have been 
found only rarely in breast cancer. However, stabilisation and nuclear translocation of 
β catenin protein has been reported in the majority of human breast tumors (Howe and 
Brown, 2004). Nuclear β-catenin can function as an oncogene when it binds to TCF family 
members and increase the expression of genes involved in breast cancer proliferation such as 
cyclin D1. High β-catenin activity significantly correlated with poor prognosis of breast 
cancer patients (Lin et al., 2000). The cause of β-catenin accumulation has not yet been 
determined but overexpression of some Wnt glycoproteins (Wnt 2, 3, 4, 5A, 7B, 10B, 13 and 
14) has been documented in human breast tissue and may be at the origin of this 
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accumulation. Altered activity of Wnt signalling modulators such as the protein kinase GSK-3 
may also be responsible for β-catenin stabilisation. 
 
II - 4.4.3) Early findings concerning possible ERα regulation by GSK-3β 
ERα acts as a transcription factor and its ligand-dependent regulation is under the 
influence of phosphorylation. Some protein kinases have already been described to control 
ERα transcriptional activity (see part II - 4.3) but they failed to explain the whole mechanistic 
machinery responsible for the effects of estrogen signalling. Therefore, new alternative 
protein kinase candidates may play an important role. Several evidences indicate that GSK-3β 
influences ERα function and activity. In rat hippocampus, Cardonna-Gomez et al. (2004) 
observed that estradiol regulates interaction of ERα, GSK-3β and β-catenin. In 2004, 
Kouzmenko et al. suggested a functional interaction between β-catenin and ERα in human 
colon and breast cancer cells. However, the other components involved in the cross-talk 
between Wnt, estrogen signalling pathways must still be identified, and GSK-3β is only a 
putative candidate.  
Recently, our group (De Servi et al., 2005) demonstrated that GSK-3β plays a role in 
TPA-induced or ligand-independent ERα activation and translocation in breast cancer cells 
(Fig. II - 12). In the same cell line, we observed that ERα phosphorylation by GSK-3β 
stabilises this receptor under resting conditions and modulates ERα transcriptional activity 
upon ligand binding. This dual action of GSK-3β suggests a key role for this protein kinase in 
the regulation of the ligand-dependent activation of ERα (Medunjanin et al., 2005). 
 
 
Figure II - 12: Model for PKCδ involvement in TPA-induced activation of ERα. In unstimulated 
cells, PKCδ is localized to the cytoplasm. After TPA treatment, active PKCδ translocates to the 
membrane fraction and phosphorylates GSK-3. GSK3, which in unstimulated cells is active and forms 
a complex with ERα, is inactivated by phosphorylation. The phosphorylation of GSK-3 may trigger 
the nuclear translocation of both ERα and GSK3 proteins. ERα is activated by phosphorylation in the 
nucleus. (De Servi et al., 2005). 
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II - 5) Aims  
 
The majority of breast cancers show estrogen-dependent growth via the activation of 
the ERα signalling pathway. The observation that ERα negative tumors may arise from ERα 
positive neoplasms reinforces the significance of estrogens for early breast cancer 
development. However, open questions are still encountered regarding the mechanism(s) 
leading to activation of the estrogen-dependent signalling pathway(s) and their particular role 
in breast tumorigenesis. It is assumed that both nongenomic and genomic actions of E2 via 
the ERα signalling pathway(s) are involved. 
Cytoplasmic proteins, especially protein kinases that are components of various signal 
transduction pathways, are rapidly phosphorylated upon stimulation of cells with E2. These 
rapid effects of E2 are considered nongenomic effects. In addition, rapid E2-activated 
signalling reactions result in translocation of cytoplasmic ERα into the nucleus where 
phosphorylation in the AF-1 domain of the receptor occurs. This ligand-dependent activation 
of ERα leads to genomic effects of E2/ERα and triggers the expression of ERE-dependent 
target genes. 
The aim of this study is to unravel the functional relationship of GSK-3 and ERα and 
to clarify the specific role of GSK-3 in the signalling processes related to E2-dependent ERα 
activation. A dual role of GSK-3 is postulated with reactions on ERα taking place in both the 
cytoplasm and the nucleus. In the cytoplasm, GSK-3 is assumed to interact with ERα and to 
stabilise the receptor. In the nucleus, Ser-118 is considered the major ERα phosphorylation 
site for GSK-3, phosphorylation leading to full transcriptional activity of the receptor. The 
studies are performed mainly on MCF-7 cells, a human ERα-positive breast cancer cell line. 
Furthermore, initial studies regarding GSK-3 expression in human breast cancer specimens of 
different grade are also performed, the ultimate aim being to investigate the role of the newly 
depicted GSK-3/ERα pathway for breast cancer progression. 
 
The following aspects are specifically addressed: 
• In MCF-7 cells, the rapid effects of E2 treatment on GSK-3 and ERα are first depicted by 
cellular fractionation and western blot analysis as well as immunofluorescence 
microscopy. The kinetics of GSK-3 phosphorylation and its sub-cellular localisation are 
determined upon E2 stimulation. This phosphorylation is assumed to represent non-
Introduction  34 
genomic effects of the E2/ERα signalling pathway. Additionally, the kinetics of nuclear 
translocation and Ser-118 phosphorylation of ERα are determined following E2-exposure. 
• The major part of this work is dedicated to the clarification of the role of GSK-3 in E2-
induced ERα activation in ERα-positive human breast carcinoma cell lines. Different 
methodological approaches including various chemical GSK-3 inhibitors, cellular 
transfection of GSK-3β mutants, and RNA interference using siRNA and miR specifically 
targeting GSK-3α and GSK-3β isoforms are used.  
o The impact of GSK-3 on ERα stability and proteasomal degradation is studied 
in GSK-3 silenced cells. Rescue of silenced endogenous GSK-3 using xenopus 
GSK-3 construct shows the role of the docking properties of GSK-3 regarding 
its interaction with ERα. 
o The role of GSK-3 in E2-induced ERα phosphorylation at Ser-118 is clarified 
using in vitro protein kinase assays and western blot analysis with phospho-
specific antibody. In cells and especially in cells treated with GSK-3 inhibitors 
and in GSK-3 silenced cells, immunoblots performed after cellular 
fractionation identify the cellular compartment where this reaction takes place.  
o To investigate the impact of GSK-3β on E2-dependent ERα transcriptional 
activity, ERE-controlled luciferase reporter assays and quantitative analysis of 
mRNA expression of estrogen-dependent genes (pS2, progesterone receptor) 
are performed in GSK-3 silenced cells and in cells overexpressing GSK-3β 
mutants. 
• Finally, immunohistochemical staining using a GSK-3β antibody is performed on 
formalin-fixed human breast tissue sections. The aim is to determine the expression 
pattern of GSK-3β according to the histopathological grade of tumors surgically removed 
from patients and to evaluate the relevance of GSK-3β expression for the progression of 
breast cancer. 
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III - Experimental procedures 
 
III - 1) Materials  
 
III - 1.1) Equipment 
 
▪ Name ▪ Company  
Analytical balance 2002 MP1  Sartorius, Göttingen  
Balance (max. 5500 g)  Sartorius, Göttingen  
Blotting chamber for wet blotting 
(incl. porous pads and plastic support)  Sigma, Deisenhofen  
Centrifuge GPK  Beckman Instruments, München  
Centrifuge for Eppendorf tubes Biofuge  Heraeus, Hanau  
Dichroic Mirror (XF2043) Omega, Brattleboro, VT, USA 
Gel Doc XR Bio Rad, München  
Heating block Dri Block DB3  Thermo-Dux, Wertheim  
Incubator (bacterial culture)  Heraeus, Hanau 
Luminometer Biolumat LB9505 incl. tubes  Berthold, Bad Wildbad  
Magnetic stirrer MR 2002  Heidolph, Kelheim  
Microscope (light) Leica Microsystems, Solms  
Microscope (fluorescence) Axioplan Zeiss, Oberkochen  
Microscope camera DFC 480 Leica Microsystems, Solms 
Microwave Micromat 135  AEG, Nürnberg  
Microtome  Leica Microsystems, Solms 
Multiskan Ex (Plate Reader) Thermo Fisher Scientific, Dreieich 
Neubauer hemacytometer  Schott, Hofheim  
PCR Primus96 Plus machine MWG Biotech, Martinsried 
PTC-200 Peltier Thermal Cycler  MJ Research, Miami, USA  
pH electrode InLab 410  Mettler Toledo, Steinbach  
pH meter 535 Multical  WTW, Weilheim  
Photometer Ultrospec III  Amersham Pharmacia Biotech, Freiburg 
Pipetboy acu  Integra, Hamburg  
Powersupply EPS 300  Amersham Pharmacia Biotech, Freiburg  
Refrigerated centrifuge “fresco”  Heraeus, Hanau 
SDS-PAGE Mini Protean II and III Bio-Rad, München  
Shaker for bacterial cultures  Infors HT, Stuttgart   
Spin-over rotator Bioblock  Novodirect, Kehl  
Thermomixer compact  Eppendorf, Hamburg  
Water-purification system Milli-Q  Millipore, Eschwege  
Vortex mixer  Bender u. Hobein AG, Zürich (Switzerland) 
X-ray film developer Hyperprocessor  Amersham Pharmacia Biotech, Freiburg 
 
 
III - 1.2) Chemicals and other compounds 
 
▪ Name ▪ Company  
Acetic acid  Merck, Darmstadt 
Acrylamide/bis-acrylamide, 30% solution  Sigma, Deisenhofen 
Adenosine triphosphate (ATP) Roche, Mannheim 
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Agarose Sigma, Deisenhofen 
Ammonium persulfate Merck, Darmstadt 
Ampicillin Sigma, Deisenhofen 
Bacto-agar Merck, Darmstadt 
Bovine serum albumin, 30% solution Bio Rad, München 
Braun H2O (aqua ad iniectabilia) Braun, Melsungen 
Bromophenol blue Serva, Heidelberg 
Citric acid Merck, Darmstadt 
Complete mini EDTA-free protease inhibitor   
cocktail tablet  Roche, Mannheim 
Cycloheximide (CHX) Sigma, Deisenhofen 
DC protein assay kit Bio Rad, München 
Dimethyl sulphoxide (DMSO) Merck, Darmstadt 
Dithiothreitol (DTT) Sigma, Deisenhofen 
dNTPs mix Stratagene, Amsterdam, The Netherlands 
ECL-plus reagent Amersham Pharmacia Biotech, Freiburg 
17β-estradiol (E2) Sigma, Deisenhofen 
Ethanol absolute Riedel de Haen, Seezle 
Ethidium bromide Invitrogen, Karlsruhe 
Ethylenediaminetetraacetate (EDTA) Fluka, Buchs (Switzerland) 
Fugene HD Roche, Mannheim 
Glutaraldehyde Serva, Heidelberg 
Glycerol Roth, Karlsruhe 
Glycine GERBU Biotech GmbH, Gaiberg 
HEPES GERBU Biotech GmbH, Gaiberg 
HEPES/KOH Fluka, Buchs (Switzerland) 
HistoBond adhesion microscope slides Superior Marienfeld, Lauda-Königshofen  
Hydrochloric acid (HCl) Fluka, Buchs (Switzerland) 
JetPEI™ polyplus transfection Biomol, Hamburg 
Luciferase assay reagent (LAR) Promega, Mannheim 
Lithium chloride (LiCl) Fluka, Buchs (Switzerland) 
Luciferase cell culture lysis 5 x reagent Promega, Mannheim 
2-Mercaptoethanol Sigma, Deisenhofen 
Methanol Merck, Darmstadt 
Manganese chloride (MnCl2) Merck, Darmstadt 
Magnesium chloride (MgCl2) PeqLab, Erlangen  
Magnesium sulfate (MgSO4) Sigma, Deisenhofen 
MG132 (Proteasome inhibitor) EMD Bioscience, Darmstadt 
Milk powder Fluka, Buchs (Switzerland) 
Micro RNAs (miR) Operon, Köln 
Microtome blades Thermo Fisher Scientific, Dreieich 
Oligo(dT) primers Qiagen, Hilden 
Oligofectamine Invitrogen, Karlsruhe 
Oligonucleotide PCR primers Operon, Köln 
2-nitrophenyl-β-D-galactopyranoside (ONPG) Biomol, Hamburg 
Paraformaldehyde (PFA) Merck, Darmstadt  
Para-nitrophenyl phosphate EMD biosciences, Darmstadt 
PMSF Sigma, Deisenhofen   
Poly-D-lysine BD biosciences, Erembodegem, Belgium 
Potassium chloride (KCl) Merck, Darmstadt  
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Protein A sepharose beads Sigma, Deisenhofen 
Protein phosphatase-λ EMD biosciences, Darmstadt 
PVDF-membrane Immobilon-P  Millipore, Eschwege  
Pwo-polymerase  PeqLab, Erlangen 
Recombinant rabbit GSK-3β New England Biolabs, Frankfurt 
Recombinant human estrogen receptor α (rhERα) Invitrogen, Karlsruhe 
Restriction endonucleases (Bgl II, Bam HI, Nhe I) Roche, Mannheim 
RNase inhibitor Roche, Mannheim 
SB415286 (SB4) Tocris, Ballwin, MO, USA 
SB216763 (SB2) Tocris, Ballwin, MO, USA 
Sodium azide (NaN3) Merck, Darmstadt 
Sodium chloride (NaCl) Fluka, Buchs (Switzerland) 
Sodium citrate Merck, Darmstadt 
Sodium carbonate (Na2CO3) Merck, Darmstadt 
Di-sodium-hydrogen-phosphate (Na2HPO4) Merck, Darmstadt 
Sodium dihydrogen phosphate monohydrate  
(NaH2PO4) Merck, Darmstadt 
Sodium dodecyl sulfate (SDS) Serva, Heidelberg 
Sodium fluoride (NaF) Merck, Darmstadt 
Sodium hydroxide (NaOH) Riedel de Haen, Seezle 
Sodium molybdate  Sigma, Deisenhofen 
Sodium orthovanadate (Na3VO4) Sigma, Deisenhofen  
Spectinomycin Sigma, Deisenhofen 
Superscript II reverse transcriptase Invitrogen, Karlsruhe 
SYBR green supermix Bio Rad, München 
T4 DNA ligase Promega, Mannheim 
Taq-polymerase Invitrogen, Karlsruhe 
N,N,N’,N’-tetramethyl ethylenediamine (TEMED) Serva, Heidelberg 
Tris-base Sigma, Deisenhofen 
Tris-HCl Roth, Karlsruhe 
Triton X-100 Serva, Heidelberg 
Trypan blue Biochrom, Berlin 
Trypton Difco, Detroit, USA 
Tween-20 GERBU, Gaiberg 
Yeast extract Difco, Detroit, USA 
X-ray film  Konica, Tokyo (Japan) 
Xylene Fluka, Buchs (Switzerland) 
 
Disposable materials such as laboratory plastic and reaction tubes were purchased from 
Becton Dickinson (Franklin Lakes, New Jersey, USA), Bio-Rad (München) Eppendorf 
(Hamburg), Greiner (Frickenhausen) and Sarstedt (Nümbrecht).  
 
 
III - 1.3) Solutions and media for bacterial culture  
 
▪ Specification ▪ Composition 
 
▪ LB medium (pH 7,4) 1 % (w/v) NaCl 
 1 % (w/v) Yeast extract 
 0,5 % (w/v) Trypton 
  in distilled H2O 
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▪ LB agar (pH 7,4) 1,5 % (w/v) bacto-agar in LB medium 
 100 µg/ml Ampicillin 
 
▪ Ampicillin stock solution 10 mg/ml Ampicillin in distilled H2O 
 
▪ Spectinomycin 10 mg/ml Spectinomycin in distilled H2O 
 
 
III - 1.4) Molecular biology kits 
 
Kit Description Company 
One Shot TOP10 chemically 
competent cells 
Transformation of bacteria with plasmid DNA to 
amplify the vector construct Invitrogen, Karlsruhe 
QIAprep miniprep/maxiprep Plasmid DNA extraction from bacteria Qiagen,  Hilden 
QIAquick gel extraction Extraction of nucleotide fragments from agarose gels 
Qiagen,  
Hilden 
QIAquick PCR purification and 
nucleotide removal 
To cleanup DNA fragments from enzymatic 
reactions 
Qiagen,  
Hilden 
QuickChange site-directed 
mutagenesis kit 
To make point mutations, switch amino acids, 
delete or insert single or multiple amino acids in a 
vector construct sequence 
Stratagene, 
Amsterdam,  
The Netherlands 
RNeasy Extraction of total RNA from cells or tissues Qiagen,  Hilden 
BLOCK-iT Pol II miR RNAi 
expression vector kits 
Gateway-adapted expression vector for the RNAi 
analysis of a target gene in mammalian cells Invitrogen, Karlsruhe 
 
Table III - 1: Commercially available kits. 
 
 
III - 1.5) Plasmid constructs 
 
Figure III - 1: pcDNA3.1 construct map. GSK-3β was cloned in a pcDNA3.1(+) vector from 
Invitrogen and tagged with 2 x Flag. The restriction enzymes used are written in italics at the 
beginning and the end of every inserts (adapted from pcDNA3.1 Vectors Datasheet, Invitrogen). 
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Plasmid name Vector Insert Plasmid size [bp] Source 
pcDNA GSK-3β 
WT pcDNA3.1/2xFlag Human GSK-3β 6793 Senad Medunjanin 
pcDNA GSK-3β 
CA pcDNA3.1/2xFlag 
Human GSK-3β 
S9A 6793 Senad Medunjanin 
pcDNA GSK-3β 
R96A pcDNA3.1/2xFlag 
Human GSK-3β 
R96A 6793 - 
pcDNA GSK-3β 
R96K pcDNA3.1/2xFlag 
Human GSK-3β 
R96K 6793 - 
pCMV β-gal pCMV-Script β-galactosidase 7164 Margit Klier 
pCS2+ GSK-3β 
WT pCS2+ Xenopus GSK-3β 5400 Gary Davidson 
pCS2+ GSK-3β 
DN pCS2+ 
Xenopus GSK-3β 
Dominant Negative 5400 Gary Davidson 
 
Table III - 2: Expression plasmid DNA constructs. 
 
 
 
Figure III - 2: pcDNA6.2-GW/EmGFP-miR construct map. Double stranded microRNA 
oligonucleotides (miR-ds oligo) targeting GSK-3β were inserted into pcDNA6.2-GW/EmGFP vector 
(adapted from BLOCK-iT Pol II miR RNAi expression vector kits datasheet, Invitrogen). 
 
 
Plasmid 
name Vector miR-ds oligo sequence (5’ → 3’) 
Plasmid 
size [bp] 
CT miR 
pcDNA6.2-
GW/EGFP-
miR 
Top strand: TGCTGTTAACTAAACCATTAACCACCGTTTTGGCCA 
Bottom strand: CCTGTTAACTAAACCTAACCACCGTCAGTCAGTGGC 5735 
GSK-3β  
miR 741 
pcDNA6.2-
GW/EGFP-
miR 
Top strand: TGCTGTAGATGATTTAGGACTTGGGAGTTTTGGCCACT 
GACTGACTCCCAAGTTAAATCTCTA 
Bottom strand: CCTGTAGATGATTTAACTTGGGAGTCAGTCAGTGGC 
CAAAACTCCCAAGTCCTAAATCATCTAC 
5762 
GSK-3β  
miR 599 
pcDNA6.2-
GW/EGFP-
miR 
Top strand: TGCTGTTATATTTTCCTCGGGGATTTGTTTTGGCCACTG 
ACTGACAAATCCCCGGAAAATATAA 
Bottom strand: CCTGTTATATTTTCCGGGGATTTGTCAGTCAGT GGC 
CAAAACAAATCCCCGAGGAAAATATAAC 
5762 
GSK-3β  
miR 1839 
pcDNA6.2-
GW/EGFP-
miR 
Top strand: TGCTGTAAATTCTGTGTAGTTTGGGTGTTTTGGCCACTG 
ACTGACACCCAAACCACAGAATTTA 
Bottom strand:  CCTGTAAATTCTGTGGTTTGGGTGTCAGTCAGTGGC 
CAAAACACCCAAACTACACAGAATTTAC 
5762 
 
Table III - 3: microRNA expression vectors. The negative control (CT miR) targeting a mouse brain 
receptor (GPR54) was kindly provided by Milen Kirilov and was used as reference. GSK-3β miR 741, 
GSK-3β miR 599 and GSK-3β miR 1839 were designed to target the human GSK-3β.   
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III - 1.6) Small interfering RNA (siRNA) sequences 
 
Targets siRNA references and/or sequences Company 
GL3 Luciferase GL3 duplex siRNA Dharmacon, Lafayette, CO, USA 
GSK-3α/β Signal Silencing GSK-3α/β siRNA New England Biolabs, Frankfurt 
GSK-3α Signal Silence GSK-3α siRNA New England Biolabs, Frankfurt 
GSK-3β validated siRNA (ID # 42839) Ambion, Austin, TX, USA 
GSK-3β siRNA duplex: 5’-AUCUUUGGAGCCACUGAUU-3’ (Phiel et al. 2003) Dharmacon, Lafayette, CO, USA 
 
Table III - 3: List of siRNA constructs. 
 
 
 
III - 1.7) PCR primers 
 
Name Specificity Organism Length [N] Sequence (5’ → 3’)   
Tm 
[°C] 
SYBR β-actin Fwd β−actin H. Sapiens 18 CCAACCGCGAGAAGATGA 59,9 
SYBR β-actin Rev β−actin H. Sapiens 20 CCAGAGGCGTACAGGGATAG 64,5 
SYBR ERα Fwd ERα H. Sapiens 20 TTACTGACCAACCTGGCAGA 60,4 
SYBR ERα Rev ERα H. Sapiens 20 ATCATGGAGGGTCAAATCCA 58,4 
SYBR GSK-3β Fwd GSK-3β H. Sapiens 21 GACATTTCACCTCAGGAGTGC 62,6 
SYBR GSK-3β Rev GSK-3β H. Sapiens 20 GTTAGTCGGGCAGTTGGTGT 62,5 
GSK-3β WT Fwd GSK-3β H. Sapiens 34 
TATAGCTAGCATGTCAGGGCGGC
CCAGAACCACC 64,2 
GSK-3β WT Rev GSK-3β H. Sapiens 34 
TATAAGATCTGGAGGAGTTGGAA
GCTGATGCAGA 58,1 
GSK-3β R96A Fwd GSK-3β R96A 
H. 
Sapiens 25 
GCGATTTAAGAACGCAGAGCTCC
AG 66,2 
GSK-3β R96A Rev GSK-3β R96A 
H. 
Sapiens 25 
CTGGAGCTCTGCGTTCTTAAATC
GC 66,2 
GSK-3β R96K Fwd GSK-3β R96K 
H. 
Sapiens 28 
GCGATTTAAGAACAAAGAGCTCC
AGATC 64,6 
GSK-3β R96K Rev GSK-3β R96K 
H. 
Sapiens 28 
GATCTGGAGCTCTTTGTTCTTAAA
TCGC 64,6 
SYBR pS2 Fwd pS2 H. Sapiens 20 ATACCATCGACGTCCCTCCA 62,5 
SYBR pS2 Rev pS2 H. Sapiens 20 AAGCGTGTCTGAGGTGTCCG 64,5 
SYBR PR Fwd PR  Receptor 
H. 
Sapiens 18 GGCATGGTCCTTGGAGGT 62,2 
SYBR PR Rev PR  Receptor 
H. 
Sapiens 18 CAATGGCTGTGGGAGAGC 62,2 
 
Table III - 4: Oligonucleotides used for PCR and quantitative real-time PCR. 
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III - 1.8) Buffers and solutions for agarose gel electrophoresis 
 
▪ Specification Composition 
 
▪ TAE buffer (50 x, 1l) 2 M Tris 
 57 ml Glacial Acetic Acid 
 100 ml 0,5 M EDTA (pH 8,0) 
  in distilled H2O 
 
▪ Ethidium Bromide 10 mg/ml (Invitrogen) 
▪ TE buffer (pH 8,0) 10 mM Tris-HCl 
 1 M EDTA 
 
▪ Agarose gel (100 ml) 1 g Agarose (Sigma) in 1 x TAE buffer (DNA)  
  
▪ Sample Buffer (6 x) 100 mM EDTA (pH 8,0) 
 30 % (v/v) Glycerol 
 0,025 % Bromophenol Blue 
 0,025 % Xylene Cyanol 
 
▪ DNA marker DNA molecular weight marker VII and XVI (Roche) 
 
 
III - 1.9) Cell culture equipments and chemicals 
 
▪ Name ▪ Company  
Dextran 60 Serva, Heidelberg 
Dulbecco’s MEM, 3,7 g/l NaHCO3,  
4,5 g/l D-glucose, phenol-red free, glutamine-free,  
pyruvate-free (DMEM) Biochrom, Berlin 
EDTA 1 % (w/v) in PBS Biochrom, Berlin 
Falcon tissue culture plates 
(96-wells, 6 wells and 10 cm diameter) Becton Dickinson, Heidelberg 
Falcon tubes (15 ml, 50 ml) polystyrene Becton Dickinson, Heidelberg 
Foetal calf serum (FCS) Biochrom, Berlin 
Humidified CO2 incubator  Forma Scientific, Labotech Göttingen 
L-glutamine, 200 mM Biochrom, Berlin 
Norrit A (charcoal) Serva, Heidelberg 
Penicillin/streptomycin  
(10.000 U/10.000 µg/ml) Biochrom Berlin 
RPMI 1640, phenol-red free, glutamine-free,  
pyruvate-free (RPMI) PAA, Linz, Austria 
Sodium pyruvate (1 M) Biochrom, Berlin) 
Sterile bench Heraeus, Hanau 
Trypsin/EDTA, 0,05 %/0,02 % (w/v) in PBS Biochrom, Berlin 
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III - 1.10) Cell lines  
 
Cell line Medium Source - Description 
MCF-7 DMEM Human (ER+) epithelial breast adenocarcinoma cells derived from metastatic pleural effusion (DSMZ, Braunschweig) 
MELN DMEM MCF-7 cells (ER+) stably transfected with ERE-controlled luciferase reporter plasmid  (Le Bail et al., 1998) 
T47D RPMI Human (ER+) epithelial breast ductal carcinoma cells derived from metastatic pleural effusion  (ATCC, Wesel) 
BT-474 RPMI Human (ER+) epithelial breast ductal carcinoma cells isolated from solid invasive tumour  (ATCC, Wesel) 
 
Table III - 5: Culture cell lines used. 
 
 
III - 1.11) Solutions and media for cell culture  
 
▪ Specification ▪ Composition 
 
▪ M2 phenol-red free DMEM or RPMI 
 100 U/ml resp. 100 µg/ml  Penicillin/Streptomycin  
 10 %  FCS  
 1 mM  sodium pyruvate  
 2 mM  L-glutamine  
 
▪ M3 phenol-red free DMEM or RPMI 
 100 U/ml resp. 100 µg/ml  Penicillin/Streptomycin  
 10 %  dextran-coated charcoal-treated FCS (DCC-FCS) 
 1 mM sodium pyruvate  
 2 mM L-glutamine  
  
▪ M4 phenol-red free DMEM 
 100 U/ml resp. 100 µg/ml  Penicillin/Streptomycin  
 1 mM sodium pyruvate  
 2 mM  L-glutamine  
 
▪ DCC solution 0,01 M Tris-HCl (pH 8,0) 
 0,25 % (w/v)  Charcoal Norrit A 
 0,0025 % (w/v)  Dextran 60 
  in distilled H2O 
 
▪ EDTA 1 %  EDTA in PBS  
 
▪ Trypsin/EDTA 0,05 %  Trypsin 
 0,02 %  EDTA in PBS 
 
▪ PBS (10x) 0,86 M NaCl 
 0,58 M Na
2 
HPO
4 
 0,17 M NaH
2
PO
4 
x 2H
2
O 
  in distilled H2O 
  (pH 7,4 was adjusted in 1 x PBS working solution) 
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▪ Lysis Buffer 50 mM  HEPES (pH 7,6) 
 150 mM  NaCl  
 1,5 mM  MgCl2  
 10 mM  Na4P2O7 x 10 H2O 
 2 mM  EDTA  
 10 % (v/v)  Glycerol  
 1,5 % (v/v)  Triton X-100  
 100 mM  Na-Fluoride  
 2,7 mM  Na-Orthovanadate (Na3VO4) 
 1 (/10 ml) Protease Inhibitor Cocktail Tablet  
  in distilled H2O 
 
▪ Buffer I  10 mM  HEPES/KOH (pH 7,9)  
 1,5 mM  MgCl2
 10 mM  KCl 
 0,5 mM  DTT  
 0,2 mM  PMSF 
 1 mM  Na3VO4  
 1 (/10 ml) Protease Inhibitor Cocktail Tablet  
  in distilled H2O 
 
▪ Buffer II 20 mM  HEPES/KOH (pH 7,9) 
 1,5 mM  MgCl2  
 420 mM  NaCl  
 0,2 mM  EDTA  
 0,5 mM  DTT  
 0,2 mM  PMSF  
 1 mM  Na3VO4  
 0,5 % (v/v)  Glycerol  
 in distilled H2O 
 
 
III - 1.12) Buffers and solutions for western blot  
 
▪ Specification ▪ Composition 
 
▪ Sample buffer (5 x) 50 mM Tris-HCl (pH 6,7) 
 200 mM  DTT  
 2 %  SDS  
 2,5 %  Glycerol 
 0,1 %  Bromophenol blue  
 1,75 M β-Mercaptoethanol 
 
▪ TBS (10 x) 0,1 M Tris-HCl (pH 7,6)  
 1,5 M NaCl 
 
▪ TBS/T 1 x  TBS 
 0,1 % Tween  
 
▪ Tris-buffer  1,5 M Tris-HCl (pH 8,8) 
(stacking gel)  0,4 % SDS 
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▪ Tris-buffer  1 M Tris-HCl (pH 6,8)  
(separation gel) 0,4 % SDS 
 
▪ Acrylamide solution 30:0,8  acrylamide/bisacrylamide 
 
▪ APS 10 % (w/v) Ammonium Persulfat in distilled H2O  
 
▪ SDS-PAGE gel  4,02 ml H2O 
(10 %, 2 mini gels) 3,3 ml  30 % acrylamide solution 
 2,5 ml  1,5 M Tris (pH 8,8)   
 100 µl 10 % SDS  
 50 µl 10 % Ammonium Persulfat   
 30 µl  Temed  
 
▪ Stacking gel  3 ml H2O 
(5 %, 2 mini gels) 0,66 ml  30 % acrylamide solution 
 1,26 ml  1 M Tris (pH 6,8)   
 50 µl 10 % SDS  
 38 µl 10 % Ammonium Persulfat   
 30 µl  Temed  
 
▪ Running buffer (1 x) 25 mM Tris-HCl (pH 8,3) 
 250 mM Glycine 
 0,1 % SDS 
 
▪ Protein Standard Protein All Blue precision plus standard (Bio-Rad) 
 
▪ Transfer buffer 50 mM Tris-base 
 380 mM Glycine 
 20 % Methanol 
 
▪ Blocking buffer 5 % Non-fat dry milk in TBS/T 
   
▪ Stripping buffer 62 mM Tris-HCl (pH 6,7) 
 7,18 ml β-Mercaptoethanol 
 200 ml 10 % SDS  
  adjust to 1 l with distilled H2O 
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III - 1.13) Antibodies 
 
III - 1.13.1) Primary antibody 
 
Specification Clone Species Sub-class 
Dilution 
      WB            IF         IHC 
Company 
supplier 
α β-actin AC-15 mouse monoclonal IgG 1:200000 - - 
Abcam  
Cambridge, UK 
α β-catenin  rabbit polyclonal IgG 1:500 - - 
Cell Signalling 
NEB, Frankfurt 
α phospho-β-catenin 
(Ser-33/37/Thr-41)  
rabbit 
polyclonal IgG 1:500 - - 
Cell Signalling 
NEB, Frankfurt 
α cyclin D1 H-295 rabbit polyclonal IgG 1:200 - - 
Santa Cruz Biot. 
Heidelberg 
α phospho-cyclin D1 
(Thr-286)  
rabbit 
polyclonal IgG 1:750 - - 
Cell Signalling 
NEB, Frankfurt 
α ERα HC-20 rabbit polyclonal IgG 1:1000 1:100 - 
Santa Cruz Biot. 
Heidelberg 
α ERα 6F11 mouse monoclonal  IgG 1:1000 - - 
Novocastra 
Newcastle, UK 
α phosphor-ERα 
(Ser-118) 16J4 
mouse 
monoclonal  IgG 1:5000 1:100 - 
Cell Signalling 
NEB, Frankfurt 
α Flag-tag  mouse monoclonal IgG 1:20000 - - 
Sigma       
München 
α GSK-3α/β  mouse monoclonal IgG 1:50000 1:100 - 
Biosource  
Solingen 
α GSK-3β  rabbit monoclonal  IgG 1:800 - 1:100 
Cell Signalling 
NEB, Frankfurt 
α phospho-GSK-3α/β 
(Ser-21/9)  
rabbit 
polyclonal IgG 1:800 1:100 - 
Cell Signalling 
NEB, Frankfurt 
α RPA / p34 
(replication protein ) 
9H8 or 
34A 
mouse 
monoclonal IgG 1:200 - - 
Lab Vision        
CA, USA 
α β-tubulin 2G10 mouse monoclonal IgG 1:10000 - - 
Upstate            
NY, USA 
α ubiquitin  rabbit polyclonal IgG 1:1000 - - 
DAKO      
Glostrup Denmark 
 
Table III - 6: List of primary antibodies. 
 
 
 
 
III - 1.13.2) Secondary/labelled antibody 
 
Enzyme/dye Specificity Species Sub-class WorkingDilution  
Company 
supplier 
HRP α mouse goat IgG 1:5000 (WB) Dianova    Hamburg 
HRP α rabbit goat IgG 1:20000 (WB) Dianova    Hamburg 
Alexa 488 α mouse goat IgG 1:400 (IF) Invitrogen Karlsruhe 
Cy3 α rabbit goat IgG 1:300 (IF) Invitrogen Karlsruhe 
 
Table III - 7: List of secondary antibodies. 
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III - 1.14) Buffers and solutions for β-galactosidase activity measurement  
 
▪ Specification ▪ Composition 
 
▪ LacZ reaction buffer 100 mM  Na-Phosphate pH 7,4 
10 mM  KCl 
1 mM  MgSO4
Add freshly β-Mercaptoethanol (35µl/10ml LacZ reaction 
buffer) 
 
▪ ONPG solution 100 mM  Na-Phosphate pH 7,0 
4 mg/ml  ONPG 
 
▪ Stop solution 1 M  Na2CO3
 
 
III - 1.15) Buffers and solutions for immunofluorescence analysis  
 
▪ Specification ▪ Composition 
 
▪ Fixation buffer 4 % (w/v) PFA in PBS 
  Dissolved at 65°C and sterile filtrated 
 
▪ Permeabilisation buffer 0,2 % Triton X-100 in PBS 
 
▪ Blocking buffer 1 % BSA in PBS 
 
▪ Mounting media Elvanol (Merck) 
  
 
III - 1.16) Buffers and solutions for immunohistochemistry  
 
▪ Specification ▪ Composition 
 
▪ Citrate buffer 0,01 M Sodium citrate/citric acid (pH 6,0) 
 
▪ Blocking buffer 5 % BSA in PBS 
 
▪ 2ary Antibody staining LSAB2-kit (DAKO, Glostrup, Denmark) 
 
▪ Counter staining Haematoxylin (Mayer’s Hemalum, AppliChem, Darmstadt) 
 
▪ Eosin 0,5 % Eosin Y (Merck, Darmstadt) 
 1 drop Acetic Acid 
  adjust to 100 ml with distilled H2O 
 
▪ Mounting media Kaiser’s glycerol/gelatin (Merck, Darmstadt) 
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III - 2) Methods  
 
III - 2.1) Molecular biology 
 
III - 2.1.1) RNA isolation and cDNA synthesis 
After treatment, cell pellets were collected by trypsinisation and total RNA was 
isolated with the RNeasy kit. First, the cell pellets were thoroughly resuspended in lysis buffer 
and homogenised by passing the cells through a RNase-free 20-gauge needle using a syringe. 
70 % ethanol was added and the lysate was loaded onto RNeasy mini column. After 
centrifugation and washing, the RNA retained in the column was eluted in RNase-free water. 
The RNA concentration was determined and the samples were stored at - 80°C. 
1 µg RNA was reverse transcribed using 10 µg/ml (final concentration) oligo(dT) 
primers. After incubation of RNA/oligo(dT) mix (74°C, 4 min), a mastermix containing at 
final concentration 0,02 M DTT, 2 U/µl protector RNase inhibitor, 0,5 mM dNTPs, 
1 x enzyme buffer and 10 U/µl SuperScript II reverse transcriptase was added. After 
incubation program (37°C, 2 min; 42°C, 5 min; 50°C, 1 h and 65°C, 15 min), cDNA was 
purified with the QIAquick PCR purification kit and stored at – 20°C. 
 
III - 2.1.2) Determination of nucleic acid concentration 
A dilution (1/20 to 1/100) in Braun H2O was performed on all the nucleic acid 
samples. Diluted samples were placed in a silica cuvette. Absorbance was then read against a 
Braun H2O blank with a spectrophotometer at 260 nm and 280 nm.  
Assuming that an absorbance of one unit at 260 nm is equivalent to 40 ng/µl of single 
stranded RNA, the following equation was applied to calculate the RNA concentration in the 
samples: 
 
 [RNA in µg/ml] = λ260nm x dilution factor x 40  
   
Assuming that an absorbance of one unit at 260 nm is equivalent to 50 ng/µl double 
stranded DNA, the following equation was applied to calculate the DNA concentration in the 
samples:   
  
[DNA in µg/ml] = λ260nm x dilution factor x 50  
 
A ratio of λ260 nm /λ280 nm between 1.5 and 2.0 indicates a satisfactory purity of the 
DNA or the RNA extracted. 
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III - 2.1.3) Polymerase chain reaction (PCR) 
Specific PCR thin wall tubes with flat caps (Scientific-labs) were used. 2 µl of cDNA 
were mixed with a mastermix composed of 1 x polymerase buffer, 1,25 mM MgCl2, 0,15 mM 
dNTPs, 0,4 µM forward (Fwd) primer, 0,4 µM reverse (Rev) primer at final concentration and 
volume was adjusted with Braun H2O. Finally, 0,02 U/µl polymerase was added and the tubes 
were placed into PCR thermal cycler. The cycler program depends on the primers, the 
polymerase and the final product expected. For the selection of gene-specific primers an 
online application “Primer3 application” (Whitehead Institute for Biomedical Research, 
http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) was used. This program gives 
advice on the required annealing temperature. Primers were synthesised by Operon. Indeed, 
each cycle of the program is constituted by a DNA denaturation step at 94°C, an annealing 
step (generally between 55°C and 65°C depending on the set of primers) and an extension 
step at a temperature depending on the polymerase used (72°C for the Taq-polymerase). 
Cycle number was generally set to 25-35 in the case of semi-quantitative RT-PCR analysis to 
check the cDNA synthesised and to compare the expression levels of RNA after different 
treatments of the cells. For cloning, sequences were amplified up to 40 cycles using Pwo 
polymerase which contained a proof-reading activity. The amplified DNA was finally 
checked with an agarose gel electrophoresis after determination of the DNA concentration.  
For quantitative PCR, optimal sets of primers were designed for each studied gene 
using the “ProbeFinder” (Roche Applied Bioscience) website interface 
(http://qpcr2.probefinder.com) and synthesised by Operon. Quantitative PCR using 5 µl 
cDNA (from 1:10 dilution), 1 µl SYBR Fwd primer (from 10 µM stock), 1 µl SYBR Rev 
primer (from 10 µM stock), 3 µl MgCl2 (from 25 mM stock) and 10 µl of iQ SYBR Green 
supermix were performed following the manufacturers’ instructions on PTC-200 Peltier 
Thermal Cycler and the MJ OpticonMonitor analysis software, version 3.1 (Bio Rad).  
  
III - 2.1.4) Agarose gel electrophoresis 
PCR samples were run on a 1 % (w/v) agarose gel. In a sterilised beaker, 1 g of 
agarose was added to 100 ml of 1 x TAE (for DNA), heated in a microwave oven, and 4µl of 
ethidium bromide was added to the agarose solution after it cooled down (around 60°C). 
Then, the solution was poured into a gel tray with slot former (comb). When the gel had 
polymerised, it was placed in an electrophoresis tank filled with running buffer. The DNA 
ladder and the samples supplemented with 1 x loading buffer (final concentration) were 
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loaded onto the gel and separated by electrophoresis (100 V, 1 h). The gel was finally 
observed using UV light and photographed (Gel Doc XR device and software, Bio Rad).   
 
III - 2.1.5) Cloning using restriction endonucleases 
For the directed cloning of DNA sequences, the insert sequence extremities were 
flanked during PCR by two different restriction sites. The two class II restriction 
endonucleases specific for these sites were used also for linearization of the pcDNA3.1 vector 
to create “sticky ends”.  The restriction of the vector and the insert sequence was carried out 
overnight (O/N) at 37°C and stopped by heating for 10min at 65°C. Then, the DNA was 
purified from short oligonucleotides using the nucleotide removal kit for the insert sequence. 
Gel electrophoresis was performed to get rid of undigested vector. The linearized vector was 
excised from the gel and purified with the QIAquick Gel Extraction Kit. Subsequently, insert 
and vector were added to a ligation reaction mix in an appropriate molar ratio (usually 3:1) 
and ligation was carried out O/N at 16°C using T4 DNA ligase. After stopping the reaction by 
heating at 65°C for 10 min the ligation product was ready for transformation of competent 
bacteria.  
 
III - 2.1.6) Cloning of DNA expression vectors with miR for RNAi 
Cloning of micro RNAs (miR) into DNA expression vectors for RNAi (RNA 
interference) was performed using the BLOCK-iT Pol II miR RNAi expression vector kit. 
First, candidates micro RNA (miR) targeting GSK-3β were selected using the Wadsworth 
Bioinformatics Centre website interface (http://sfold.wadsworth.org). Then, complementary 
DNA oligonucleotides containing the sequence coding for the required miR were designed 
following the manual’s instructions from the kit mentioned above and synthesised by Operon. 
After annealing of the DNA oligonucleotides, the resulting dsDNA was cloned into the 
pcDNA6.2-GW/EmGFP expression vector using T4 DNA ligase (provided in the kit) and 
competent bacteria were transformed.  
 
III - 2.1.7) Single or multiple site mutations  
To analyse the effects of amino acids changes on the functions of proteins and 
especially kinases, single or multiple site mutations were performed using the QuickChange 
site-directed mutagenesis kit. A proof-reading Pfu Turbo DNA polymerase was used to 
replicate both plasmid strands with high fidelity without displacing the mutant oligonucleotide 
primers. Indeed, plasmid constructs containing the wild-type inserts were amplified by PCR 
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with two synthetic oligonucleotide primers containing the desired mutation. Each primer was 
extended by the polymerase and the mutant plasmid products were treated with DpnI. This 
endonuclease will digest the parental non-mutated DNA. Then, the vector containing the 
desired mutation will be transformed into supercompetent cells, amplified and finally 
analysed by sequencing.  
 
III - 2.1.8) Transformation of competent bacteria with plasmid DNA 
1-10 µl of ligation reaction or 1 µl (1-10 ng) of purified plasmid DNA were added on 
competent TOP10 bacteria previously thawed on ice. After gentle mix, the bacteria 
suspension was incubated for 30 min on ice. Then, the bacteria were submitted to a heat shock 
at 42°C for 42 sec and placed on ice for 2 min. 250µl of pre-warmed SOC medium was added 
and the bacteria were incubated (37°C for 60 min). 100µl of transformed bacteria were plated 
on LB-antibiotic agar plates and incubated O/N at 37°C.  
 
III - 2.1.9) DNA mini- and maxi-prep 
Isolated transformed bacteria colonies were amplified in 5 ml or 200 ml LB-antibiotic 
culture media, respectively for mini-prep and maxi-prep. After O/N incubation (37°C, 
225 rpm), the bacteria were centrifuged (10 min at 6000 x g, 4°C). A glycerol stock of 
transformed bacteria can be stored at - 80°C for later amplification (850 µl of bacterial culture 
with 150 µl of 100 % glycerol). From the bacterial pellet, mini-prep and maxi-prep were 
performed according to the manufacturer’s instruction (Qiagen kits). The extracted plasmid 
DNA was dissolved in TE buffer and stored at - 20°C. For each purified construct, the insert 
DNA sequence was determined by A. Hunziker (Oligonucleotides synthesis and DNA 
sequencing group, DKFZ) and checked by comparison of nucleotide sequences alignment 
using the “Heidelberg UNIX Sequence Analysis Resources” (HUSAR, http://genome.dkfz-
heidelberg.de) interface and database research (National Centre for Biotechnology 
Information, http://www.ncbi.nlm.nih.gov) 
 
III - 2.2) Cell culture 
 
III - 2.2.1) Cell culture media and treatments 
MCF-7 and MELN cells were maintained routinely (5 % CO2, 37°C) in M2 medium. 
To freeze the cells in liquid nitrogen (Working stock in Nunc cryovial, 1 x 106 cells/ml/vial), 
10 % DMSO in M2 medium was added to trypsinised cells and the following freezing steps 
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were performed: 2 h on ice, 6 h at - 20°C, 24 h at - 80°C (at this temperature, the cells can 
also be stored for 6 months) and finally in liquid nitrogen tank for long-term storage.  
Prior to experimental use, cells maintained in M2 medium were grown for 72 h in M3 
medium. M3 medium was supplemented with 10 % DCC-FCS. The serum was prepared as 
described by Migliaccio et al. (1993). The DCC suspension was centrifuged for 10 min at 
15000 x g. 500 ml FCS was mixed with the pellet obtained from 1 l of DCC suspension and 
incubated at 56°C for 30 min in order to remove the steroids. Then, the DCC-FCS was 
centrifuged for 10 min at 15000 x g. The supernatant was collected and the procedure was 
repeated once more, but the incubation was this time performed at 37°C. Finally, the collected 
serum was filtered using a 0,22 µm pore size filter, aliquoted and frozen at -20°C.  
If not indicated, the following standard protocol was used. 3 x 105 cells were plated in 
6-well plates and grown for 24 h in M3 medium. Prior to hormonal treatment with 10 nM or 
100 nM E2, M4 medium was added to the cells for 24 h and cells were kept in this medium 
until the end of the experiment. 1 h or 6 h prior to long term (6 h) and short term (20 min) E2 
treatment, respectively, 5 µM (final concentration) of proteasome inhibitor MG132 was 
added. 50 µg/ml (final concentration) of translation inhibitor cycloheximide was added 1 h 
prior to hormonal treatment. Different GSK-3β inhibitors were tested by direct addition to the 
cell culture media. The cells were treated with 30 mM LiCl, 30 µM of SB415286 and 5 µM of 
SB216763 for the time point indicated in each experiment.  
 
III - 2.2.2) Cell proliferation study 
After different treatment times, the cells were collected by trypsinisation and 
resuspended in medium. Cell number was determined after staining an aliquot of the cell 
suspension by addition of 0,05 % (w/v) Trypan Blue solution (1:2 ratio). Under the 
microscope in a bright-line hemacytometer, living cells respectively white cells were counted 
to obtain the number of cells per ml. Counting the cells at various time points will allow to 
draw a proliferation curve of the cells according to the treatment.   
 
III - 2.2.3) Lysis of cells  
After treatment and washing with PBS, the cells were scraped off the culture dish in 
cold PBS. Then, the cells were transferred into sterile Eppendorf tubes and centrifuged for 
5 min at 2000 rpm, 4°C. The supernatant was discarded. For total cell lysate preparation, cell 
pellet was suspended in ice-cold lysis buffer, incubated on ice for 30 min and centrifuged for 
10 min at 13000 rpm, 4°C. The supernatant represents the lysate and it was stored at - 80°C.  
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III - 2.2.4) Preparation of cytoplasmic and nuclear cell extracts 
After treatment, a cell pellet was obtained (cf. lysis of cells). Cells were incubated on 
ice for 15 min in hypo-osmotic Buffer I, homogenized using a glass potter and centrifuged 
(2000 × g, 5 min). The resulting pellets were used later to generate nuclear extracts. The 
supernatants were centrifuged (10000 × g, 30 min) and the resulting supernatants were used 
as the cytoplasmic extracts. The nuclear pellets obtained after the first centrifugation step 
were resuspended in hyper-osmotic Buffer II. After 15 min incubation on ice, nuclear debris 
were pelleted by centrifugation (10000 × g, 30 min) and the resulting supernatants represented 
the nuclear protein extracts. The cytoplasmic and nuclear extracts were stored at - 80°C.  
 
III - 2.2.5) Transient transfection of cells with plasmids DNA 
MELN cells were transiently co-transfected with β-galactosidase reporter gene and 
with GSK-3β construct. Several GSK-3β constructs were analysed. GSK-3β WT (Wild Type) 
was the naturally occurring form of the enzyme. The constitutively active or CA form was 
obtained by mutation of the Ser-9 by an Ala (S9A). The mutation of Arg-96 to Ala (R96A) or 
Lys (R96K) abolished GSK-3β activity toward primed substrates, but not unprimed substrates 
(Frame et al., 2001). Cells were transiently transfected with plasmid DNA using the jetPEI™ 
reagent. This cationic polymer transfection reagent compacts DNA into positively charged 
particles capable of interacting with anionic proteoglycans at the cell surface and entering 
cells by endocytosis. This reagent also protects DNA from degradation in the cytoplasm. 
Following the instruction delivered by the jetPEI™ reagent company, plasmid DNA and 
jetPEI reagent were mixed into 150 mM NaCl and incubated at RT for 15 min. The volume of 
jetPEI™ added was proportional to the amount of DNA (2 µl of jetPEI™ for 1 µg of DNA). 
2,8 µg of GSK-3β plasmid DNA and 0,2 µg of β-galactosidase plasmid DNA were added per 
well. Without changing the medium, 200 µl of jetPEI/DNA complexes in NaCl were added to 
each well. After 18 h incubation, the medium was replaced with new M3 medium. Then, cells 
were treated for 48 h with 10 nM E2 and lysates were analysed by Western blot and luciferase 
assay.  
 
III - 2.2.6) Transient transfection of cells with siRNA 
MCF-7, MELN, T47D and BT-474 cells were transfected with 50 nM siRNA using 
Oligofectamine (6 µl per well of 6 wells/plate). Luciferase GL3 duplex siRNA was used as a 
control. Experiments have shown that GL3 duplex siRNA did not interfere with luciferase 
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expression in MELN cells. Signal Silencing GSK-3α/β siRNA were used to target both 
GSK-3 isoforms. GSK-3α isoform was specifically targeted by Signal Silence GSK-3α 
siRNA and GSK-3β isoform was specifically targeted using either siRNA duplex from 
Dharmacon or validated siRNA from Ambion. At 18 h post-transfection, the medium was 
replaced first for 24 h with M3 medium and then with M4 medium for another 24 h. After 
short-term (20 min) or long-term (3 h to 48 h) E2 treatment, lysis of the cells, cytoplasmic and 
nuclear extractions, or total RNA isolation were performed. 
 
III - 2.2.7) Transient transfection of cells with miR expression vectors 
Isolated DNA plasmid coding for candidate miRs were transiently transfected into 
MCF-7 and MELN cells using FuGENE HD reagent (ratio 2:6 or 5 µg of DNA plasmid for 
15 µl of FuGENE HD per well of 6 wells/plate). At 18 h post-transfection, the medium was 
replaced with new M3 medium and 48 h later, the cells were harvested or lysed. The 
transfection efficiency was checked by fluorescent microscope analysis of GFP expression 
(excitation: 487 nm; emission: 509 nm) in the cells. For rescue study, 5 µg of xenopus 
GSK-3β constructs were co-transfected with miR plasmids using 15 µl of FuGENE HD per 
well. Medium replacement and harvesting were performed as mentioned above. 
 
III - 2.2.8) Immunofluorescence analysis 
MCF-7 or MELN cells were grown in M3 medium for 24 h on poly-D-lysine-coated 
glass coverslips and the procedures described above (treatments and transfections of cells) 
were followed thereafter. After the required experimental time, cells were washed with PBS 
and fixed for 15 min with 4 % PFA. Then, cells were washed and permeabilized for 5 min 
with 0,2 % Triton X-100. After washing with PBS and blocking (15 min at RT), cells were 
incubated (1 h at RT) with specific primary antibodies diluted in PBS + 1 % BSA. After 
washing, coverslips were incubated (1 h at RT) with Alexa 488-conjugated anti-mouse and/or 
Cy3-conjugated anti-rabbit secondary antibodies diluted in PBS + 1 % BSA. After washing, 
coverslips were mounted on microscope slides with elvanol. The microscope slides were 
stored in the dark at 4°C. For immunofluorescence microscopy, Zeiss Axioplan fluorescence 
microscope, Leica DFC 480 camera and Leica DFC camera (Release Notes V6.8.0) software 
were used. Alexa 488 and Cy3 fluorescence signals were visualized by excitation at 
wavelengths of 490 nm and 550 nm, respectively, using a XF2043 Dichroic Mirror. 
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III - 2.3) Biochemistry 
 
III - 2.3.1) In vitro kinase assay 
Commercially available rhERα turned out to be highly phosphorylated. The first step 
was therefore to dephosphorylate the receptor. The rhERα was incubated for 30 min at 30°C 
in 50 mM Tris (pH 7.5), 5 mM DTT, 2 mM MnCl2 and 20 U/µg rhERα of λ-protein 
phosphatase. The reaction was stopped by the addition of 1 mM molybdate and 10 mM 
p-nitrophenyl phosphate and 10 min incubation at RT. The mix was stored at -20°C or 
directly used for in vitro kinase assay. For this reaction, a volume corresponding to 100 ng of 
dephosphorylated rhERα was added to 1 x GSK-3β kinase buffer and to 1 µl of recombinant 
rabbit GSK-3β (250000 U/ml or 50 ng/µl). After 10 min incubation at 30°C, the reaction was 
stopped by the addition of 1 x SDS sample buffer. The samples were subjected to SDS-PAGE 
and the kinase effects were detected by an antibody specific for the ERα phosphorylation site.  
 
III - 2.3.2) Western blot analysis 
Protein concentrations of lysates, cytoplasmic and nuclear extracts were determined 
with the DC protein assay kit from Bio-Rad. Reading of the protein concentrations was 
performed in 96-well plates using the Multiskan EX plate reader. Lysates, cytoplasmic and 
nuclear extracts containing equal amounts of proteins (20 µg/sample) were boiled in 1 x SDS 
sample buffer (5 min, 95°C), subjected to 12 % SDS-PAGE and blotted on an Immobilon-P 
membrane. After blocking of the membrane (1 h, RT in blocking buffer), the membrane was 
incubated overnight at 4°C with diluted primary antibody (see table II - 6), washed and 
incubated with horseradish peroxidase-conjugated goat anti-mouse or anti-rabbit antibodies 
(45 min, RT) (see table II - 7). Immunoreactive protein bands were detected with ECL-plus 
system. Phosphoproteins and respective proteins were detected on the same membrane after 
stripping (20 min, 60°C in stripping buffer). The intensities of the bands were quantified by 
the Image J software (NIH, USA). Results were expressed as relative phosphoprotein or 
protein levels standardized such that values obtained in cells treated with vehicle only were 
set to 1. Data represent the mean and standard errors (SEM) from a minimum of three 
independent experiments. 
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III - 2.3.3) Ubiquitination assay 
MCF-7 cells were treated with 5 µM MG132 and/or 10 nM E2 in presence or absence 
of siRNA targeting GSK-3α/β. Cell lysates were produced and 200 µg proteins were used for 
ubiquitination assay. After pre-clearing the lysates for 2 h with protein A-Sepharose beads, 
overnight immunoprecipitation using anti-ERα antibody and protein A-Sepharose beads was 
performed. Beads were centrifuged, washed and boiled in 1 x SDS sample buffer for 10 min. 
After centrifugation, the supernatants were processed by SDS-PAGE and western blotting. 
Ubiquitinated ERα was detected using anti-ubiquitin polyclonal antibody. After stripping of 
the membrane, immunoblotting using anti-ERα polyclonal antibody was performed as 
loading control.   
 
III - 2.3.4) Firefly luciferase reporter gene assay  
MELN cells were seeded at a density of 3 x 105 cells/well in 6-well plates. After 
treatment for 3 h to 48 h, cells were washed with PBS, lysed (10 min, RT) with 150 µl/well of 
luciferase cell culture lysis reagent and collected by scraping. After centrifugation (10000 × g, 
10 min), the supernatant was collected and stored at - 80°C. The luciferase activity was 
analyzed using the firefly luciferase assay system from Promega. 20 µl of lysate was mixed 
with 100µl of LAR (Luciferase Assay Reagent). This reagent contains all the substances 
needed for the reaction (Fig. III - 3), especially luciferin (substrate of the luciferase enzyme) 
and ATP/Mg2+. The luminescence was immediately measured at 560 nm, RT for 1 min in a 
luminometer. The luminescence expressed in counts per minute (cpm) was proportional to the 
rate of luciferase reaction. The luciferase activity was obtained by normalizing the light 
intensity with the lysate protein concentration (cpm/mg protein).  
 
Figure III - 3: Reaction catalysed by luciferase. Mono-oxygenation of luciferin is catalysed by 
luciferase in the presence of Mg2+, ATP and molecular oxygen. (Source: www.promega.com, Bright-
Glo™ Luciferase Assay System Datasheet). 
 
In the case of transient transfection with GSK-3β plasmid-DNA constructs, 
co-transfection with the reporter gene β-galactosidase was used to normalize the luciferase 
activity with the transfection efficiency (cpm/β-gal O.D.). β-galactosidase activity was 
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determined using the LacZ assay. 30 µl of protein extracts was incubated at 37°C with 450 µl 
of LacZ reaction buffer and 90 µl ONPG solution and after 20 min, 225 µl stop solution was 
added and optical density was measured with the photometer at 405 nm. 
 
III - 2.4) Histological methods 
 
III - 2.4.1) Tissue sections  
Tissue samples from breast cancer patients were obtained from collaboration with the 
Department of Gynecology and Obstetrics (Heidelberg University; see Schnarr et al., 2000). 
Other breast cancer samples were from collaboration with Yun Niu (Breast Cancer 
Pathological Department and Research Laboratory, Tianjin Cancer Hospital and Tianjin 
Medical University, Tianjin, China). Material was obtained with informed consent of the 
patients in both hospitals.  
Tissues were fixed with buffered PFA, dehydrated in a graded ethanol series, 
embedded into paraffin and stored at RT. For further histological staining, 5 µm sections were 
cut from cooled (on ice) paraffin blocks using a rotation microtome and disposable blades. 
After a first bath in cold water, the sections were stretched in a 42°C warm bath and taken up 
on Histobond microscope glass slides. Then, they were dried O/N at 37°C in an incubator and 
stored at RT thereafter.  
 
III - 2.4.2) Hematoxylin and Eosin (H & E) staining  
Quality of the patients’ material was checked by H & E staining. Paraffin sections 
were rehydrated (as described in the following paragraph), stained for 1 min with Mayer’s 
hemalum followed by colour development in running tap water, stained for 5 min in eosin 
staining solution, washed and finally mounted in Kaiser’s glycerol/gelatin.   
 
III - 2.4.3) Immunohistochemical staining 
Formalin-fixed paraffin sections were dewaxed with xylene (2 x 10 min), rehydrated 
with a graded series of ethanol (2 x 5 min ethanol absolute, for 2 min each 96 %, 70 % and 
50 % ethanol) and sections were incubated for 5 min in distilled water. Then, the sections 
were submitted to heat induced antigen retrieval by microwaving in citrate buffer and humid 
atmosphere (water bath). The GSK-3 antigen retrieval was carried out for 2 x 5 min. After 
cooling down for 30 min at RT in the citrate buffer, the sections were rinsed with water 
(5 min), incubated with 3 % hydrogen peroxide (LSAB2 kit) for 5 min to inactivate the 
endogenous peroxidase, rinsed with water again and washed in PBS for 5 min. After 1 h 
Experimental procedures  57 
incubation with blocking buffer, the sections were incubated O/N at 4°C in a humid chamber 
with antigen specific antibody diluted in PBS containing 5 % BSA. Then, the sections were 
washed (3 x 5 min in PBS) and detection was performed using the manufacturer’s instruction 
from the LSAB2 DAKO kit. The sections were incubated with a secondary biotinylated link 
antibody (10 min at RT), washed (3 x 5 min in PBS), incubated with Streptavidin-HRP 
(10 min at RT), washed (3 x 5 min in PBS) and finally stained using the DAB substrate-
chromogen solution. Finally, sections were rinsed with distilled water, were counterstained 
with hematoxylin and mounted in Kaiser’s glycerol/gelatin. For the documentation of the 
staining, a Zeiss Axioplan microscope equipped with a digital camera was used.  
 
III - 2.4.4) Scoring of immunoreactivity 
After immunohistochemical staining, the slides were examined by light microscopy 
and were scored together by two observers (D. Mayer and J. Grisouard). GSK-3β 
immunostaining was mainly cytoplasmic and overall constant for each tissue slide. Therefore, 
the slides were scored as negative/faint (0), very weak to weak (1) and moderate to strong (2) 
according to the cytoplasmic intensity of the staining. In few rare cases, only parts of the 
tissue sections were stained or nuclear staining was observed.  
 
III - 2.5) Statistical Analysis 
For quantitative analysis of western blots, signal intensities were determined with the 
Image J software and were normalized with β-actin used as loading control. Luciferase 
analysis was performed using Berthold LB 9505 C (version 4.08) software. For quantitative 
PCR, MJ opticon monitor analysis software (version 3.1) from Bio-Rad was used and loading 
variations were normalized by β-actin. For each set of data, mean ± SEM was calculated 
evaluating three independent experiments. Differences between groups were statistically 
evaluated using t-test. A P value < 0.05 was considered significant. 
Data obtained from immunohistochemical staining of patients’ tissue specimens were 
statistically evaluated using MedCalc statistical software and Fisher’s exact test was applied 
to reveal differences between the observed proportions of two independent samples. 
A P value < 0.05 was considered significant. 
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IV - Results 
 
Previous work using confocal microscopy showed a co-localisation of ERα and 
GSK-3β in MCF-7 breast cancer cells. Co-localisation was observed in the cytoplasm in 
resting cells and in the nucleus in estradiol-treated cells. These results suggested a functional 
correlation of the two proteins (Medunjanin et al., 2005) and a possible role of 17β-estradiol 
(E2) both in the sub-cellular localisation of these proteins and in the regulation of the 
ERα/GSK3 interaction. The present work unravels the functional relationship of GSK-3 and 
ERα and the role of E2 therein.  
 
IV - 1) Effects of E2 on ERα and GSK-3α/β cellular localisation and phosphorylation 
 
IV - 1.1) E2 induced nuclear translocation of ERα but did not alter GSK-3α/β 
cellular localisation 
First, the sub-cellular localisation status of GSK-3 and ERα were studied by 
immunofluorescence imaging in MCF-7 cells treated or not with E2 (Fig. IV - 1). In untreated 
cells, ERα and GSK-3 were localised both in the cytoplasm and in the nucleus of the cells. An 
increase of the nuclear staining of ERα was observed after E2 treatment suggesting an E2-
induced translocation of the receptor upon ligand binding. However, GSK-3 sub-cellular 
protein content and distribution did not seem to be altered upon E2 stimulation.  
 
Figure IV - 1: Effects of E2 treatment on cellular localisation of ERα and GSK-3α/β. MCF-7 
cells were left untreated (CT) or were treated with 100 nM E2 for 20 min (E2). Immunofluorescence 
staining of ERα protein (red) and GSK-3α/β (green) shows E2-dependent increase of nuclear ERα, 
whereas GSK-3α/β cellular localization did not seem to be altered by E2 treatment.  
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IV - 1.2) E2-induced phosphorylation of ERα at Ser-118 and E2-related 
phosphorylation of GSK-3α/β at Ser-21/9 
To study the time-dependent effects of E2 on ERα and GSK-3 function in MCF-7 
cells, western blot analysis was performed on cell lysates from E2-treated cells using 
phospho- and protein-specific antibodies. The phosphorylation status of ERα and GSK3 
indicates the level of activation or inhibition of these proteins, respectively. Indeed, E2-
induced phosphorylation of ERα at Ser-118 is crucial for full activation of the receptor 
(Lannigan et al., 2003), whereas phosphorylation of GSK-3α and GSK-3β at Ser-21 and 
Ser-9, respectively, inhibits the kinase activities.   
After treatment of MCF-7 cells with 100 nM E2 for 5 to 60 min, ERα protein content 
in cell lysates was not altered indicating that this protein was stable during 60 min of E2 
treatment (Fig. IV - 2). From 0 to 30 min of E2 exposure, ERα phosphorylation at Ser-118 
increased progressively and a plateau was reached thereafter. Regarding GSK-3α/β, the 
protein contents were not altered by E2 treatment of the cells and progressive phosphorylation 
of both kinase isoforms was observed upon E2 stimulation (Fig. IV - 2). GSK-3α 
phosphorylation signal at Ser-21 (51 kDa band) was weaker than GSK-3β phosphorylation 
signal at Ser-9 (47 kDa band). This result may be explained by the more prominent expression 
of the GSK-3β isoform in comparison with GSK-3α isoform (47 kDa GSK-3β versus 51 kDa 
GSK-3α bands after GSK-3α/β immunostaining).  
 
 
Figure IV - 2: E2-induced phosphorylation of ERα at Ser-118 and E2-related phosphorylation of 
GSK-3α/β at Ser-21/9. Cells were left untreated (-) or were treated with 100 nM E2 from 5 min to 
60 min. After lysis of the cells, immunoblot (IB) analysis showed that E2 time-dependent exposure 
increases both Ser-118 phosphorylation of ERα and Ser-21/9 phosphorylation of GSK-3α/β. 
Immunodetection of ERα and GSK-3α/β proteins was used as respective loading control.  
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IV - 1.3) E2-induced nuclear phosphorylation of ERα and E2-related cytoplasmic 
phosphorylation of GSK-3α/β 
 
Specific co-immunofluorescence staining (yellow) of ERα (red) and Ser-118 
phosphorylation at the ERα (green) revealed the appearance of nuclear speckles representing 
phosphorylated receptors after 5 min of E2 stimulation (Fig. IV – 3A). With increased E2 
exposure time, cytoplasmic ERα content seemed to decrease and nuclear accumulation of the 
receptor seemed to be enhanced. Furthermore, a transient ERα accumulation at the plasma 
membrane was observed at 20 min of E2 exposure. At this time point of E2 stimulation, the 
speckled phospho-receptor pattern was not observed anymore but the nuclei of the cells were 
stained in yellow suggesting an increase of Ser-118 phosphorylated ERα. At 60 min of E2 
exposure, the intensity of the yellow colour was even more pronounced. In addition, cellular 
fractionation followed by western blot analysis (Fig. IV - 4) demonstrated more quantitatively 
the ERα translocation from the cytoplasm to the nucleus upon E2 stimulation. The longer the 
cells were stimulated with E2, the less ERα protein was in the cytoplasm and the more ERα 
protein was in the nucleus. Phosphorylation of the receptor at Ser-118 was only observed in 
the nucleus and increased with the time of E2 exposure. These data confirmed the E2-induced 
Ser-118 phosphorylation pattern (Fig. IV - 2) and the co-immunofluorescence data 
(Fig. IV - 3A) previously described. 
Analysis of GSK-3 proteins (green) and their phosphorylated forms (red) by co-
immunofluorescence suggested that GSK-3 proteins were present both in the cytoplasm and 
nucleus of MCF-7 cells and the phosphorylation of the kinases was mainly cytoplasmic and 
more specifically located in the peri-nuclear region of the cells (Fig. IV – 3B). Additionally, 
these data suggest that E2-related phosphorylation of GSK-3 reached a maximum at 20 min of 
E2 treatment. The cellular fractionation did not show any clear E2-induced alteration between 
the cytoplasmic and nuclear GSK-3 protein levels (Fig. IV - 4). Moreover, the cellular 
fractionation confirmed the E2-induced increase of the GSK-3β phosphorylation at Ser-9 and 
confirmed that this phosphorylation was mainly located in the cytoplasm of the cells. 
However, E2-related GSK-3α phosphorylation seen in cell lysates (see Fig. IV - 2) was 
hardly observed after cellular fractionation. This may be explained by the fact that GSK-3α 
isoform protein level was lower than GSK-3β isoform protein level. 
In conclusion, E2 induced ERα translocation into the nucleus, where phosphorylation 
of the receptor at Ser-118 occurred suggesting a role for phosphorylation of this serine residue 
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in the nuclear activation of the receptor. Moreover, E2-related phosphorylation of GSK-3, and 
especially the GSK-3β isoform, was observed in the cytoplasm and strategically located at the 
peri-nuclear site suggesting that GSK-3 is a gatekeeper at the nuclear membrane and may be 
involved in the regulation of ERα translocation from the cytoplasm to the nucleus.  
 
 
Figure IV - 3: Effects of E2 treatment on cellular localisation and phosphorylation of ERα and 
GSK-3α/β. MCF-7 cells were left untreated (CT) or were treated with 100 nM E2 for 5 min, 20 min 
and 60 min. Panel A. Immunofluorescence staining of ERα protein (red) and pSer-118 ERα (green) 
shows E2 time-dependent increase of nuclear co-localization (yellow) resulting from close association 
of red and green fluorescence. Transient events were also observed. At 5 min of E2 treatment, a 
speckled pattern of Ser-118 phosphorylation of nuclear ERα  was observed (white arrows). At 20 min 
of E2 treatment, membrane accumulation of ERα was detected (green arrow). Panel B. 
Immunofluorescence staining of GSK-3α/β protein (green) and pSer-21/9 GSK-3α/β (red) shows peri-
nuclear co-localization (black arrows) resulting from close association of red and green fluorescence 
(yellow). At 20 min E2 treatment, phosphorylation of GSK-3α/β seemed to reach a maximum (orange 
colour of co-localization) and was localized mainly throughout the cellular cytoplasm. At 60 min, a 
strong co-localization signal was still observed and it was more distinctly located in the peri-nuclear 
region of the cells. 
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Figure IV - 4: E2-induced ERα translocation accompanied by nuclear phosphorylation of the 
receptor at Ser118 and E2-related cytoplasmic phosphorylation of GSK-3α/β at Ser-21/9. Cells 
were left untreated (-) or were treated with 100 nM E2 from 10 min to 30 min. Cellular fractionation 
was performed and immunoblots (IB) show E2 time-dependent increase of both ERα translocation 
into the nucleus and nuclear ERα phosphorylation at Ser-118 as well as E2 time-dependent exposure 
increase of cytoplasmic phosphorylation of GSK-3α/β at Ser-21/9. β-actin and replication protein A / 
p34 were used as loading controls for cytoplasmic and nuclear extracts, respectively. 
 
 
IV - 2) GSK-3β phosphorylated ERα at Ser118 in vitro 
Since Ser-118 phosphorylation is an important step in ERα activation we investigated 
if this site is a target for GSK-3. In order to demonstrate that GSK-3 phosphorylates ERα, 
radioactive in vitro kinase assay was performed, which showed an increase of recombinant 
human ERα (rhERα) phosphorylation in presence of rabbit GSK-3β (Medunjanin et al., 
2005). In addition, in vitro kinase assay using wild type and mutant (Ser- to Ala-) GST-ERα 
fusion proteins were performed to identify Ser-118 ERα residues as GSK-3β phosphorylation 
site (Medunjanin et al., 2005). These results were confirmed by in vitro kinase assay and 
immunoblotting. Using rhERα, GSK-3β and an antibody detecting specifically 
phosphorylation of ERα at Ser-118, we demonstrated that ERα can be phosphorylated by 
GSK-3β at Ser-118 (Fig. IV - 5). Overall, these results suggest that GSK-3 may play a role in 
ERα activation.  
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Figure IV - 5: GSK-3 phosphorylates ERα at Ser-118 in vitro. Kinase assay using 
dephosphorylated recombinant human ERα (rhERα) and purified GSK-3β followed by 
immunoblotting (IB) with pSer-118 phosphorylation-site specific antibody for ERα shows that 
GSK-3β phosphorylates ERα at Ser-118.  
 
 
IV - 3) Effect of GSK-3β inhibitors on ERα signalling pathway and on MCF-7 cell 
proliferation 
 
Next, in order to unravel the role of GSK-3 regarding E2 signalling pathway and to 
investigate the role of GSK-3 on E2-induced ERα-positive breast cancer cell proliferation, the 
effect of GSK-3β inhibitors on ERα phosphorylation and intracellular localisation as well as 
on E2-induced MCF-7 cells proliferation was studied.  
 
IV - 3.1) LiCl-inhibits E2-induced ERα phosphorylation at Ser-118 and 
maleimide inhibitors are inefficient regarding this signalling pathway 
MCF-7 cells were treated for 20 min with 100 nM E2 in presence or absence of LiCl 
and maleimide inhibitors (SB415286 and SB216763). After cell fractionation, the effects of 
these ATP/Mg2+ competitive inhibitors of GSK-3 kinase were studied on cytoplasmic and 
nuclear extracts used for immunoblot analysis (Fig. IV - 6A-B).  
In accordance with the part IV - 1, E2 triggered ERα translocation from the cytoplasm 
to the nucleus, where phosphorylation at Ser-118 occurred (Fig. IV - 6A-B). LiCl alone did 
not show any effects regarding Ser-118 phosphorylation of ERα and the intracellular 
localisation of the receptor. However, LiCl decreased E2-induced nuclear ERα 
phosphorylation at Ser-118 without any change regarding E2-induced ERα translocation into 
the nucleus. For SB216763 alone, ERα protein content in each extracts and nuclear Ser-118 
phosphorylation were similar to the control. Interestingly, an increase of ERα translocation 
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and Ser-118 phosphorylation were observed with SB415286 treatment alone. Moreover, none 
of the maleimide inhibitors altered E2-induced translocation of the ERα into the nucleus and 
phosphorylation at Ser-118. However, after E2 treatment and in comparison with LiCl, a 
stronger ERα cytoplasmic decrease was observed in presence of these maleimide inhibitors.  
 
 
Figure IV - 6: Effect of GSK-3 inhibitors on ERα phosphorylation and intracellular localisation. 
Cells were left untreated or were treated with either 30 mM LiCl or 30 µM SB415286 (SB4) or 5 µM 
SB216763 (SB2) alone for 30 min. When cells were treated with both GSK-3 inhibitors and E2, cells 
were first pre-treated with inhibitors for 10 min and then treated with 100 nM E2 for 20 min. After 
treatment, cellular fractionation was performed. Panel A. Immunoblots (IB) show decrease of E2-
induced nuclear ERα phosphorylation at Ser-118 by LiCl treatment whereas the maleimide inhibitors 
SB4 and SB2 did not alter this phosphorylation. Upon E2 treatment, GSK-3α/β phosphorylation status 
at Ser-21/9 increased in the cytoplasm of the treated cells. Both in absence and presence of E2, LiCl 
increased cytoplasmic and nuclear GSK-3β phosphorylation whereas maleimide inhibitors decreased 
GSK-3β phosphorylation in both cellular compartments. β-actin and replication protein A / p34 were 
used as loading controls for cytoplasmic and nuclear extracts, respectively. Panel B, left. Quantitative 
analysis of cytoplasmic ERα protein level given as fold of control and corrected for potential loading 
variations using β-actin. Panel B, right. Quantitative analysis of nuclear ERα protein level and pS118 
ERα signal intensity given as fold of control and corrected for potential loading variations using  
replication protein A / p34. Three independent experiments were analyzed.  
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E2-related GSK-3β phosphorylation at Ser-9 was observed in the cytoplasmic fraction 
and no obvious effects of E2 on GSK-3α/β intracellular distribution was noticed 
(Fig. IV - 6A). After LiCl treatment (with or without E2 treatment), a strong signal was 
obtained for GSK-3β phosphorylation at Ser-9 in both cytoplasmic and nuclear extracts. At 
the opposite, GSK-3α or β were not phosphorylated after maleimide treatments, neither in the 
cytoplasm, nor in the nucleus. The GSK-3 protein contents were difficult to analyse from 
these blots and variations of signal, especially in the nuclear extracts may be explained by 
loading discrepancies. 
Overall, LiCl inhibited kinase activity of GSK-3 by phosphorylation of GSK-3β at 
Ser-9, while maleimide inhibitors markedly decreased the phosphorylation status of 
GSK-3α/β. None of the GSK-3 inhibitors altered E2-induced ERα translocation and LiCl was 
the only studied inhibitor to decrease E2-induced ERα phosphorylation at Ser-118. Finally, 
SB415286 alone induced ERα translocation and Ser-118 phosphorylation suggesting 
estrogenic effects of this inhibitor.  
 
IV - 3.2) GSK-3β inhibitors blocked MCF-7 cells proliferation  
MCF-7 cells growth curves were obtained by counting of the cells after 24 h, 48 h and 
72 h treatment (Fig. IV - 7). Basal growth rate was determined by counting untreated cells. E2 
increased the growth rate. LiCl and maleimide inhibitors inhibited basal and E2-induced 
proliferation of the MCF-7 cells suggesting that GSK-3 plays a role in MCF-7 cell 
proliferation. However, the molecular mechanisms affected by GSK-3 inhibitors to inhibit 
MCF-7 cell proliferation are unclear and the hypothetical effects of GSK-3 on the E2 
signalling pathway can not be solved by this approach. 
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Figure IV - 7: GSK-3β inhibitors blocked MCF-7 cells proliferation. MCF-7 cells were grown in 
DMEM supplemented with 10 % DCC-FCS and remained untreated (CT) or were treated with E2 
(100 nM), LiCl (30 mM), SB4 (30 µM), SB2 (5 µM) and combinations thereof. Cells were counted at 
24 h intervals and the number of seeded cells was taken as reference (0 h time point). E2-induced cell 
proliferation (red curve) and basal cell proliferation (black curve) were inhibited by the use of GSK-3β 
inhibitors (green, blue and purple curves for LiCl, SB4 and SB2, respectively).  
 
 
IV - 4) Silencing of GSK-3 and its consequences on ERα signalling pathway in ERα-
positive human breast carcinoma cell lines  
 
RNA interference (RNAi) using small interfering RNA (siRNA) targeting GSK-3 was 
used to specifically silence GSK-3 protein expression in order to investigate the involvement 
of GSK-3 in ERα function and activity. 
 
IV - 4.1) GSK-3α/β silencing causes decrease of ERα protein content 
MCF-7 cells were transfected with siRNA targeting GSK-3α/β in order to silence 
GSK-3 expression. After transfection with siRNA, GSK-3α and GSK-3β protein levels were 
reduced by 60 % to 70 % in comparison with the untransfected and control siRNA-transfected 
cells (Fig. IV - 8A-B). The addition of 100 nM E2 for 48 h did not affect the silencing of 
GSK-3α/β. 
E2 treatment of untransfected cells for 48 h resulted in an approximately 50 % 
decrease of ERα protein level (Fig. IV - 8C-D) which agreed with previous reports that 
prolonged treatment with E2 downregulates the steady-state level of ERα in MCF-7 cells 
(Saceda et al., 1988; Laios et al., 2005). In cells not treated with E2, silencing of GSK-3α/β 
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caused a significant decrease of ERα protein level (approximately 35 %). Combination of 
GSK-3α/β  silencing and treatment with 100 nM E2 for 48 h, led to an even more pronounced 
and significant ERα downregulation (approximately 90 %) in MCF-7 cells. 
Similar results as described for MCF-7 cells were also observed in T47D and BT-474 
ERα-positive human breast carcinoma cells (Fig. IV - 9). In both cell lines, GSK-3α/β  
silencing led to a significant reduction of ERα protein levels. 
 
 
Figure IV - 8: Decrease of ERα protein in MCF-7 cells after GSK-3α/β silencing. Cells were left 
untransfected (CT) or were transfected either with 50 nM GL3 control siRNA (CT siRNA) or with 
50 nM siRNA targeting GSK-3α/β (GSK-3α/β siRNA); then the cells were treated or not with 
100 nM E2 for 48 h. Panel A. Immunoblot (IB) showing silencing of GSK-3α/β. β-actin was used as 
loading control. Panel B. Quantitative analysis of GSK-3α (black), GSK-3β (white) or both isoforms 
(grey) from three independent RNAi experiments. Panel C. Immunoblot showing downregulation of 
ERα protein after GSK-3α/β  silencing. Panel D. Quantitative analysis of ERα protein level given as 
fold of control and corrected for potential loading variations using β-actin. Three independent 
experiments were analyzed and error bars represent the standard error of the mean (*, p < 0.05 
determined by t-test).  
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Figure IV - 9: Decrease of ERα protein in T47D and BT-474 cells after GSK-3α/β silencing. Cells 
were transfected either with 50 nM GL3 control siRNA (CT siRNA) or with 50 nM siRNA targeting 
GSK-3α/β (GSK-3α/β siRNA) and treated or not with 100 nM E2 for 48 h. Immunoblots (IB) show 
down-regulation of ERα protein after GSK-3α/β  silencing in T47D cells (Panel A) and BT-474 cells 
(Panel C). Quantitative analysis in T47D cells (Panel B) and BT-474 (Panel D) of ERα protein level 
given as fold of control and corrected for potential loading variations using β-actin and β-tubulin, 
respectively. Three independent experiments were analyzed and error bars represent the standard error 
of the mean (*, p < 0.05 determined by t-test). 
 
 
IV - 4.2) Effect of GSK-3 silencing on ERα mRNA expression 
GSK-3 silencing-related decrease of ERα protein level described above might be due 
to a decrease of ERα gene transcription leading to downregulation of ERα biosynthesis. To 
investigate the hypothetical regulation of ERα transcription by GSK-3, quantitative real-time 
PCR experiments were performed using ERα primers with cDNA synthesized from RNA 
extracted from MCF-7 cells that had been transfected or not with GSK-3α/β  siRNA and 
treated or not with 10 nM E2 for 6 h, 24 h, or 48 h (Fig. IV - 10). Basal ERα mRNA 
expression in the GSK-3α/β siRNA-transfected cells was significantly decreased at the 6 h 
time point compared to control siRNA-transfected cells. However, basal ERα mRNA 
expression was similar for the control siRNA and GSK-3α/β  siRNA transfected cells at the 
24 h and the 48 h time points. It has been reported that E2 treatment induces decrease of ERα 
mRNA expression in MCF-7 cells (Saceda et al., 1988; Read et al., 1989; Berthois et al., 
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1990; Pink and Jordan, 1996). In our experiments E2-related decrease of ERα mRNA 
expression was confirmed and was similar (about 50 to 60 %) in control siRNA and 
GSK-3α/β siRNA transfected cells at all time points studied. After 48 h E2-treatment the 
decrease of ERα mRNA expression was slightly stronger upon GSK-3 silencing, this was, 
however, not statistically significant. Taken together, the results show that GSK-3 silencing 
has a transient effect on basal ERα mRNA expression level whereas GSK-3 silencing does 
not significantly alter E2-related decrease of ERα mRNA levels.   
 
 
Figure IV - 10: Effect of GSK-3α/β silencing on ERα mRNA expression in MCF-7 cells. Cells 
were transfected either with GL3 control siRNA (CT siRNA) or with siRNA targeting GSK-3α/β 
(GSK-3α/β siRNA) and treated or not with 10 nM E2 for 6 h, 24 h and 48 h. Total RNA was extracted 
and used to synthesize cDNA by reverse transcription. Quantitative real- time PCR using ERα primers 
showed that E2-related decrease of ERα mRNA expression was not significantly altered upon 
GSK-3α/β silencing. β-actin was used as an internal control. Three independent experiments were 
analyzed and error bars represent the standard error of the mean (*, p < 0.05 determined by t-test). 
 
 
IV - 4.3) Increase of ERα   proteasomal degradation rather than reduction of 
ERα protein synthesis downregulates ERα protein upon GSK-3α/β silencing 
The results described above raise the question on the mechanism leading to ERα 
protein decrease in GSK-3α/β silenced cells. Experiments using the translation inhibitor 
cycloheximide (CHX) and the proteasome inhibitor MG132 were performed to investigate the 
role of GSK-3 regarding ERα protein synthesis and ERα proteasomal degradation, 
respectively (Fig. IV - 11).  
In cells transfected with control siRNA (Fig. IV - 11, left panel), CHX slightly 
decreased ERα protein content whereas MG132 slightly increased ERα protein content. In 
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cells transfected with GSK-3α/β siRNA and not stimulated with E2, the proteasome inhibitor 
MG132 significantly rescued GSK-3α/β silencing related-ERα protein decrease. Such 
significant rescue was also observed when MG132 was used in combination with CHX. In E2 
treated cells (Fig. IV - 11, right panel), MG132 treatment rescued E2 induced- as well as 
GSK-3α/β silencing related-ERα protein decrease. In GSK-3α/β silenced cells treated with 
both CHX and E2, a significant MG132 mediated rescue of ERα was still observed. Taken 
together, these results suggest that downregulation of ERα upon GSK-3α/β silencing either in 
unstimulated or in E2 treated cells is due to increase of ERα proteasomal degradation rather 
than alteration of ERα protein synthesis. 
 
 
Figure IV - 11: ERα protein decrease caused by GSK-3α/β silencing is due to an increase of 
proteasomal degradation rather than decreased ERα protein synthesis. Cells were transfected 
with CT siRNA or with siRNA targeting GSK-3α/β (GSK-3α/β siRNA). After 1 h pre-treatment with 
either 5 µM MG132 or 50 µg/ml cycloheximide (CHX) or a combination of both, cells were treated 
(right panel) or not (left panel) with 10 nM E2 for 6 h. Panel A. Immunoblots (IB) showing rescue of 
GSK-3α/β silencing-related ERα protein decrease by inhibition of proteasomal degradation even 
where translation was blocked with CHX. β-actin was used as loading control. Panel B. Quantitative 
analysis of ERα protein level given as fold of control and corrected for potential loading variations 
using β-actin. Three independent experiments were analyzed and error bars represent the standard 
error of the mean (*, p < 0.05 determined by t-test).  
 
Results  71 
IV - 4.4) GSK-3 prevents ERα ubiquitination and proteasomal degradation 
Several studies recently described the involvement of the ubiquitin-proteasome 
pathway in the E2-induced degradation of ERα (Nawaz et al., 1999; Lonard et al, 2000; 
Preisler-Mashek et al., 2002). From the results shown in Fig. IV - 8, we hypothesized that 
GSK-3α/β may be involved in ERα stabilization, preventing its ubiquitination and 
proteasomal degradation.  
 
 
Figure IV - 12: ERα ubiquitination and proteasomal degradation is increased upon GSK-3 
silencing. Cells were transfected either with GL3 control siRNA (CT siRNA) or with siRNA targeting 
GSK-3α/β (GSK-3α/β siRNA). After 1 h pre-treatment with 5 µM MG132 where indicated, cells 
were treated or not with 10 nM E2 for 6 h. Panel A. ERα immunoprecipitates (IP) from MCF-7 cells 
were subjected to immunoblotting (IB) detecting ubiquitinated forms of ERα which were found 
strongly increased upon silencing of GSK-3α/β. Panel B. Detection of ERα on the same membrane 
shown in panel A. Panel C. Quantification of ERα protein levels given as fold of control from three 
independent experiments including that shown in panel B and error bars represent the standard error of 
the mean (*, p < 0.05 determined by t-test; ns, not significant). 
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To analyze this, ERα was immunoprecipitated from cells transfected with control or 
GSK-3α/β siRNA followed by immunoblotting with anti-ubiquitin antibody (Fig. IV - 12A). 
After GSK-3α/β silencing, we detected an increase in ubiquitination of ERα in cells treated or 
not with E2 compared to the control siRNA-transfected cells. When proteasomal degradation 
was inhibited using MG132, further accumulation of ubiquitinated forms of ERα was 
observed. Detection of ERα protein in these samples confirmed ERα downregulation caused 
either by E2 treatment or by GSK-3α/β silencing (Fig. IV - 12B-C). Addition of MG132 
rescued the downregulation of ERα caused by E2 in control siRNA-transfected cells and, 
more importantly, in cells after GSK-3α/β silencing both in presence or absence of E2. These 
results suggest an important role of GSK-3 regarding ERα stabilization. 
 
IV - 4.5) ERα is a substrate for GSK-3 and is phosphorylated at Ser-118 
In Fig. IV - 5, it was shown that GSK-3 phosphorylated ERα at Ser-118 in an in vitro 
kinase assay. In order to investigate if ERα is a substrate for GSK-3 in vivo, we further 
analyzed the effects of GSK-3α/β silencing on the phosphorylation of ERα at Ser-118 
induced by 100 nM E2 stimulation for 20 min. In untransfected and control siRNA-
transfected cells, short-term E2 treatment induced ERα phosphorylation at Ser-118 
(Fig. IV - 13A-B). This phosphorylation was significantly reduced after GSK-3α/β silencing. 
Furthermore, in accordance with our results shown in Fig. IV - 8, ERα protein content was 
reduced in these cells (Fig. IV - 13A-B). In addition, a clear although not significant decrease 
of the pS118/ERα ratio was observed (Fig. IV - 13B) suggesting that ERα downregulation 
was not the only reason for the reduction of ERα phosphorylation level at Ser-118.  
In order to further clarify the role of GSK-3 in ERα phosphorylation in vivo, we 
investigated Ser-118 phosphorylation of ERα after inhibition of the proteasome. Under this 
condition, we confirmed that ERα degradation due to GSK-3α/β silencing was partly 
prevented by MG132 addition (Fig. IV - 13C-D, right part). Importantly, ERα protein 
rescue was not accompanied by a rescue of E2-induced Ser-118 phosphorylation in 
GSK-3α/β silenced cells (Fig. IV - 13C), which is also evident from the reduced 
pS118 / ERα ratio (Fig. IV - 13D). These results provide further evidence that Ser-118 of 
ERα is a target for E2-induced phosphorylation by GSK-3α/β in MCF-7 cells. Interestingly, 
E2-induced phosphorylation of ERα at Ser-118 was also decreased in MG132-treated cells 
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transfected with control siRNA showing that ERα was less phosphorylated at Ser-118 after 
inhibition of the proteasome.  
 
 
Figure IV - 13: GSK-3 phosphorylates ERα at Ser-118 in MCF-7 cells. Panel A. Cells were left 
untransfected (CT) or were transfected either with GL3 control siRNA (CT siRNA) or with siRNA 
targeting GSK-3α/β (GSK-3α/β siRNA) and treated or not with 100 nM E2 for 20 min. Immunoblots 
(IB) show reduction of E2-induced ERα phosphorylation at Ser-118 upon GSK-3 silencing. Panel B. 
Quantitative analysis of pS118 and ERα protein signals given as fold of control. Data from three 
independent experiments including that shown in panel A revealed reduction of Ser-118 
phosphorylation, of ERα protein, as well as of pS118/ERα ratio (*, p < 0.05 determined by t-test; 
ns, not significant). Panel C. Cells were transfected either with GL3 control siRNA or with siRNA 
targeting GSK-3α/β. Where indicated, cells were pretreated with 5 µM MG132 for 6 h and then 
treated or not with 100 nM E2 for 20 min. Panel D. Quantification of data shown in panel C and of 
two additional experiments carried out under the same conditions (*, p < 0.05 determined by t-test). 
E2-induced and GSK-3α/β silencing-related downregulation of ERα was rescued by MG132; but 
reduction of E2-induced Ser-118 phosphorylation in cells transfected with GSK-3α/β siRNA was not 
rescued. 
 
Previous work from our group showed that GSK-3 and ERα are detected in both the 
cytoplasm and the nucleus of MCF-7 cells (Medunjanin et al., 2005; De Servi et al., 2005). 
Fig. IV – 1, Fig. IV - 3 and Fig. IV – 4 shown in this thesis confirm the cytoplasmic and 
nuclear localization of GSK-3 and ERα in serum-starved cells. We now studied the effect of 
GSK-3 silencing on intracellular localization of ERα. Fig. IV - 14A shows that transfection of 
control siRNA did not interfere with E2-induced nuclear translocation of ERα. In GSK-3 
silenced cells the overall ERα fluorescence signal was markedly weaker whether the cells 
were treated with E2 or not, which agrees with results from western blotting. Moreover, 
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GSK-3 silencing did not seem to affect E2-induced nuclear translocation of ERα. Cell 
fractionation studies (Fig. IV - 14B) showed similar GSK-3α/β silencing in both 
compartments. In agreement with the results shown in Fig. IV - 14A E2-induced ERα nuclear 
translocation was still occurring in GSK-3 silenced cells. Furthermore, Fig. IV - 14B shows 
that GSK-3 silencing resulted in reduced E2-induced ERα phosphorylation at Ser-118 in the 
nucleus. Taken together, these data suggest a direct role of nuclear GSK-3 regarding ERα 
phosphorylation at Ser-118 in the nucleus. 
 
 
 
 
Figure IV - 14: GSK-3α/β silencing did not alter E2-induced nuclear translocation of ERα. Cells 
were transfected either with GL3 control siRNA or with siRNA targeting GSK-3α/β  and treated or 
not with 100 nM E2 for 20 min. Panel A. Immunofluorescence staining of ERα protein (red) shows 
that cytoplasmic and nuclear ERα levels were reduced after GSK-3α/β silencing. E2-induced ERα 
translocation from the cytoplasm to the nucleus of MCF-7 cells was still occurring after GSK-3α/β 
silencing. The same settings were used for all fluorescence micrographs. Panel B. Cellular 
fractionation was performed and immunoblots (IB) show silencing of GSK-3α/β in both cytoplasmic 
and nuclear compartments upon RNAi. After GSK-3α/β silencing, E2-induced ERα phosphorylation 
at Ser-118 in the nucleus was decreased. β-actin and replication protein A / p34 were used as loading 
controls for cytoplasmic and nuclear extracts, respectively. 
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IV - 4.6) Decrease of ERα activity due to GSK-3 silencing is not rescued by 
inhibition of the proteasome 
Next, functional assays were performed to assess the role of GSK-3 in modulating 
ERα activity. First, MELN cells carrying an ERE-luciferase reporter plasmid were transfected 
with control siRNA or GSK-3α/β siRNA and treated with 10 nM E2 for different time 
periods before luciferase activity was measured. In control siRNA-transfected cells, luciferase 
activity was increased up to 7-fold after E2 treatment for 3 h, 6 h and 8 h and declined 
thereafter (Fig. IV - 15A). As expected, ERα was downregulated over time upon 
E2 treatment. In presence of GSK-3α/β siRNA, the basal luciferase activity (without 
E2 treatment) was significantly lower compared to the control at any time point analyzed. 
Moreover, E2-induced luciferase activity was significantly reduced by about 40 % in 
comparison with the respective controls when cells were treated with E2 from 3 h to 12 h. At 
24 h, the luciferase activity after GSK-3 silencing was similar to the one obtained with control 
siRNA. Detection of ERα protein in the same samples used for luciferase reporter assay 
revealed reduction of ERα protein levels in cells transfected with GSK-3α/β siRNA 
compared to control siRNA-transfected cells. Further reduction of ERα protein content was 
observed by E2 treatment after GSK-3α/β silencing.  
Next, we examined the effects of ERα rescue by proteasome inhibition on luciferase 
activity (Fig. IV - 15B-C). In agreement with results shown in Fig. IV - 15A, treatment of 
cells with 10 nM E2 for 6 h resulted in E2-induced luciferase activity, which was significantly 
inhibited in the presence of GSK-3α/β siRNA (Fig. IV - 15B). In control siRNA-transfected 
cells, addition of MG132 slightly increased basal luciferase activity but did not alter E2-
induced luciferase activity. After GSK-3α/β silencing, the reduced E2-triggered luciferase 
activity was not rescued by MG132 treatment. However, ERα protein content in these cells 
was restored by MG132 treatment (Fig. IV - 15C). These findings show that GSK-3α/β is 
required for full ERα activation. 
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Figure IV - 15: ERα transcriptional activity is decreased upon GSK-3α/β silencing. Panel A. 
MELN cells transfected either with GL3 control siRNA (CT siRNA) or with siRNA targeting 
GSK-3α/β (GSK-3α/β siRNA) were treated with 10 nM E2 for 3, 6, 8, 12 or 24 h and ERE-dependent 
luciferase expression was measured in cell lysates. Relative luciferase activity given as fold of control 
was evaluated from three independent experiments (histogram). Immunoblot from the same lysates 
shows E2-induced and GSK-3α/β silencing-related downregulation of ERα (western blot). Panel B. 
Cells were transfected as above, pretreated with 5 µM MG132 for 1 h and treated or not with 10 nM 
E2 for 6 h. Relative luciferase activity was evaluated from three independent experiments (*, p < 0.05 
determined by t-test). GSK-3α/β silencing-related reduction of E2-induced luciferase activity was not 
rescued by the addition of MG132. Panel C. Immunoblot (IB) showing that ERα protein in samples 
analyzed in panel B was restored by MG132 treatment. 
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IV - 4.7) GSK-3α/β silencing decreases E2-induced expression of endogenous 
ERα target genes  
Furthermore, we studied the effect of GSK-3 silencing on endogenous estrogen 
responsive genes. Quantitative real-time PCR was performed using primers specific for pS2 
and progesterone receptor (PR), which are both well-known estrogen responsive genes 
(Klinge, 2001). After GSK-3α/β silencing, E2-induced expression of these genes was 
significantly decreased at 3 h, 6 h and 24 h of E2-treatment (Fig. IV - 16A-B). These results, 
in agreement with the luciferase assay performed in MELN cells, confirm the involvement of 
GSK-3α/β in the regulation of ERα target genes expression and demonstrate the necessity of 
GSK-3α/β for full ligand-dependent activity of ERα. 
 
 
Figure IV - 16: E2-induced expression of ERα target genes (pS2 and progesterone receptor) was 
downregulated upon GSK-3α/β silencing. MCF-7 cells were transfected either with GL3 control 
siRNA (CT siRNA) or with siRNA targeting GSK-3α/β (GSK-3α/β siRNA) and then were treated or 
not with 10 nM E2 for 1 h, 3 h, 6 h, 8 h and 24 h. Total RNA was extracted and used to synthesize 
cDNA by reverse transcription. Quantitative real-time PCR of the cDNA using pS2 primers (Panel A) 
and progesterone receptor (PR) primers (Panel B) showed that E2-induced mRNA expression of these 
ERα target genes was decreased upon GSK-3α/β silencing. β-actin was used as an internal control. 
Three independent experiments were analyzed and error bars represent the standard error of the mean 
(*, p < 0.05 determined by t-test).  
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IV - 4.8) Silencing of either GSK-3α or GSK-3β isoform results in ERα 
downregulation and reduced transcriptional activation 
Since most reports in the literature claim that the GSK-3β isoform is of greater 
importance for biological functions in comparison with GSK-3α (Hoeflich et al., 2000; 
Grimes and Jope, 2001; Jope and Johnson, 2004), we were interested in the role of the two 
individual GSK-3 isoforms regarding ERα signalling. Indeed, a recent publication (Doble et 
al., 2007) highlights the importance of considering the contributions of both homologs when 
studying GSK-3 functions in mammalian systems. Therefore, the impact of individual GSK-3 
isoforms on ERα protein level and activity were assessed using siRNA specifically targeting 
either GSK-3α or GSK-3β (Fig. IV - 17A-C). Fig. IV - 17B demonstrates the selective 
targeting of GSK-3α and GSK-3β by the respective siRNA. Selective silencing of GSK-3α 
resulted in ERα downregulation in the absence of E2 (Fig. IV - 17A and 17B) and in 
decrease of ERα phosphorylation at Ser-118 induced after 20 min E2 treatment 
(Fig. IV - 17A). After 6 h E2 treatment, selective silencing of GSK-3α led to a more 
pronounced E2-induced ERα downregulation (Fig. IV - 17B) and to a decrease of E2-induced 
luciferase activity (Fig. IV - 17C). The effects caused by GSK-3α silencing were similar to 
those described for GSK-3α/β silencing. Furthermore, selective silencing of GSK-3β had 
similar effects on ERα protein level, Ser-118 phosphorylation and ERα activity like GSK-3α 
or GSK-3α/β silencing (Fig. IV - 17A-C). Surprisingly, specific targeting of the GSK-3β 
isoform resulted also in partial silencing of GSK-3α. The lack of specificity of siRNA 
targeting GSK-3β is so far unclear. The results shown in Fig. IV - 17 were obtained with the 
validated siRNA targeting GSK-3β from Ambion. Furthermore, similar results (data not 
shown) were obtained using the GSK-3β specific siRNA sequence described in (Phiel et al., 
2003).  
 
Results  79 
 
Figure IV - 17: ERα level and activity are decreased upon silencing GSK-3α or GSK-3β 
individually. Cells were transfected with 50 nM GL3 control siRNA (CT siRNA) or with 50 nM 
siRNA targeting either GSK-3α/β (GSK-3α/β siRNA), or GSK-3α (GSK-3α siRNA), or GSK-3β 
(GSK-3β siRNA). Panel A. Immunoblots (IB) showing ERα levels and Ser-118 phosphorylation in 
MCF-7 cells treated or not with 100 nM E2 for 20 min. Panel B. Immunoblots showing GSK-3α, 
GSK-3β and ERα levels in MCF-7 cells treated with 10 nM E2 for 6 h. Panel C. Relative luciferase 
activity given as fold of control was evaluated from three independent experiments in MELN cells 
treated with 10 nM E2 for 6 h and error bars represent the standard error of the mean (*, p < 0.05 
determined by t-test).   
 
We performed an additional experiment in which GSK-3α/β silencing was compared 
with the combined silencing of GSK-3α and GSK-3β individual isoforms (Fig. IV - 18). Both 
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approaches yielded similar results regarding GSK-3α/β downregulation (about 60 % at 50 nM 
final siRNA concentrations), GSK-3α/β silencing related ERα downregulation as well as 
GSK-3α/β silencing related decrease of E2-induced ERα activity. To summarize, similar 
results were obtained using different siRNA sequences specific for GSK-3α/β or the 
individual isoforms regarding ERα signalling.  
 
 
Figure IV - 18: siRNA targeting GSK-3α/β or mix of siRNA targeting GSK-3α and siRNA 
targeting GSK-3β decreased ERα level and activity. MELN cells were transfected with 50 nM GL3 
control siRNA (CT siRNA) or with 50 nM siRNA targeting GSK-3α/β (GSK-3α/β siRNA), or with a 
mix of 25 nM siRNA targeting GSK-3α and 25 nM siRNA targeting GSK-3β (GSK-3α + β siRNA). 
Then, the cells were treated or not with 10 nM E2 for 6 h. Panel A. Immunoblots (IB) showing ERα 
levels after GSK-3α/β silencing. β-actin was used as loading control. Panel B. Quantitative analysis 
of GSK-3α/β immunoblots corrected for potential loading variations using β-actin. Three independent 
experiments were analyzed (*, p < 0.05 determined by t-test). Panel C. Relative luciferase activity 
given as fold of control was evaluated from three independent experiments in MELN cells (*, p < 0.05 
determined by t-test).   
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IV - 4.9) GSK-3 silencing causes increase of β-catenin protein content and 
enhances proteasomal degradation of cyclin D1 
GSK-3β plays a crucial role in the regulation of the Wnt signalling pathway and 
induces β-catenin proteasomal degradation (Cohen and Goedert, 2004). Moreover, GSK-3β 
was shown to trigger proteolysis of cyclin D1 (Diehl et al., 1998). Therefore, we investigated 
the effects of GSK-3α/β silencing on these specific substrates of GSK-3 kinase.  
In cells transfected with GSK-3α/β siRNA, β-catenin phosphorylation at 
Ser-33/37/Thr-41 was decreased and β-catenin protein content was increased (Fig. IV - 19A). 
In agreement with the findings from Cohen and Goedert (2004), these data showed that 
GSK-3 phosphorylates β-catenin at Ser-33/37/Thr-41 thus triggering the proteasomal 
degradation of this transcription factor. Additionally, these results confirmed the efficiency of 
the GSK-3 silencing. 
Interestingly, after transfection with siRNA targeting GSK-3α/β, cyclin D1 
phosphorylation at Thr-286 was decreased and down-regulation of cyclin D1 protein content 
was observed (Fig. IV - 19A). Additionally, cyclin D1 was rescued by inhibition of the 
proteasome with MG132 (Fig. IV - 19B). Taken together, these results suggest that GSK-3 
phosphorylates cyclin D1 at Thr-286 and that GSK-3 may prevent proteolysis of cyclin D1. 
These results are at variance with previous studies (Diehl et al., 1998; Alt et al., 2000) which 
reported that GSK-3 induces Thr-286 phosphorylation of cyclin D1 and thereby triggers its 
proteasomal degradation. In our experiments, breast cancer cell lines were used, whereas the 
other papers mentioned used NIH-3T3 mouse fibroblast and Hela human cervix carcinoma 
cell lines. This may explain the differences of results. 
To summarize, GSK-3 interacts with, phosphorylates and induces proteasomal 
degradation of β-catenin. Moreover, similar to the data we obtained regarding ERα/GSK-3 
interaction and stabilization, GSK-3 may interact with and protect cyclin D1 from 
proteasomal degradation. Additionally, the phosphorylation of cyclin D1 at Thr-286 by 
GSK-3 may play a role in the protection of cyclin D1 from proteolysis. Hypothetically, this 
phosphorylation may reinforce the putative interaction between GSK-3 and cyclin D1. 
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Figure IV - 19: GSK-3 silencing-related increase of β-catenin protein content and GSK-3 
silencing-related increase of cyclin D1 proteasomal degradation in MCF-7 cells. Panel A. Cells 
were left untransfected or were transfected either with GL3 control siRNA (CT siRNA) or with siRNA 
targeting GSK-3α/β (GSK-3α/β siRNA) for 66 h, and were then treated or not with 100 nM E2 for 
20 min. After GSK-3 silencing, in absence or in presence of E2, immunoblots (IB) show reduction of 
β-catenin phosphorylation at Ser-33/37 and Thr-41 and consequent increase of β-catenin protein 
content, whereas cyclin D1 phosphorylation at Thr-286 and protein levels were both decreased. β-actin 
was used as loading control. Panel B. Cells were transfected either with GL3 control siRNA or with 
siRNA targeting GSK-3α/β. Where indicated, cells were pretreated with 5 µM MG132 for 6 h and 
then treated or not with 100 nM E2 for 20 min. Immunoblot shows rescue by proteasomal inhibitor 
MG132 of GSK-3α/β silencing-related downregulation of cyclin D1. E2 treatment does not seem to 
alter the downregulation and the rescue of cyclin D1 previously described. β-actin was used as loading 
control.  
 
 
IV - 5) GSK-3β WT, CA, R96A and R96K enhanced E2-induced ERE-dependent 
luciferase activity of MELN cells 
To determine the relevant amino acid residues or domains of GSK-3 involved in 
modulation of ERα activity, MELN cells were transiently transfected with expression 
constructs carrying different GSK-3β mutants. The GSK-3β WT (Wild Type) form was used 
as a control for overexpression of the kinase. The GSK-3β CA (constitutively active) form 
was obtained by mutation of the Ser-9 to Ala- (S9A). The mutation of Arg-96 to Ala (R96A) 
or Lys (R96K) abolished GSK-3β activity toward primed substrates, but these mutations did 
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not alter GSK-3β activity toward non-primed substrates (Frame et al., 2001). To check the 
expression levels of the flag-tagged GSK-3 constructs, western blot analysis was performed 
with the cell lysates used for luciferase activity measurement later on (Fig. IV - 20A). All the 
constructs had a similar flag expression pattern and their expression was not altered by 48 h of 
E2 treatment. In the same lysates, GSK-3 protein level was also detected by immunoblot 
analysis. GSK-3β protein level was increased after transfection of the cells with WT, CA, 
R96A or R96K GSK-3β constructs in comparison with cells transfected with an empty vector 
(Mock). Interestingly, the increase of the GSK-3β protein level was always accompanied by 
an increase of protein level for the GSK-3α isoform. Additionally, our results suggest for each 
GSK-3 construct studied, a slight increase of protein levels for both GSK-3 isoforms in E2 
treated cells in comparison with untreated cells. 
Furthermore, we tested the effect of these GSK-3β constructs on ERE-dependent 
luciferase activity in MELN cells. In these experiments, the constructs were co-transfected 
with β-galactosidase which was used as an internal control for transfection efficiency while 
quantifying the luciferase activity (Fig. IV - 20B). In absence of E2, a slight increase of basal 
luciferase activity was observed after overexpression of GSK-3β WT, R96A and R96K 
constructs. The CA GSK-3β construct did not seem to alter the basal ERE-dependent 
luciferase expression. In cells treated for 48h with E2, overexpression of GSK-3β WT, R96A 
and R96K resulted in significant increase of luciferase activity (about 3-fold) in comparison 
with the Mock control. GSK-3β CA showed only about 1,5-fold increase of luciferase activity 
compared to the Mock control).  
All together, these data suggested that GSK-3β overexpression increased ERα activity 
upon E2 treatment and that ERα may be an un-primed substrate of GSK-3β. Moreover, 
phosphorylation of GSK-3β at Ser-9 seemed to be important for full E2-induced ERα activity. 
Additionally, effects of GSK-3 constructs on E2-induced ERα nuclear translocation and 
Ser-118 phosphorylation were studied, but no clear conclusions were possible (data not 
shown). Furthermore, the endogenous GSK-3α and GSK-3β were still strongly effective in 
these experiments and did not allow a specific study of each construct. 
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Figure IV - 20: GSK-3β WT, CA, R96A and R96K enhanced E2-induced ERE-dependent 
luciferase activity of MELN cells. MELN cells were transiently co-transfected with empty vector 
(Mock), expression vectors carrying wild-type (WT) or mutant GSK-3β such as constitutively active 
(CA), R96A or R96K GSK-3β constructs and a β-galactosidase expression vector. Then, these cells 
were incubated for 48 h with E2 (10 nM). Panel A. Immunoblots (IB) of cell lysates show expression 
of the different flag-tagged GSK-3β constructs. In comparison with Mock transfected cells, increased 
expression of GSK-3 protein level was observed in WT, CA, R96A and R96K GSK-3β transfected 
cells. β-tubulin was used as loading control. Panel B. In the same lysates used previously for 
determination of GSK-3 overexpression, ERE-dependent gene expression was quantified by 
measuring luciferase activity. Data are expressed as fold of the luciferase activity measured in 
untreated Mock-transfected cells. These data were normalised by the measurement of the 
β-galactosidase activity of the cells (β-gal O.D.). Error bars represent standard deviation from three 
independent experiments in MELN cells (*, p < 0.05 determined by t-test). 
 
 
IV - 6) Silencing of the endogenous GSK-3β in MCF-7 cells using miR RNAi expression 
vectors and rescue of the kinase and ERα with xenopus GSK-3β constructs  
 
As described above, the effects of overexpressed GSK-3β mutants on ERE-controlled 
luciferase activity were difficult to interpret since endogenous GSK-3β was still present and 
interfered with the mutants. The investigation of the effect of GSK-3β mutants on ERα 
stability and function required the elimination of endogenous GSK-3β. Therefore, the aim 
was to silence the endogenous human GSK-3 kinase using miR expression constructs and to 
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overexpress specifically the GSK-3β mutants of interest. In order to avoid targeting and 
degradation of the transfected mutants by the GSK-3β-targeting miR sequences, GSK-3β 
constructs with sequences from xenopus were used for transfection. 
 
IV - 6.1) Evaluation of the efficiency of miR RNAi expression vectors regarding 
GSK-3β silencing to select the most appropriate candidate 
Three promising miR sequences targeting human GSK-3β were selected using the 
criteria advised by the Wadsworth Bioinformatics Centre website interface. Moreover, the 
miR candidates chosen should avoid targeting of the human GSK-3α isoform and of the 
xenopus GSK-3α and GSK-3β isoforms. The specificity of the candidate sequences for 
human GSK-3β was checked using the HUSAR and NCBI interfaces. The 741 miR, 599 miR 
and 1839 miR were selected and cloned into pcDNA6.2 vectors expressing the green 
fluorescence protein (GFP). After transfection of MCF-7 cells with the miR constructs, 
GSK-3β silencing was observed using immunofluorescence, quantitative PCR and western 
blot analyses. Fig. IV - 21 shows a representative field of cells transfected with the different 
constructs and assessed with double fluorescence. The green fluorescence shows the GFP 
expression of the constructs in transfected cells and the red immunofluorescence evaluates the 
GSK-3β protein levels of the cells using an anti-GSK-3β specific antibody. Overlay of red 
and green immunofluorescence indicates the efficiency of GSK-3β silencing in transfected 
cells. Cells transfected with the control miR construct showed an orange colour overlay 
reporting a lack of GSK-3β silencing. For the candidate miRs, a green colour overlay 
demonstrated that GSK-3β expression was greatly reduced in cells expressing GFP due to the 
presence of the miR. The fluorescence overlay results suggested that the 599 miR was the best 
candidate to silence endogenous GSK-3β. The 1839 miR was also efficient and it seemed that 
the 741 miR was only weakly reducing GSK-3β protein level.  
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Figure IV - 21: GSK-3β silencing using miR expression vectors. MCF-7 cells were transfected 
either with miR expression vector targeting the mouse brain glucocorticoid receptor GPR54 and used 
as a negative control (CT miR) or with GSK-3β miR expression vectors (GSK-3β miR 741, GSK-3β 
miR 599 and GSK-3β miR 1839) targeting different sequences of the human GSK-3β gene. After 48 h 
transfection, cells were fixed and stained. The same field of cells is shown in each row to reveal 
EmGFP (auto-fluorescence), GSK-3β (immunofluorescence using rabbit GSK-3β primary antibody 
and Cy3 labelled anti-rabbit secondary antibody), and the overlay of EmGFP and GSK-3β 
fluorescences. Transfection efficiency reached about 50 % for each construct (evaluation of GFP 
tagged cells vs. the total number of cells per microscopic field). The orange overlay observed for the 
CT miR transfected cells suggests the presence of both miR expression vector and GSK-3β protein in 
these cells. This overlay colour was also observed for most of the GSK-3β miR 741 transfected cells. 
For the GSK-3β miR 599 and the GSK-3β miR 1839 expression vectors, the majority of the cells 
expressing GFP do not appear to have GSK-3β present, and cells stained red for GSK-3β do not 
appear to have any GFP expression. This demonstrates that cells expressing EmGFP miR 599 and 
EmGFP miR 1839 are greatly reduced in GSK-3β expression due to the presence of the miR.   
 
 
The 599 miR was confirmed to be a highly potent candidate reducing GSK-3β mRNA 
expression quantified by real-time PCR (Fig. IV - 22A), and GSK-3β protein level analysed 
by western blotting (Fig. IV - 22B). The 1839 miR was also efficient in decreasing GSK-3β 
mRNA and protein levels and the 741 miR was confirmed to poorly silence GSK-3β. 
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Surprisingly, although care was taken when choosing the miR, reduced GSK-3α isoform 
protein levels (Fig. IV - 22B) were also observed each time when the GSK-3β isoform was 
successfully silenced. This agrees with data obtained by GSK-3β silencing using siRNA (see 
Fig. IV - 17B). Taken together, these data suggest that the GSK-3β isoform may be involved 
in the regulation of the GSK-3α isoform protein content. Additionally, these data reveal that 
the strongest silencing of GSK-3β was achieved using the 599 miR expression vector.   
 
 
Figure IV - 22: Silencing of GSK-3β was efficient with the 599 miR and the 1839 miR expression 
vectors. Panel A. MCF-7 cells were transfected either with CT miRNA plasmid or with expression 
vectors targeting GSK-3β (741 miRNA, 599 miRNA and 1839 miRNA). 66 h post-transfection, total 
RNA was extracted and used to synthesize cDNA by reverse transcription. Quantitative real- time 
PCR using GSK-3β primers showed that miR-related decrease of GSK-3β mRNA expression was 
significantly achieved upon 599 miRNA and 1839 miRNA transfection. β-actin was used as an 
internal control. Three independent experiments were analyzed and error bars represent the standard 
error of the mean (*, p < 0.05 determined by t-test). Panel B. MCF-7 cells were left untransfected 
(CT no miRNA) or were transfected either with CT miRNA plasmid or with expression vectors 
targeting GSK-3β (741 miRNA, 599 miRNA and 1839 miRNA). Lysates were obtained after 66 h of 
transfection. Immunoblots (IB) showing GSK-3α/β protein levels confirmed the results obtained in 
Panel A. β-actin was used as loading control.  
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IV - 6.2) Rescue of endogenous human GSK-3β silencing with xenopus GSK-3β 
constructs and effect on ERα protein level 
The 599 miR expression vector was used to silence endogenous GSK-3β. Co-
transfection of the MCF-7 cells with different constructs of xenopus GSK-3β aimed to rescue 
the loss of endogenous GSK-3β and to find the domain or amino acid residues of GSK-3β 
relevant for protecting ERα from proteasomal degradation. GSK-3β is highly conserved 
between the human and the xenopus species (92 % similarity according to Forde and Dale, 
2007) suggesting that the xenopus GSK-3β wild type (WT) may have a similar role in 
comparison with the human isoform and may be suitable to replace the human GSK-3β 
(Fig. IV - 23A). Moreover, key amino acids involved in the regulation of GSK-3β kinase are 
conserved between the two species suggesting that xenopus GSK-3β mutants will have the 
same effects as the human mutants. If this proofs true, the specific effects of each mutant 
regarding ERα function could be strictly determined without interference of the endogenous 
GSK-3β. While the 599 miR was shown to specifically target the human GSK-3β cDNA 
sequence, numerous mismatches of 599 miR with the xenopus GSK-3β cDNA sequence were 
encountered (Fig. IV - 23B), suggesting a specific silencing of the human isoform. Therefore, 
interference of the endogenous GSK-3β with the overexpressed xenopus GSK-3β is 
anticipated.  
Using anti-GSK-3α/β antibody recognizing the human as well as the xenopus GSK-3 
epitopes, we observed a rescue of the 599 miR-related silencing of the human GSK-3β 
isoform by the xenopus GSK-3β (Fig. IV - 23C). This rescue was shown for the WT and the 
dominant negative (DN or K85M/K86I) xenopus mutants and this rescue was confirmed 
using an antibody recognizing the GSK-3β isoform alone. Importantly, rescue of ERα protein 
content was observed after the rescue of the GSK-3 protein. Silencing of GSK-3β decreased 
ERα protein level, and rescue of GSK-3β with WT or DN xenopus constructs resulted in 
increased ERα. Overall, these results suggest that GSK-3β stabilizes ERα and stabilization is 
independent of GSK-3 kinase activity. Interestingly, GSK-3α overexpression was also 
observed when GSK-3β isoform was rescued. Together with the findings on GSK-3α down-
regulation after GSK-3β silencing, this observation suggests a regulation of GSK-3α 
expression level by GSK-3β. Additionally, a role of the overexpression of the endogenous 
GSK-3α isoform in the rescue of the ERα protein cannot be excluded. 
 
Results  89 
 
Figure IV - 23: Xenopus GSK-3β rescue of 599 miR-silenced human GSK-3β and rescue of 599 
miR-related ERα protein decrease. Panel A. Using the HUSAR interface and the database from 
NCBI website, best fit was performed between amino acid sequences of the human GSK-3β (upper 
line) and the xenopus GSK-3β (lower line) showing that GSK-3β is highly conserved between these 
two species which suggests a similar role of the two proteins regarding GSK-3β substrates. For 
example, the Ser-9 residue (green), Lys-85 and Lys-86 residues (red) as well as Arg-96 (blue) residue 
are shown to be conserved. These residues are important for the phosphorylation and inactivation of 
GSK-3β, for kinase activity of the enzyme and for primed-phosphate substrate binding to its GSK-3β 
docking site, respectively. Panel B. Using the same websites as in Panel A, the DNA sequence related 
to the 599 miRNA construct was shown to be 100 % similar to the human GSK-3β and only 77 % 
similarity was achieved for the xenopus GSK-3β with 10 mismatches present. This proves that the 
599 miRNA specifically targets the human GSK-3β. Panel C. MCF-7 cells were transfected with the 
control miR plasmid (CT miRNA) or with the 599 miR expression vector (599 miRNA), or MCF-7 
cells were co-transfected with the CT miRNA or the 599 miR and either with the xenopus GSK-3β 
wild type construct (X GSK-3β WT) or with the 599 miR and xenopus GSK-3β dominant negative 
construct (X GSK-3β DN). Lysates were obtained after 66 h of plasmid transfection. Immunoblots 
(IB) showing 599 miR-related silencing of GSK-3β and rescue of this kinase by the xenopus 
constructs. Immunoblots also show that the 599 miR-related decrease of ERα was rescued by WT and 
DN xenopus GSK-3β expression. β-actin was used as loading control.     
 
 
IV - 7) GSK-3β protein expression pattern in human breast cancer 
 
The ultimate aim of the project will be to prove that the GSK-3β/ERα signalling 
pathway depicted in immortalized cell culture lines may have some impact on breast 
tumorigenesis. Therefore, we first investigated the expression of GSK-3β protein in breast 
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cancer samples. Immunohistochemistry was performed on human breast tissue sections that 
contained tumors of different grades in order to determine the expression pattern of GSK-3β 
protein according to the tumor grade.  
 
IV - 7.1) From normal breast tissue to breast cancer 
The histological evaluation and grading of patient’s pre-cancerous and cancerous 
breast tissues is an important diagnostic performed by pathologists to orientate the patient in 
the most appropriate treatment strategy. After surgery, histological diagnosis represents a 
powerful tool to estimate complete removal of the tumor. Histopathological grading of the 
tumor contributes to determine the strategy of the patients’ treatment. Grade 1 tumors 
represent cancer with slower cell growth, high differentiation status and better prognosis, 
whereas cancers with faster cell growth, low differentiation status, bad prognosis and high 
probability of recurrence are classified into grade 3.  
 
 
Figure IV - 24: Expression of GSK-3β in normal human mammary tissues and breast cancers. 
Immunohistochemical staining using GSK-3β antibody (yellow to brown colour developed by DAB 
peroxidase reaction) and hematoxylin counterstaining (blue colour) on formalin-fixed paraffin sections 
from breast cancer patients. Normal mammary tissue (A) showing a central duct surrounded by lobules 
consisting of alveoli (inset showing higher magnification). The outer layer of the alveolus is formed by 
myoepithelial cells while the inner layer is composed by luminal epithelial cells. Benign hyperplastic 
alterations, i.e. papilloma-like and apocrine cyst-like structures are shown in (B) and (C), respectively. 
These pre-cancerous lesions may evolve into cancer. Intraductal grade 1 tumor cell mass is shown in 
(D). (E) shows a grade 2 ductal invasive carcinoma. The structure of the duct is destroyed and tumor 
cells are invading the stromal tissue of the breast. A highly malignant grade 3 tumor (F) shows nuclear 
polymorphism and variation in nuclear size as well as mitotic figures. The inset in the upper left 
corner shows a metaphase and the inset in the lower left corner shows an aberrant mitotic figure with 
annular arrangement of chromosomes in metaphase. [Magnifications: Panel A: x 50 (inset: x 160); 
Panel B: x 160; Panel C: x 160; Panel D: x 100; Panel E: x 100; Panel F: x 200 (insets: x 400)].   
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Normal mammary tissue is shown in Fig. IV - 24A. We observe that the normal breast 
consists of ducts and lobules embedded into stromal tissue. Higher magnification of two 
lobular alveoli is shown in the inset. Most breast tumors arise from the ducts of the mammary 
glands. Hyperplasia may arise within the ducts (Fig. IV - 24B-C) and this pre-cancerous 
lesion may evolve into cancer. First, intraductal growth of tumors is observed. Fig. IV - 24D 
shows a grade 1 intraductal tumor. Then, cancer cells will cross beyond the ductal cell layers 
and the basement membrane to invade the breast stromal tissue (Fig. IV - 24E). Finally, 
highly malignant grade 3 tumors are observed (Fig. IV - 24F). A hallmark of grade 3 tumors 
is a strong aberration in the morphology and size of the nuclei as well as an increased number 
of mitotic figures (Fig. IV - 24F). Besides regular mitotic figures (Fig. IV - 24F, upper left 
corner), aberrant mitotic figures (Fig. IV - 24F, lower left corner) are observed.  
In normal tissue, a weak and cytoplasmic-localised staining of GSK-3β protein was 
observed in both lobular and ductal epithelial cells. In pre-cancerous and cancerous lesions, 
various intensities were detected. To statistically evaluate GSK-3β protein content according 
to the tumor grade, scoring of the GSK-3β staining intensity was performed thereafter. 
 
IV - 7.2) Scoring of the GSK-3β immunohistochemical staining intensity 
Immunohistochemical staining of GSK-3β protein was performed and the intensity of 
the staining was scored as (0) for negative/faint staining, (1) for very weak/weak staining and 
(2) for moderate/strong staining (Fig. IV - 25). Since GSK-3β protein was mainly detected in 
the cytoplasm of the tumor cells, the scoring was based on the cytoplasmic staining of 
GSK-3β. Only rarely and exclusively for the scoring intensity of (2), nuclear staining of 
tumor cells were observed. Primarily, five scores were considered, but thereafter, the very 
weak and weak as well as the moderate and strong staining intensities were regrouped 
together into scores 1 and 2, respectively. The aim was to increase the number of cases for 
each score.  
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Figure IV - 25: Immunohistochemical staining of GSK-3β and scoring of the staining intensity. 
Using a monoclonal antibody, GSK-3β was detected in formalin-fixed paraffin sections from grade 
1/2 and grade 3 breast cancer tissues and the intensity of the staining was scored as indicated for the 
representative fields shown (magnification x 100): negative to faint (score 0, left panel), very weak to 
weak (score 1 or yellow colour, middle panel) and moderate to strong (score 2 or orange/brown 
colour, right panel). For each score, a representative field is shown at higher magnification (x 200). 
GSK-3β is mainly located to the cytoplasm. Inflammatory cells often observed in breast cancer appear 
negative (black arrows, right panel).  
 
Immunohistochemical staining of GSK-3β was evaluated semi-quantitatively 
according to the previously described scoring. 29 tumor samples from German patients 
(16 cases of grade 1/2 and 13 cases of grade 3) and 43 tumor samples from Chinese patients 
(23 cases of grade 1/2 and 20 cases of grade 3) were analyzed (Fig. IV - 26).  
In the samples from German patients, among the grade 1/2 tumors, 4 cases had a 
GSK-3β scoring intensity of (0), 8 cases had a GSK-3β scoring intensity of (1) and 4 cases 
had a GSK-3β scoring intensity of (2). Among the grade 3 tumors, 2 cases had a GSK-3β 
scoring intensity of (0), 3 cases had a GSK-3β scoring intensity of (1) and 8 cases had a 
GSK-3β scoring intensity of (2). Using the Fisher’s exact statistical test for comparison of 
grade 1/2 and grade 3 tumors, a P-value of 0,148 was calculated meaning that no statistically 
significant difference was achieved for the GSK-3β scoring intensity between grade 1/2 and 
grade 3 tumors. If the (0) and (1) scores were regrouped together, a P-value of 0,067 was 
reached between grade 1/2 and grade 3 tumors. Under the latter conditions, the difference of 
GSK-3β staining intensity between grade 1/2 and grade 3 tumors was still not statistically 
significant but a trend towards a higher GSK-3β staining intensity in grade 3 tumors could be 
observed. For the samples from the Chinese patients, the P-values obtained were too high to 
draw any conclusions. No obvious tendency for the GSK-3β scores was observed between the 
grade 1/2 tumors and the grade 3 tumors. Overall, the number of cases studied was too low to 
obtain any statistically significant differences in staining intensities according to the tumor 
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grade. However, analysis of the tumor samples from the German patients suggests that 
GSK-3β protein expression may increase with the tumor grade.  
 
 
Figure IV - 26: Evaluation of immunohistochemical staining for GSK-3β. Tumor samples from 
two ethnic populations were studied (29 German and 43 Chinese patients). For the German patients, 
16 cases were grade 1/2 and 13 cases were grade 3. For the Chinese patients, 23 cases were grade 1/2 
and 20 cases were grade 3. No statistically significant difference in GSK-3β staining intensity between 
the tumor grades was obtained using the Fisher exact test within both populations. However, a 
tendency toward an increase of GSK-3β staining intensity from the low grade to the high grade tumors 
was observed within the German patients.    
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V - Discussion 
 
We previously established functional links between GSK-3β activity and E2-
dependent ERα activation and provided evidence that GSK-3β modulates ERα function by 
phosphorylation of relevant serine residues (Medunjanin et al., 2005). In the present work, the 
aim was to unravel the specific role of GSK-3 in ligand-dependent activation of ERα in 
human ER+ breast cancer cell lines. More precisely, we showed that GSK-3 not only plays a 
role in ERα activation by phosphorylating Ser-118, but also contributes significantly to the 
stability of ERα by complex formation in unstimulated cells. By this dual regulation of ERα, 
GSK-3 may link the nongenomic (cytoplasmic) and genomic (nuclear) effects of E2. Indeed, 
cytoplasmic GSK-3 is phosphorylated and inactivated upon E2 stimulation of cells, 
hypothetically, by nongenomic or rapid effects of E2. This releases ERα from its complex 
with GSK-3, allowing translocation of ERα into the nucleus. In this cellular compartment, 
E2-induced phosphorylation of the receptor at Ser-118 by a nuclear pool of GSK-3 will 
activate genomic action of ERα and stimulate transcription of ERα target genes. 
This newly depicted signalling pathway, describing the regulation of ERα function 
and activity by GSK-3, may have some impact regarding breast cancer progression. 
Therefore, our actual aim is to study the relevance of GSK-3/ERα interaction according to the 
tumor grade. Preliminary data were obtained using GSK-3 immunostaining of formalin-fixed 
human tissue section. 
 
 
V - 1) Rapid effects of E2 treatment on the intracellular localisation and the 
phosphorylation status of ERα and GSK-3 
After treatment of MCF-7 cells with E2, the phosphorylation status of GSK-3 and 
ERα and the intracellular localisation of ERα were rapidly altered, maximum effects being 
observed within less than 20 min after E2 stimulation. The genomic activity of E2-bound 
ERα can not explain these quick cellular responses and nongenomic effects of E2 were 
suggested to be responsible for these alterations. After E2 treatment, rapid translocation of 
ERα from the cytoplasm to the nucleus and nuclear phosphorylation of the receptor at 
Ser-118 were observed. Moreover, E2 treatment caused a rapid cytoplasmic GSK-3 
phosphorylation leading to inactivation of the cytoplasmic fraction of the enzyme, while the 
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nuclear pool of GSK-3 was not affected. This allows nuclear GSK-3 to be a potential kinase 
phosphorylating nuclear ERα at Ser-118. 
 
V - 1.1) E2-induced translocation of ERα into the nucleus 
In agreement with previous work from our group (Medunjanin et al., 2005; De Servi 
et al., 2005) and work from others (Horwitz and McGuire, 1978), ERα was detected in both 
the cytoplasm and the nucleus in serum-starved MCF-7 cells. After E2 treatment, 
translocation of the receptor from the cytoplasm to the nucleus of MCF-7 cells was observed. 
In resting MCF-7 cells, a smaller portion of this steroid receptor was reported to be localized 
in the cytoplasm (about 35 %) and the greater proportion of ERα was located in the nucleus; 
after E2 treatment, ERα was almost exclusively localized in the nucleus of these cells 
(Horwitz and McGuire, 1978). Moreover, E2-induced nuclear translocation of ERα is a 
prerequisite for the activation and function of ERα regarding genomic effects of the receptor, 
which are restricted to the nucleus of the cells.  
 
V - 1.2) E2-induced nuclear phosphorylation of ERα at Ser-118 
E2-induced phosphorylation of Ser residues in the AF-1 domain of ERα is described 
as one of the most important features in signal transduction cascade leading to activation of 
the steroid receptor. In response to estradiol, ERα becomes predominantly phosphorylated in 
the AF-1 domain at Ser-118 and to a lesser extent at Ser-104 and Ser-106 (Lannigan, 2003). 
In agreement with these observations, we recently described that ERα was mainly 
phosphorylated at Ser-118 residue upon E2 treatment of MCF-7 breast cancer cells 
(Medunjanin et al., 2005). In the present work, we confirmed the strong E2-induced increase 
of ERα phosphorylation at Ser-118. After cellular fractionation, the data obtained suggest that 
this phosphorylation mainly occurs in the nucleus of MCF-7 cells. More precisely, a speckled 
nuclear accumulation of pSer118 ERα was first observed after E2 treatment. Then, pSer-118 
ERα signal was detected in the whole nucleus. This suggests a time-scheduled organization of 
the molecular events in response to external stimuli and this is in agreement with the 
intranuclear mobility of ERα in association with nuclear matrix dynamics described by 
Matsuda et al. (2007).  
A recent report (Valley et al., 2005), in agreement with the fact that Ser-118 
phosphorylation was required for full ERα transcriptional activity (Lannigan, 2003), 
demonstrated that Ser-118 phosphorylation regulates transcriptional efficiency through the 
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differential recruitment of coactivators and transcriptional machinery to estrogen-responsive 
promoters. Work from our group, in agreement with these publications, also showed by co-
transfection of constructs carrying ERα mutants and ERE-luciferase reporter plasmid in 
MDA-MB-231 ERα-negative cells that the S118A mutant construct activated ERE-dependent 
luciferase activity significantly less (about 3-fold) than the WT ERα construct (Medunjanin 
et al., 2005). Overall, phosphorylation of ERα at Ser-118 seems to be crucial for E2-induced 
ERα transcriptional activity. However, the protein kinases responsible for this 
phosphorylation are still under investigations. Work from our group (Medunjanin et al., 2005) 
suggested that ERα is a substrate for GSK-3, being phosphorylated at Ser-118. Therefore, 
GSK-3 may be one of the kinases involved in E2-induced ERα activation. This issue will be 
discussed in the part V - 2.2.3  
 
V - 1.3) Nongenomic effects of E2 regarding cytoplasmic GSK-3β activity 
Since we suggested that GSK-3 plays a role in ERα activation, our first aim was to 
determine the effects of E2 on GSK-3 function. After E2 treatment, GSK-3α/β 
phosphorylation at Ser-21/9 was increased mainly in the cytoplasm, especially at the peri-
nuclear site of MCF-7 cells. The kinetics of this E2-induced phosphorylation and consequent 
inactivation of GSK-3 kinase coincides with ERα translocation, which suggests a role for this 
kinase in the regulation of ERα translocation and implies that GSK-3 might be a gatekeeper 
to ERα nuclear entry. Nongenomic (cytoplasmic) effects of E2 may be responsible for this 
rapid phosphorylation. Unpublished work from our group has shown that PKB/Akt is rapidly 
activated by phosphorylation upon E2 treatment in MCF-7 cells. Interestingly, Greger et al. 
(2007) identified a so-called modulator of nongenomic action of estrogen receptor (MNAR) 
in MCF-7 cells and they suggested that phosphorylation of this novel scaffold protein 
promotes phosphorylation and activation of PI3K upon E2 stimulation, leading to increased 
phosphorylation of PKB/Akt. This mechanism could be responsible for the phosphorylation 
of the PKB/Akt-substrate GSK-3 in E2 treated cells. 
Moreover, we observed an accumulation of ERα at the plasma membrane after 20 min 
E2 treatment. This event was transient and only minute amounts of ERα seemed to be 
involved. However, this accumulation may have relevant impacts on the E2 signalling 
pathway. Indeed, the aim of all signal transduction pathways is to amplify a signal to adapt 
the cells to the change of their environment. Only recently, a number of papers have been 
published on this topic to explain the modality of ERα membrane association and the rapid 
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effects (milliseconds to minutes) of this plasma membrane associated ERα in the non-
genomic actions of estrogens (Vasudevan and Pfaff, 2007).  
Taken together, these data suggest that E2 may bind to the plasma membrane-
associated ERα and then activate the PI3K/Akt signalling pathway leading to rapid 
phosphorylation and inactivation of cytoplasmic GSK-3. Moreover, this does not exclude a 
role for putative nuclear GSK-3 regarding E2-induced ERα activation. 
 
 
V - 2) Sub-cellular roles of GSK-3β regarding E2 signalling pathway 
 
As GSK-3 is involved in numerous signalling pathways, formation of intracellular 
GSK-3 pools was suggested. Cellular distribution of GSK-3 to the cytosol, mitochondria and 
nuclei enables local separation of GSK-3 functions (Ali et al., 2001; Jope and Johnson, 2004). 
In agreement with the assumption that a pool of GSK-3 related to a specific signalling 
pathway may be activated or inactivated upon a specific stimulus, we suggested that the 
regulation of ERα-mediated estrogen signalling was controlled by a dual action of GSK-3. 
Cytoplasmic GSK-3 may interact with and stabilize ERα under resting conditions and nuclear 
GSK-3 may be involved in ligand-dependent activation of the receptor (Medunjanin et al., 
2005). Thus, GSK-3 may be the missing link and mediator between nongenomic and genomic 
effects of E2. Indeed, our results showed, in agreement with previous work form our group 
(De Servi et al., 2005; Medunjanin et al., 2005), that GSK-3 is present both in the cytoplasm 
and nucleus of the cells. Originally, GSK-3 was described mostly sequestered in cytosolic 
protein complexes. Recently, Meares and Jope (2007) identified a bipartite nuclear 
localization sequence (NLS) which is necessary for the nuclear accumulation of GSK-3β; and 
they discussed potential sub-cellular actions of the cytosolic and nuclear GSK-3. Additionally, 
E2 treatment did not seem to alter GSK-3 cellular localization suggesting that cytoplasmic 
and nuclear GSK-3 pools are distinct and work independently from each other in E2 treated 
cells.  
To unravel the specific role of cytoplasmic and nuclear GSK-3 in ligand-dependent 
activation of ERα, several methodological approaches were considered. In the following, the 
results obtained will be discussed and their respective contributions to the model summarizing 
our findings and presented at the end of this part will be described. 
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V - 2.1) Discrepancies of GSK-3β inhibitors regarding E2 signalling pathway 
To study the role of GSK-3 regarding ERα signalling pathway, MCF-7 cells were 
treated with different GSK-3 inhibitors and their effects on E2-induced ERα translocation and 
nuclear phosphorylation at Ser-118 were monitored.  
Jope (2003) showed that lithium ions reduce GSK-3 activity in two ways, both 
directly, as a competitive inhibitor of Mg2+, and indirectly, by increasing phosphorylation of 
GSK-3. In agreement with this work, increased phosphorylation of GSK-3β at Ser-9 was 
observed in our experiments when cells were treated with LiCl. However, these data are at 
variance with another study. Indeed, Stambolic et al. (1996) described that LiCl did not 
inhibit GSK-3 by Ser-9 phosphorylation. They also suggest that LiCl inhibits GSK-3 kinase 
by mimicking the Wnt signalling pathway, inducing the accumulation of cytoplasmic 
β-catenin. Even if the molecular mechanisms leading to inhibition of GSK-3 by LiCl are still 
under discussion, lithium was unanimously shown to be a potent inhibitor of GSK-3. 
Regarding the ERα signalling pathway, LiCl did not influence the receptor protein level and 
did not alter the E2-induced ERα translocation. However, E2-induced Ser-118 
phosphorylation of nuclear ERα was dramatically reduced. This suggests that GSK-3 
phosphorylates ERα at Ser-118 upon E2 stimulation. However, the specificity of LiCl has 
been questioned. According to Coghlan et al. (2000), LiCl cause an acute inhibition of GSK-3 
activity in cells, but LiCl also showed inhibitory effects on other protein kinases (as a low 
mM inhibitor of casein kinase-2 and p38 regulated/activated kinase). The LiCl-related 
decrease of ERα phosphorylation at Ser-118 after E2 treatment may therefore not exclusively 
be due to an inhibition of GSK-3.  
To confirm the result obtained with LiCl, the recently described maleimide inhibitors 
SB4 and SB2 were used. These small-molecules are potent and selective inhibitors of GSK-3 
(Cross et al., 2001). These cell permeable inhibitors act in an ATP competitive manner and 
25 different serine/threonine and tyrosine protein kinases were tested to prove their high 
specificity regarding inhibition of GSK-3β kinase activity (Coghlan et al., 2000). However, 
while SB2 inhibitor did not alter E2-induced ERα translocation and phosphorylation at 
Ser-118, treatment of MCF-7 cells with SB4 inhibitor alone induced ERα translocation and 
increased Ser-118 phosphorylation of nuclear ERα. This unexpected observation implies 
unclarified mechanisms and unravels potential estrogenic properties of SB4. 
LiCl and maleimide inhibitors have all been shown to elevate the level of β-catenin in 
transformed cell lines and therefore might be expected to mimic the Wnt signalling pathway 
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and be potentially oncogenic (Cohen and Goedert, 2004). In our experiments, the oncogenic 
properties of these inhibitors were not observed. Indeed, LiCl and maleimides inhibited basal 
and E2-induced proliferation of MCF-7 cells. In breast cancer cells, these inhibitors may 
inhibit mammary tumor proliferation but the mechanisms are so far not understood and must 
be further investigated.  
 
V - 2.2) Effects of GSK-3 silencing on estrogen signalling pathway 
To more specifically inhibit GSK-3, RNAi was used to silence both GSK-3 isoforms 
simultaneously or separately. The aim was to specifically target and therefore decrease the 
protein level of GSK-3 and to investigate if GSK-3 was involved in ligand-dependent 
activation of ERα.  
 
V - 2.2.1) GSK-3 silencing disrupts ERα turnover 
In absence of hormonal stimulation, a tightly regulated protein turnover allows the 
cells to maintain a balance between ERα protein synthesis and degradation leading to 
constant cellular level of the receptor (Reid et al., 2003). Our data clearly show that efficient 
silencing of GSK-3 in MCF-7 cells provokes a decrease of ERα protein level. First, we 
hypothesized that GSK-3 silencing-related decrease of ERα protein level was a consequence 
of a decrease in ERα transcription. In order to address this hypothesis, ERα mRNA was 
quantitated in cells transfected with GSK-3 siRNA. According to our results, an early 
transient decrease of basal ERα mRNA expression was observed (Fig. IV - 10). Adaptation of 
the cells to GSK-3 silencing on the one hand and to changes of the cell culture medium due to 
the experimental protocol on the other hand seemed to compensate this transient ERα mRNA 
decrease while the ERα protein level remained reduced in these cells. Furthermore, a 
downregulation of ERα protein level was observed upon E2 treatment and this 
downregulation was reinforced in cells transfected with GSK-3 siRNA. Once again, a 
reduction of ERα transcription was assumed regarding both E2 treatment and GSK-3 
silencing. Interestingly, our data showed an E2-related decrease of ERα mRNA in control 
siRNA transfected cells, which can explain the decrease of the ERα protein level observed 
after E2 treatment. Indeed, an autologous downregulation pathway of ERα, which involves 
binding of liganded ERα to the promoter of its own gene, has been described (Saceda et al., 
1988; Kaneko et al., 1993; Davis et al., 1999). By this mechanism, estrogens induce a decline 
in ERα mRNA and protein (Saceda et al., 1988). Surprisingly, GSK-3 silencing did not 
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further affect the autologous downregulation of ERα mRNA, although a tendency to a more 
pronounced decrease of ERα mRNA expression, which we cannot explain, was observed in 
cells treated with E2 for 48 h Overall, our data indicated that GSK-3 silencing did not 
significantly or only transiently alter basal and E2-related decrease of ERα mRNA levels at 
the time points investigated. These results suggest that the GSK-3 silencing-related ERα 
protein decrease might not be due to regulation of ERα transcription. 
Then, inhibition of protein biosynthesis was considered as a putative mechanism 
leading to GSK-3 silencing-related decrease of ERα protein level. The translation inhibitor 
CHX was used to address this alternative. However, the use of this inhibitor did not support 
the hypothesis that GSK-3 silencing caused a decrease of ERα translation.  
Our last hypothesis was that GSK-3 silencing resulted in increased ERα proteasomal 
degradation . The use of the proteasome inhibitor MG132 showed a significant rescue of ERα 
protein upon GSK-3 silencing both in unstimulated and E2-stimulated cells demonstrating a 
direct impact of GSK-3 on ERα proteasomal degradation. While these results do not exclude 
any modulation of ERα translation by GSK-3, GSK-3 is suggested to have an effect on ERα 
proteasomal degradation rather than on ERα biosynthesis. To confirm the GSK-3 silencing-
related increase of ERα proteasomal degradation, immunoprecipitation of ERα was 
performed in presence of proteasome inhibitor MG132. Immunoblotting using anti-ubiquitin 
and ERα antibodies clearly showed an accumulation of ubiquitinated ERα and a rescue of 
ERα protein levels, respectively. These data showed that ERα degradation observed after 
GSK-3 silencing was due to proteasomal proteolysis. By this mechanism, GSK-3 silencing 
deregulates ERα protein turnover and decreases ERα protein level. 
 
V - 2.2.2) The docking properties of GSK-3 stabilizes ERα 
Previous findings on direct interaction of the docking kinase GSK-3 with ERα raised 
the hypothesis that formation of an ERα/GSK-3 complex stabilizes ERα in the cytoplasm 
(Medunjanin et al., 2005). This hypothesis is corroborated by the observation presented in this 
report. It is shown that GSK-3 silencing using specific siRNA results in reduction of cellular 
ERα protein levels. Taken together, these findings permit the conclusion that GSK-3 protects 
ERα from proteasomal degradation and that complex formation between GSK-3 and ERα 
plays a crucial role in ERα protein stabilization and turnover. Complex formation involving 
GSK-3 has been shown to be important for stabilization of other proteins as well. In the Wnt 
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signalling pathway, active GSK-3 appears in a multiprotein complex that includes the 
transcription factor β-catenin and the scaffold protein axin (Frame and Cohen, 2001). Axin 
binding to GSK-3 and subsequent phosphorylation leads to stabilization of this protein 
(Yamamoto et al., 1999). In analogy to axin, the interaction of ERα with GSK-3 appears to be 
required for stabilization of the receptor.  
In a separate independent approach, we confirmed that ERα protein levels were 
decreased upon GSK-3 silencing using miR expression vectors targeting GSK-3β. 
Transfection of xenopus GSK-3β constructs, in order to rescue the silencing of endogenous 
GSK-3, also resulted in the rescue the GSK-3-silencing related decrease of ERα protein 
content. This result does not only confirm the data described above regarding the stabilization 
of ERα by GSK-3, it also demonstrates the similarity in activity of the xenopus and the 
human GSK-3 kinase regarding ERα substrate. Interestingly, ERα protein rescue was 
achieved with both WT and DN xenopus GSK-3β constructs suggesting that the kinase dead 
GSK-3 may also form a complex with ERα. Therefore, GSK-3 kinase activity may not be 
required to stabilize ERα and the docking properties of GSK-3 protein may be responsible for 
complex formation with this receptor. However, reinforcement of ERα stabilisation by 
phosphorylation can not be excluded. Our first published model (Medunjanin et al., 2005) 
suggested a cytoplasmic GSK-3β-dependent phosphorylation of the Ser-102, 104, 106 motif 
of ligand-free ERα in resting cells. This phosphorylation may increase the stability of the 
complex formation between ERα and GSK-3β. 
 
V - 2.2.3) GSK-3 phosphorylates ERα at Ser-118 and is required for full 
E2-induced ERE-dependent ERα transcriptional activity 
A second important role of GSK-3 regarding ERα function is phosphorylation of the 
receptor. In vitro kinase assay showed that ERα is a GSK-3 substrate being phosphorylated at 
Ser-118. This result is in agreement with in vitro kinase assays performed by our group using 
wild type and mutant (Ser- to Ala-) GST-ERα fusion proteins to identify the ERα serine 
residue(s) phosphorylated by GSK-3β (Medunjanin et al., 2005).  
Since silencing of GSK-3 occurred in both the cytoplasm and the nucleus of the cells, 
and resulted in decrease of E2-induced ERα nuclear phosphorylation at Ser-118, we conclude 
that GSK-3 may phosphorylate this serine residue in the nuclei of MCF-7 cells. This is in 
agreement with data discussed in the part V - 1.2 that show a nuclear localization of E2-
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induced Ser-118 phosphorylation of ERα. Another important aspect is that the ratio of 
pS118/ERα was reduced in GSK-3 silenced cells treated with E2. This clearly indicates that 
the reduction of Ser-118 phosphorylation observed after GSK-3 silencing was not the 
consequence of downregulation of ERα protein but particularly due to lack of GSK-3 kinase 
activity. However, residual pSer-118 signal was observed after GSK-3 silencing 
(Figs. IV - 13, 14B and 17A). While this was probably due to GSK-3 protein remaining after 
siRNA silencing, activity of another protein kinase cannot be excluded.  
Moreover, data presented in this study showed that GSK-3 silencing resulted in a 
decrease of E2-induced ERE-dependent luciferase activity in MELN cells suggesting that 
GSK-3 silencing altered ERE-dependent transcriptional activity of ERα. After inhibition of 
the proteasome with MG132, the decrease of E2-induced luciferase expression was not 
restored whereas ERα protein level was rescued. It is possible that the ubiquitinated ERα 
forms may not have any transcriptional activity. Importantly, MG132 treatment alone did not 
significantly alter E2-induced luciferase activity in cells transfected with either control siRNA 
or GSK-3 siRNA. These results are at variance with a study published previously (Reid et al., 
2005) which reported a reduction of E2-induced ERE-dependent luciferase expression by 
MG132 treatment. The different findings can be explained by the different experimental 
settings. To minimize the side effects of MG132 in our study, we used a low dose of 
proteasome inhibitor for a short treatment period when measuring E2-induced ERE-luciferase 
activity in MELN cells.  
The results obtained from MELN cells transfected with GSK-3β constructs showed 
that overexpression of GSK-3β increased E2-induced ERα transcriptional activity. Similar 
results were obtained for the GSK-3β WT and the GSK-3β constructs inactive regarding 
GSK-3 primed substrates (i.e. R96A and R96K GSK-3β). Considering that Ser-118 
phosphorylation is a crucial step for E2-induced ERα transcriptional activity (see part 
V - 1.2), these results suggested that ERα may be phosphorylated at Ser-118 by GSK-3 in a 
non-primed manner. This observation is in agreement with the comparative alignment 
between sequences of ERα motif at Ser-118 and sequences of motifs of non-primed substrates 
such as Tau and cyclin D1 (Medunjanin et al., 2005). 
It is concluded that ERα is a non-primed substrate of GSK-3, being activated by 
phosphorylation at Ser-118 upon E2 stimulation. Moreover, the data demonstrate that GSK-3 
is required for full E2-induced ERE-dependent ERα transcriptional activity.  
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V - 2.2.4) GSK-3 is required for E2-induced expression of endogenous 
ERα target genes 
GSK-3 silencing resulted in a decrease of E2-induced expression of pS2 and 
progesterone receptor suggesting that GSK-3 is required for transcriptional expression of 
estrogen responsive genes. Although the regulation of ERα target genes via the sole classical 
ERE binding is under debate, pS2 gene shows a consensus ERE palindromic sequence, while 
progesterone receptor gene seems to have an alternative consensus ERE sequence (Klinge, 
2001). Therefore, GSK-3 may modulate a broad-range of estrogen responsive genes and not 
only ERα target genes with the sole consensus ERE sequence.   
 
V - 2.2.5) Model for the effects of GSK-3 silencing regarding ERα 
In previous work, our group has proposed a model for the potential function of GSK-3 
in ERα activation (Medunjanin et al., 2005). This model is now complemented by including 
the present findings (Fig. V - 1A). In unstimulated cells, a complex between active GSK-3 
and ERα stabilizes the receptor in the cytoplasm. Upon E2 treatment, phosphorylation of 
GSK-3α/β at Ser-21/9 residues results in inhibition of the kinase. Consequently, ERα is 
released and translocates into the nucleus where it is phosphorylated by active nuclear GSK-3 
at Ser-118 leading to full transcriptional activity. Eventually, E2 signal is switched off by 
ubiquitination and proteasomal degradation of ERα. The effects of GSK-3 silencing are 
described in Fig. V - 1B. The lack of GSK-3 results in reduction of ERα stabilization 
triggering its ubiquitination and degradation by the proteasome. As a consequence, ERα 
protein content is decreased. Moreover, E2-induced Ser-118 phosphorylation of the remaining 
ERα is reduced due to lack of GSK-3 kinase activity in the nucleus, which results in decrease 
of E2-induced ERα transcriptional activity.  
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Figure V - 1: Model for the effects of GSK-3 silencing regarding ERα.  Panel A. In unstimulated 
cells ERα is stabilized by interaction with active GSK-3 in the cytoplasm (1). Treatment of cells with 
E2 results in phosphorylation and inactivation of GSK-3, ERα release (2), translocation of ERα into 
the nucleus where it is phosphorylated by active nuclear GSK-3 at Ser-118 (3). Eventually, E2 signal 
is switched off by ubiquitination and proteasomal degradation of ERα (4). Panel B. Lack of GSK-3 
results in reduction of ERα stabilization triggering its ubiquitination and proteasomal degradation and 
in inhibition of E2-induced ERα phosphorylation at Ser-118 (Grisouard et al., 2007). 
 
 
V - 3) GSK-3 expression in breast cancer of different grades 
 
Data discussed so far have been obtained from cell culture models. The physiological 
relevance of the results remains to be clarified. It is of utmost interest whether ERα/GSK-3 
interaction occurs in vivo and triggers similar signals as observed in cell culture. If this proofs 
true ERα/GSK-3 could contribute to progression of estrogen-dependent cancers. Preliminary 
data are available from GSK-3 immunostaining experiments of formalin-fixed breast tissue 
sections taken from two ethnically different groups, namely German and Chinese patients. 
The results suggest a tendency toward increased GSK-3 expression in grade 3 tumors in 
comparison with the grade 1/2 tumors within the German group of patients. Since grade 3 
tumors show a more aggressive phenotype and spread more easily, these first results suggest a 
role for GSK-3 in breast cancer progression and in increase of breast tumor malignancy. 
However, the statistical evaluation of the data using the Fisher’s exact test did not prove this 
tendency. The number of cases investigated must be increased to draw statistical conclusions 
regarding GSK-3 expression pattern in breast tumorigenesis. Furthermore, a correlation with 
ERα expression must be provided. Moreover, the tendency observed for the German patients 
was not confirmed for the Chinese patients. While differences between the two ethnic 
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populations cannot be excluded, variations in the procedures used to supply the tissue 
specimens may explain possible discrepancies in the GSK-3β immunostaining of the tissue 
sections between the two groups. More precisely, the fixation step before embedding of the 
tissue, which is crucial for antigen recognition by the GSK-3β antibody, may have differed.  
 
In conclusion, GSK-3 was described as a key regulator of ligand-dependent activation 
of ERα and a role for GSK-3 in breast tumor progression and malignancy was suggested. 
These data may consider GSK-3 or better GSK-3/ERα interaction as a pharmaceutical target 
to inhibit estrogen-dependent growth of breast cancer cells and to prevent breast tumor 
progression. GSK-3 inhibitors were first synthesized to treat diabetic patients and to 
normalize their blood glucose levels. These inhibitors are now under investigation for the 
treatment of neurological disorders such as Alzheimer’s disease (Cohen and Goedert, 2004). 
Additionally, several recent publications suggested a potential new therapeutic application for 
GSK-3 inhibitors in prostate cancer (Mazor et al., 2004), colorectal cancer (Shakoori et al., 
2005; Shakoori et al., 2007), ovarian cancer (Cao et al., 2006) and pancreatic cancer 
(Ougolkov et al., 2006; Garcea et al., 2007), among others. Therefore, GSK-3 inhibitors or 
modulators should be considered to treat breast cancer. However, sustained GSK-3β 
inhibition was suggested as a hallmark of tumorigenesis. In vivo, transgenic mice 
overexpressing the DN-GSK-3β under the mouse mammary tumor virus (MMTV) develop 
mammary tumors with overexpression of β-catenin and cyclin D1 (Farago et al., 2005). These 
data suggest that the inhibition of GSK-3 activity mimics the Wnt pathway and could promote 
mammary tumors.  
 
 
V - 4) Outlook 
 
Prior to consider GSK-3 inhibitors as a possible therapeutic approach for ER+ breast 
cancer, further experiments need to be performed in order to investigate the efficiency and the 
potential side effects of promising GSK-3 inhibitors in the treatment of breast cancer. GSK-3 
is involved in various signalling pathways and GSK-3 regulates a wide range of cellular 
processes including metabolism, differentiation, growth, motility and apoptosis. New insights 
into the GSK-3 signalling pathways will especially help to select novel therapeutical 
approaches. New findings regarding GSK-3 interaction particularly with ERα and β-catenin 
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substrates and improvement in the understanding of the cross-talks between the related 
signalling pathways will notably permit to target the estrogenic pathway without side effects 
on the Wnt pathway, thus avoiding harmful side effects of possible GSK-3 treatment.  
The perspective of GSK-3β mutants selectively affecting ERα and putatively 
disrupting GSK-3/ERα interaction will be preferentially studied. In this work, we described a 
role for GSK-3 in ligand-dependent activation of ERα. We showed that GSK-3 protects ERα 
from proteasomal degradation and is involved in full transcriptional activation of the receptor. 
However, the GSK-3 domains or amino acids specifically involved in the interaction with 
ERα remain to be identified to determine their specific role either in ERα stabilization or in 
ERα phosphorylation and transcriptional activation, or in both of these newly depicted GSK-3 
functions. Therefore, it will be of interest to investigate the effects of the overexpression of 
various functional mutants of xenopus GSK-3β in cells transfected with miR targeting 
endogenous human GSK-3β. While we showed that the docking properties of GSK-3 were 
important for the stabilization of ERα, more work using the WT and DN xenopus GSK-3β 
constructs will be performed to further analyse the involvement of GSK-3 in E2-induced ERα 
phosphorylation and transcriptional activity. Additionally, other GSK-3β constructs will be 
tested. They include the S9A or CA GSK-3β construct, the R96A and R96K GSK-3β 
constructs, which are inactive regarding phosphorylation of primed-phosphorylated substrates 
by GSK-3, the GSK-3β dN (delta N) showing a N-terminal deletion of 63 amino acids, as 
well as the GSK-3β GR (V267G/E268R) construct which selectively disrupts axin-GSK-3 
interaction (Fraser et al., 2002).  
The next step will be to confirm in vivo the findings obtained in cancer cell lines. The 
effect of GSK-3 inhibitors on the progression of ERα-dependent mammary tumors will be 
investigated after orthotopical injection of ER+ breast cancer cells in nude mice. Similarly, 
the effects of GSK-3 inhibitors on transgenic mice expressing genes leading to the 
development of mammary gland adenocarcinomas, such as MMTV-Wnt1 transgenic mice 
(Tsukamoto et al., 1998) may be studied and especially the ERα-dependent progression of 
these tumors should be investigated. Other transgenic mouse models such as mice with 
constitutive knock-in of homologous GSK-3α S21A/GSK-3β S9A (MacManus et al., 2005) 
and mice overexpressing the DN-GSK-3β in the mammary gland (Farago et al., 2005) could 
be used to study GSK-3/ERα interaction in vivo. 
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Finally, the impact on human breast tumorigenesis of the GSK-3/ERα signalling 
pathway depicted in cancer cell lines needs further clarification. Preliminary 
immunohistochemistry data of tumor tissues from surgically-operated patients suggested a 
role for GSK-3 in breast tumor progression and malignancy. We will extend this study to a 
larger cohort of patients. . The increase of cases studied will also permit a statistical analysis 
of GSK-3 expression according to ERα expression within a group of specific tumor grade. 
Furthermore, the protein levels of GSK-3 and ERα do not indicate their functional status. 
Therefore, the phosphorylation status or inactivation level of GSK-3 and the phosphorylation 
status or activation level of ERα will be investigated in the collected cases. The data obtained 
from immunohistochemistry will be correlated with the clinical outcome of the patients.  
  
References  108 
VI - References 
 
VI - 1) Websites 
 
National Cancer Institute, www.cancer.gov
 
World Health Organisation, www.who.int
 
American Cancer Society, http://www.cancer.org
 
Robert Koch Institut, www.rki.de
 
Medlineplus: http://www.nlm.nih.gov/medlineplus
 
American College of Surgeons National Cancer, http://www.facs.org/cancer/ncdb
 
Whitehead Institute for Biomedical Research,  
http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi
 
Roche Applied Bioscience, http://qpcr2.probefinder.com
 
Wadsworth Bioinformatics Centre, http://sfold.wadsworth.org
 
Heidelberg UNIX Sequence Analysis Resources (HUSAR), http://genome.dkfz-heidelberg.de
 
National Centre for Biotechnology Information (NCBI), http://www.ncbi.nlm.nih.gov
 
 
VI - 2) Textbooks 
 
Larsen P. R., H. M. Kronenberg, S. Melmed and K. S. Polonsky. (2002). Williams Textbook of 
Endocrinology, 10th Edition, Saunders, Philadelphia, USA. 
 
Henry H. L. and A. W. Norman. (2003). Encyclopedia of Hormones. Academic Press, San Diego, 
USA. 
 
 
VI - 3) Research articles 
 
Ali A., K. P. Hoeflich and J. R. Woodgett. (2001). Glycogen synthase kinase-3: properties, functions 
and regulation. Chem. Rev. 101, 2527-2540. 
 
Ali S. and R. C. Coombes. (2002). Endocrine-responsive breast cancer and strategies for combating 
resistance. Nature Rev. Cancer 2, 101-112. 
 
Allred D. C., P. Brown and D. Medina. (2004). The origins of estrogen receptor alpha-positive and 
estrogen receptor alpha-negative human breast cancer. Breast Cancer Res.  6, 240-245. 
 
References  109 
Alt J. R., J. L. Cleveland, M. Hannink and J. A. Diehl. (2000). Phosphorylation-dependent regulation 
of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes & Dev.  14, 
3102-3114. 
 
Anderson E. and R. B. Clarke. (2004). Steroid receptors and cell cycle in normal mammary 
epithelium. J. Mammary Gland Biol. Neoplasia 9, 3-13.  
 
Arnold S. F., J. D. Obourn, H. Jaffe and A. C. Notides. (1994). Serine 167 is the major estradiol-
induced phosphorylation site on human estrogen receptor. Mol. Endocrinol.  8, 1208-1214. 
 
Bachman K. E., P. Argani, Y. Samuels, N. Silliman, J. Ptak and S. Szabo. (2004). The PIK3CA gene 
is mutated with high frequency in human breast cancers. Cancer Biol. Ther.  3, 772-775. 
 
Bange J., E. Zwick and A. Ullrich. (2001). Molecular targets for breast cancer therapy and prevention. 
Nat. Med.  7, 548-552. 
 
Baselga J. (2006). Targeting tyrosine kinases in cancer: the second wave. Science 312, 1175-1178. 
 
Berthois Y., X. F. Dong, M. Roux-Dossetto and P. M. Martin. (1990). Expression of estrogen receptor 
and its messenger ribonucleic acid in the MCF-7 cell line: multiparametric analysis of its processing 
and regulation by estrogen. Mol. Cell. Endocrinol. 74, 11-20. 
 
Bloom H. J. and W. W. Richardson. (1957). Histological grading and prognosis in breast cancer. 
Br. J. Cancer 11, 359-377. 
 
Blume-Jensen P. and T. Hunter. (2001). Oncogenic kinase signalling. Nature 411, 355-365.  
 
Brennan K. R. and A. M. C. Brown. (2004). Wnt Proteins in mammary development and cancer. 
J. Mammary Gland Biol and Neoplasia  9, 119-131. 
 
Cao Q., X. Lu and Y. J. (2006). Glycogen synthase kinase-3beta positively regulates the proliferation 
of human ovarian cancer cells. Cell Res. 16, 671-677.  
 
Cardonna-Gomez P., M. Perez, J. Avila, L.M. Garcia-Segura and F. Wandosell. (2004). Estradiol 
inhibits GSK3 and regulates interaction of estrogen receptors, and ß-catenin in the hippocampus. 
Mol. Cell. Neurosci.  25, 363-373. 
 
Chen D., T. Riedl, E. Washbrook, P. E. Pace, R. C. Coombes, J. M. Egly, et al. (2000). Activation of 
estrogen receptor alpha by S118 phosphorylation involves a ligand-dependent interaction with TFIIH 
and participation of CDK7. Mol. Cell  6, 127-137. 
 
Clark D. E., C. E. Poteet-Smith, J. A. Smith and D. A. Lannigan. (2001). Rsk2 allosterically activates 
estrogen receptor alpha by docking to the hormone binding domain. EMBO J.  20, 3484-33494. 
 
Coghlan M. P., A. A. Culbert, D. A. E. Cross, S. L. Corcoran, J. W. Yates, N. J. Pearce, O. L. Raush, 
G. J. Murphy, P. S. Carter, L. R. Cox, D. Mills, M. J. Brown, D. Haigh, R. W. Ward, D. G. Smith, 
K. J. Murray, A. D. Reith and J. C. Holder. (2000). Selective small molecule inhibitors of glycogen 
synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem. Biol.  7, 793-803. 
 
Cohen P. (2002). Protein kinases - the major drug targets of the twenty-first century? 
Nat. Rev. Drug Discov. 4, 309-315. 
 
Cohen P. and S. Frame. (2001). The renaissance of GSK3. Mol. Cell. Biol. 2, 759-776. 
 
References  110 
Cohen P. And M. Goedert. (2004). GSK3 inhibitors: development and therapeutic potential. 
Nature Rev. 3, 479-487. 
 
Couse J. F., J. Lindsey, K. Grandien, J. Gustafsson and K. S. Korach. (1997). Tissue distribution and 
quantitative analysis of estrogen receptor-α (ERα) and estrogen receptor-β (ERβ) messenger 
ribonucleic acid in the wild-type and ERα-knockout mouse. Endocrinology  138, 4613-4621. 
  
Couse J.F. and K.S. Korach. (1999). Estrogen receptor null mice: what have we learned and where 
will they lead us? Endocrine Rev.  20, 358-417. 
 
Cross D. A., D. R. Alessi, P. Cohen, M. Andjelkovich, B. A. Hemmings. (1995). Inhibition of 
glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature  378, 785-789. 
 
Cross D. A. E., A. A. Culbert, K. A. Chalmers, L. Facci, S. D. Skaper and A. D. Reith. (2001). 
Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones 
from death. J. Neurochem. 77, 94-102. 
 
Davis M. D., J. A. Vanderkuur and S. C. Brooks. (1999). Ligand structure influences autologous 
downregulation of estrogen receptor-alpha messenger RNA. J. Steroid Biochem. Mol. Biol. 70, 27-37. 
 
Deroo B. J. and K. S. Korach. (2006). Estrogen receptors and human disease. J. Clin. Invest. 116, 
561-570. 
 
De Servi B., A. Hermani, S. Medunjanin and D. Mayer. (2005). Impact of PKCδ on estrogen receptor 
localisation and activity in breast cancer cells. Oncogene  24, 4946-4955. 
 
Diehl J. A., M. Cheng, M. F. Roussel and C. J. Sherr. (1998). Glycogen synthase kinase-3β regulates 
cyclin D1 proteolysis and subcellular localisation. Genes & Dev.  12, 3499-3511.  
 
Dillon R. L., D. E. White and W. J. Muller. (2007). The phosphatidyl inositol 3-kinase signalling 
network: implications for human breast cancer. Oncogene  26, 1338-1345. 
 
Doble B. W., S. Patel, G. A. Wood, L. K. Kockeritz and J. R. Woodgett. (2007). Functional 
redundancy of GSK-3alpha and GSK-3beta in Wnt/beta-catenin signalling shown by using an allelic 
series of embryonic stem cell lines. Dev. Cell.  12, 957-971. 
 
Enmark E., M. Pelto-Huikko, K. Grandien, S. Lagercrantz, G. Fried, M. Nordenskjold and J. A. 
Gustafsson. (1997). Human estrogen receptor beta-gene structure, chromosomal localization, and 
expression pattern. J. Clin. Endocrinol. Metab.  82, 4258-4265. 
 
Farago M., I. Domingez, E. Landesman-Bollag, X. Xu, A. Rosner, R. D. Cardiff and D. C. Seldin. 
(2005). Kinase-Inactive glycogen synthase kinase 3ß promotes Wnt signalling and mammary 
tumorigenesis. Cancer Res. 65, 5792-5801. 
 
Frame S. and P. Cohen. (2001). GSK3 takes centre stage more than 20 years after its discovery. 
Biochem. J.  359, 1-16. 
 
Fraser E., N. Young, R. Dajani, J. Franca-Koh, J. Ryves, R. S. B. Williams, M. Yeo, M. T. Webster, 
C. Richardson, M. J. Smalley, L. H. Pearl, A. Harwood and T. C. Dale. (2002). Identification of the 
axin and frat binding region of glycogen synthase kinase-3. J. Biol. Chem.  277, 2176-2185. 
 
Forde J. E. and T. C. Dale. (2007). Glycogen synthase kinase 3: a key regulator of cellular fate. 
Cell. Mol. Life Sci. 64, 1930-1944. 
 
References  111 
Frame S., P. Cohen and R. M. Biondi. (2001). A common phosphate binding site explains the unique 
substrate specificity of GSK3 and its inactivation by phosphorylation. Mol. Cell 7, 1321-1327. 
 
Frasor J., J. M. Danes, B. Komm, K. C. N. Chang, C. R. Lyttle and B. S. Katzenellenbogen. (2003). 
Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights 
into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. 
Endocrinology  144, 4562-4574. 
 
Garcea G., M. M. Manson, C. P. Neal, C. J. Pattenden, C. D. Sutton, A. R. Dennison and D. P. Berry. 
(2007). Glycogen synthase kinase-3beta; a new target in pancreatic cancer? Curr. Cancer Drug 
Targets 7, 209-215.   
 
Greger J. G., N. Fursov, N. Cooch, S. McLarney, L. P. Freedman, D. P. Edwards and B. J. Cheskis. 
(2007). Phosphorylation of MNAR promotes estrogen activation of phosphatidylinositol 3-kinase. 
Mol. Cell. Biol. 27, 1904-1913.  
 
Grimes C.A. and R.S. Jope. (2001). The multifaceted roles of glycogen synthase kinase 3ß in cellular 
signalling. Progress in Neurobiology 65, 391-426. 
 
Grisouard J., S. Medunjanin, A. Hermani, A. Shukla and D. Mayer. (2007). Glycogen synthase kinase 
3 protects estrogen receptor alpha from proteasomal degradation and is required for full transcriptional 
activity of the receptor. Mol. Endocrinol. in press (Epub ahead of print July 3, 2007 as doi: 
10.1210/me.2007-0129). 
 
Hall J. M., J. F. Couse and K. S. Korach. (2001). The multifaceted mechanisms of estradiol and 
estrogen receptor signalling. J. Biol. Chem.  276, 36869-36872. 
 
Hatsell S., T. Rowlands, M. Hiremath and P. Cowin. (2003). ß-catenin and Tcfs in mammary 
development and cancer. J. Mammary Gland Biology and Neoplasia 8, 145-158. 
 
Hens J. R. and J. Wysolmerski. (2005). Molecular mechanisms involved in the formation of the 
embryonic gland. Breast Cancer Res. 7, 220-224. 
 
Hoeflich K. P., J. Luo, E. A. Rubie, M-S. Tsao, O. Jin and J. R. Woodgett. (2000). Requirement for 
glycogen synthase kinase-3β in cell survival and NF-κB activation. Nature  406, 86-90. 
 
Hoffmann J. and A. Sommer. (2005). Steroidhormone receptors as targets fort he therapy of breast and 
prostate cancer-recent advances, mechanisms of resistance, and new approaches. J. Steroid Biochem. 
Mol. Biol. 93, 191-200. 
 
Horwitz K. B. and W. L. McGuire. (1978). Nuclear mechanisms of estrogen action. J. Biol. Chem.  
253, 8185-8191. 
 
Howe L. R. and A. M. C. Brown. (2004). Wnt signalling and breast cancer. Cancer Biology and 
Therapy 3, 36-41. 
 
Joel P. B., A. M. Traish and D. A. Lannigan. (1998). Estradiol-induced phosphorylation of Serine 118 
in the estrogen receptor is independent of p42/p44 mitogen-activated protein kinase. J. Biol. Chem.  
273, 13317-13323.  
 
Johnson S. A. and T. Hunter. (2005). Kinomics: methods for deciphering the kinome. Nature Methods 
2, 17-25. 
 
Johnston S. R. D. And M. Dowsett. (2003). Aromatase inhibitors for breast cancer: lessons from the 
laboratory. Nature Rev. Cancer 3, 821-831. 
References  112 
Jope R.S. (2003). Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes. 
Trends in Pharm. Sc. 24, 441-443. 
 
Jope R.S. and G. V. W. Johnson. (2004).The glamour and gloom of glycogen synthase kinase-3. 
Trends Biochem. Sci. 29, 95-102. 
 
Kaneko K. J., J. D. Furlow and J. Gorski. (1993). Involvement of the coding sequence for the estrogen 
receptor gene in autologous ligand-dependent down-regulation. Mol. Endocrinol. 7, 879-888. 
 
Katzenellenbogen B. S. and J. Katzenellenbogen. (2000). Estrogen receptor transcription and 
transactivation. Estrogen receptor alpha and estrogen receptor beta: regulation by selective estrogen 
receptor modulators and importance in breast cancer. Breast Cancer Res. 2, 335-344. 
 
Kim L., J. Liu and A. R. Kimmel. (1999). The novel tyrosine kinase ZAK1 activates GSK3 to direct 
cell fate specification. Cell  99, 399-408. 
 
Klinge C.M. (2001). Estrogen receptor interaction with estrogen response elements. Nucleic Acids 
Res. 29, 2905-2919. 
 
Kong E. H., A. C. W. Pike and R. E. Hubbard. (2003). Structure and mechanism of the estrogen 
receptor. Bioch. Soc. Trans.  31, 56-59. 
 
Kouzmenko A. P., K-I. Takeyama, S. Ito, T. Furutani, S. Sawatsubashi, A. Maki, E. Suzuki, Y. 
Kawasaki, T. Akiyama, T. Tabata and S. Kato. (2004). Wnt/β catenin and Estrogen signalling 
converge in vivo. J. Biol. Chem.  279, 40255-40258.  
 
Koziczak M. and N. E. Hynes. (2004). Cooperation between fibroblast growth factor receptor 4 and 
ErbB2 in regulation of cyclin D1 translation. J. Biol. Chem.  279, 50004-50011. 
 
Laios I., F. Journé, D. Nonclercq, D. S. Vidal, R. A. Toillon, G. Laurent and G. Leclerq. (2005). Role 
of the proteasome in the regulation of estrogen receptor a turnover and function in MCF-7 breast 
carcinoma cells. J. Steroid Biochem. Mol. Biol. 94, 347-359. 
 
Lannigan D. A. (2003). Estrogen receptor phosphorylation. Steroids 68, 1-9. 
 
Le Bail J. C., K. Allen, J. C. Nicolas, G. Habrioux. (1998). Dehydroepiandrosterone sulfate estrogenic 
action at its physiological plasma concentration in human breast cancer cell lines. Anticancer Res. 
18,1683-1688.  
 
Le Goff P., M. M. Montano, D. J. Schodin and B. S. Katzenellenbogen. (1994). Phosphorylation of the 
human estrogen receptor: identification of hormone-regulated sites and examination of their influence 
on transcriptional activity. J. Biol. Chem.  269, 4458-4466. 
 
Lesort M., R. S. Jope and G. V. W. Johnson. (1999). Insulin biphasically modulates tau 
phosphorylation: involvement of glycogen synthase kinase-3β and fyn tyrosine kinase. J.Neurochem. 
72, 576-584.  
 
Li Y., M. N. Corradetti, K. Inoki and K. L. Guan. (2004). TSC2: Filing the GAP in the mTOR 
signalling pathway. Trends Biochem Sci.  29, 32-38.  
 
Likhite V.S., F. Stossi, K. Kim, B.S. Katzenellenbogen and J.A. Katzenellenbogen. (2006). Kinase-
specific phosphorylation of the estrogen receptor changes receptor interactions with ligand, DNA, and 
coregulators associated with alterations in estrogen and tamoxifen activity. Mol. Endocrinol. 20, 
3120-3132. 
 
References  113 
Lin S-Y., W. Xia, J.C. Wang, K.Y. Kwong, B. Spohn, Y. Wen, R. G. Pestell and M-C. Hung. (2000). 
ß-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer 
progression. Prot. Natl. Acad. Sci. 97, 4262-4266. 
 
Lonard D. M., Z. Nawaz, C. L. Smith, B. W. O’Malley. (2000). The 26S proteasome is required for 
estrogen receptor alpha and coactivator turnover and for efficient estrogen receptor alpha 
transactivation. Mol. Cell. 5, 939-948. 
 
MacManus E. J., K. Sakamato, L. J. Armit, L. Ronaldson, N. Shpiro, R. Marquez and D. R. Alessi. 
(2005). Role that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knocking 
analysis. EMBO J. 24, 1571-1583. 
 
Matsuda K., M. Nishi, H. Takaya, N. Kaku and M. Kawata. (2007). Intranuclear mobility of estrogen 
receptor alpha and progesterone receptors in association with nuclear matrix dynamics. 
J. Cell. Biochem.in press. Epub ahead of print. 
 
Mazor M., Y. Kawano, H. Zhu, J. Waxman and R. M. Kypta. (2004). Inhibition of glycogen synthase 
kinase-3 represses androgen receptor activity and prostate cancer cell growth. Oncogene 23, 
7882-7892. 
 
Meares G. P. and R. S. Jope. (2007). Resolution of the nuclear localization mechanism of glycogen 
synthase kinase-3. J. Biol. Chem.  282, 16989-17001. 
 
Medunjanin S., A. Hermani, B. De Servi, J. Grisouard, G. Rincke and D. Mayer. (2005). Glycogen 
synthase kinase-3 interacts with and phosphorylates estrogen receptor-alpha and is involved in the 
regulation of receptor activity. J. Biol. Chem.  280, 33006-33014. 
 
Menasce L. P., G. R. White, C. J. Harrison and J. M. Boyle. (1993). Localization of the estrogen 
receptor locus (ESR) to chromosome 6q25.1 by FISH and a simple post-FISH banding technique. 
Genomics 17, 263-265. 
 
Migliaccio A., M. Pagano and F. Auricchio (1993). Immediate and transient stimulation of protein 
tyrosine phosphorylation by estradiol in MCF-7 cells. Oncogene 8, 2183-2191. 
 
Moggs J. G. and G. Orphanides. (2001). Estrogen receptors: orchestrators of pleiotropic cellular 
responses. EMBO rep. 2, 775-781. 
 
Nawaz Z., D. M. Lonard, A. P. Dennis, C. L. Smith and B. W. O’Malley. (1999). Proteasome-
dependent degradation of the human estrogen receptor. Proc. Natl. Acad. Sci. USA 96, 1858-1862. 
 
Ougolkov A. V., M. E. Fernandez-Zapico, V. N. Bilim, T. C. Smyrk, S. T. Chari and D. D. Billadeau. 
(2006). Aberrant nuclear accumulation of glycogen synthase kinase-3beta in human pancreatic cancer: 
association with kinase activity and tumor dedifferentiation. Clin. Cancer Res. 12, 5074-5081.  
 
Pasqualini J. R. (2004). The selective estrogen enzyme modulators in breast cancer: a review. 
Biochem. Biophys. Acta-Rev. Cancer 1654, 123-143. 
 
Pink J. J. and  C.V. Jordan. (1996). Models of estrogen receptor regulation by estrogens and 
antiestrogens in breast cancer cell lines. Cancer Res. 56, 2321-2330. 
 
Phiel C.J., C.A. Wilson, V. M. Y. Lee and P. S. Klein. (2003) GSK-3alpha regulates production of 
Alzheimer's disease amyloid-beta peptides. Nature 423, 435-439. 
 
Polakis P. (2000). Wnt signalling and cancer. Genes & Dev. 14, 1837-1851. 
 
References  114 
Preisler-Mashek M. T., N. Solodin, B. L. Stark, M. K. Tyriver and E. T. Alrid. (2002). Ligand-specific 
regulation of proteasome-mediated proteolysis of estrogen receptor alpha. Am. J. Physiol. Endocrinol. 
Metab. 282, 891-898. 
 
Ray A. and Mitra A. B. (2003). Estrogen and breast cancer. Indian Council of Medical Research 
(ICMR) Bulletin 33, 13-23. 
 
Read L. D., G. L. Greene and B.S. Katzenellenbogen. (1989). Regulation of estrogen receptor 
messenger ribonucleic acid and protein levels in human breast cancer cell lines by sex steroid 
hormones, their antagonists, and growth factors. Mol. Endocrinol. 3, 295-304. 
 
Reid G., M. R. Hübner, R. Métivier, H. Brand, S. Denger, D. Manu, J. Beaudouin, J. Ellenberg and F. 
Gannon. (2003). Cyclic, proteasome-mediated turnover of unliganded and liganded estrogen receptor 
alpha on responsive promoters is an integral feature of estrogen signalling. Mol. Cell 23, 4813-4823. 
 
Rogatsky I., J. M. Towbridge and M. J. Garabedian. (1999). Potentiation of human estrogen receptor 
alpha transcriptional activation through phosphorylation of serines 104 and 106 by the cyclin A-CDK2 
complex. J. Biol. Chem.  274, 22296-22302.  
 
Saal L. H., K. Holm, M. Maurer, L. Memeo, T. Su and X. Wang. (2005). PIK3CA mutations correlate 
with hormone receptors, node metastasis, and ErbB2, and are mutually exclusive with PTEN loss in 
human breast carcinoma. Cancer Res.  65, 2554-2559. 
 
Saceda M., M. E. Lippman, P. Chambon, R. L. Lindsey, M. Ponglikitmongkol, M. Puente and M. B. 
Martin. (1988). Regulation of the estrogen receptor in MCF-7 cells by estradiol. Mol. Endocrinol. 2, 
1157-1162.   
   
Scarff R. W. and H. Torloni. (1968). Histological typing of breast tumors. International histological 
classification of tumors, World Helath Organisation, Geneva 2, 13-20. 
 
Schnarr B., K. Strunz, J. Ohsam, A. Benner, J. Wacker and D. Mayer. (2000). Down-regulation of 
insulin-like growth factor-I receptor and insulin receptor substrate-1 expression in advanced human 
breast cancer.  Int. J. Cancer (Pred. Oncol.) 89, 506-513.   
 
Shakoori A., A. Ougolkov, Z. W. Yu, B. Zhang, M. H. Modarressi, D. D. Billadeau, M. Mai, Y. 
Takahashi and T. Minamoto, (2005) Deregulated GSK-3beta activity in colorectal cancer : its 
association with tumor cell survival and proliferation. Biochem. Biophys. Res. Commun. 334, 
1365-1373.  
 
Shakoori A., W. Mai, K. Miyashita, K. Yasumoto, Y. Takahashi, A. Ooi, K. Kawakami and T. 
Ninamoto. (2007). Inhibition of GSK-3β activity attenuates proliferation of human colon cancer cells 
in rodents. Cancer Sci. in press. Epub ahead of print.  
 
Singletary S. E., C. Allred, P. Ashley, L. W. Bassett, D. Berry, K. I. Bland, P. I. Borgen, G. Clark, S. 
B. Edge, D. F. Hayes, L. L. Hughes, R. V. P. Hutter, M. Morrow, D. L. Page, A. Recht, R. L. 
Theriault, A. Thor, D. L. Weaver, H. S. Wieand and F. L. Greene. (2002). Revision of the American 
Joint Committee on cancer staging system for breast cancer. J. Clin. Oncol.  20, 3628-3636. 
 
Song R. X., C. J. Barnes, Z. Zhang, Y. Bao, R. Kumar and R. J. Santen. (2004). The role of Shc and 
insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the 
plasma membrane. Proc. Natl. Acad. Sci.  101, 2076-22081.  
 
Stambolic V., L. Ruel and J. R. Woodgett. (1996). Lithium inhibits glycogen synthase kinase-3 
activity and mimics Wingless signalling in intact cells. Curr. Biol. 6, 1664-1668. 
 
References  115 
Stossi F., D. H. Barnett, J. Frasor, B. Komm, C. R. Lyttle and B. S. Katzenellenbogen. (2004). 
Transcriptional profiling of estrogen-regulated gene expression via estrogen receptor (ER) α or ERβ in 
human osteosarcoma cells: distinct and common target genes for these receptors. Endocrinology 145, 
3473-3486.  
 
Terasaka S, Y. Aita, S. Hayashi, M. Nishigaki, K. Aoyagi, H. Sasaki, Y. Wada-Kiyama, Y. Sakuma, 
S. Akaba, J. Tanaka, H. Sone, J. Yonemoto, M. Tanji and R. Kiyama (2004). Using a customized 
DNA microarray for expression profiling of the estrogen-responsive genes to evaluate estrogen 
activity among natural estrogens and industrial chemicals. Env. Health Persp.  112, 773-781. 
 
Tsukamoto A. S., R. Grosschedl, R. C. Guzman, T. Parlsow and H. E. Varmus. (1988). Expression of 
the int-1 glycoprotein gene in transgenic mice is associated with mammary gland hyperplasia and 
adenocarcinomas in male and female mice. Cell  55, 619-625. 
 
Valley C. C., R. Métivier, N. M. Solodin, A. M. Fowler, M. T. Mashek, L. Hill and E. T. Alarid. 
(2005). Differential regulation of estrogen-inducible proteolysis and transcription by the estrogen 
receptor alpha N terminus. Mol. Cell. Biol. 13, 5417-5428. 
 
Vasudevan N. and D. W. Pfaff. (2007). Membrane-initiated actions of estrogens in 
neuroendocrinology: emerging principles. Endocrine Rev.  28, 1-19. 
 
Wang X., M. Janmaat, A. Beugnet, F. E. M. Pulin and C. G. Proud. (2002). Evidence that the 
dephosphorylation of Ser535 in the ε-subunit of eukaryotic initiation factor (eIF) 2B is insufficient for 
the activation of eIF2B by insulin. Biochem. J. 367, 475-481. 
 
Wang Q. M., C. J. Fiol, A. A. DePaoli-Roach and P. J. Roach (1994). Glycogen synthase kinase-3β is 
a dual specificity kinase differentially regulated by tyrosine and serine/threonine phosphorylation. 
J. Biol. Chem.  269, 14566-14574. 
 
Woodgett J. R. (1990). Molecular cloning and expression of glycogen synthase kinase-3/factor A. 
EMBO J. 9, 2431-2438.  
 
Yamamoto H., S. Kishida, M. Kishida, S. Ikeda, S. Takada and A. Kikuchi. (1999). Phosphorylation 
of axin, a Wnt signal negative regulator, by glycogen synthase kinase-3beta regulates its stability. 
J. Biol. Chem. 274, 10681-10684.  
 
Zhang X., K. Podsypanina, S. Huang, S.K. Moshin, G.C. Chamness, S. Hatsell, P. Cowin, R. Schiff 
and Y. Li. Estrogen receptor positivity in mammary tumors of Wnt-1 transgenic mice is influenced by 
collaborating oncogenic mutations. Oncogene 24, 4220-4231. 
Publications related to my PhD thesis  116 
Publications related to my PhD thesis 
 
 
Grisouard J., S. Medunjanin, A. Hermani, A. Shukla and D. Mayer. (2007). Glycogen 
synthase kinase 3 protects estrogen receptor alpha from proteasomal degradation and is 
required for full transcriptional activity of the receptor. Mol. Endocrinol., in press 
(Epub ahead of print July 3, 2007 as doi: 10.1210/me.2007-0129). 
 
 
Grisouard J., S. Trauth, A. Hermani and D. Mayer. (2006). Glycogen synthase kinase-3β 
(GSK-3β) as a key component of estradiol signalling pathway. European Journal of Cancer, 
supplements  4, 42. 
 
 
Medunjanin S., A. Hermani, B. De Servi, J. Grisouard, G. Rincke and D. Mayer. (2005). 
Glycogen synthase kinase-3 interacts with and phosphorylates estrogen receptor-alpha and is 
involved in the regulation of receptor activity. J. Biol. Chem.  280, 33006-33014. 
 
 
Abbreviations  117 
Abbreviations 
  
- AC Adenylyl Cyclase 
- ADP Adenosine Diphosphate 
- AF-1 Transcriptional Activation Function-1 
- AF-2 Transcriptional Activation Function-2 
- AGC Group of protein kinases A, G and C 
- Ala (A) Alanine, amino acid 
- AMP Adenosine Monophosphate 
- AP-1 Activator Protein-1  
- APC Adenomatous Polyposis Coli  
- APP Amyloid Precursor Protein  
- Arg (R) Arginine amino acid 
- ATP Adenosine Triphosphate 
- bp base pair  
- BSA Bovine Serum Albumine 
- BT474 human breast carcinoma cell line, ER+ 
- CA Constitutively Active 
- Ca2+ Calcium 
- CaMK Group of protein kinases regulated by CaM 
- CaM Calcium/calmodulin  
- cAMP cyclic AMP 
- CAT scans Computerized Axial Tomography 
- Cdk Cyclin-dependent kinase  
- Cdk2 Cyclin dependent kinase 2  
- cDNA complementary or copy DNA 
- C/EBPα CCAAT/Enhancer Binding Protein α  
- cGMP cyclic GMP 
- CHX Cycloheximide 
- CK2 Casein Kinase 2 
- CNS Central Nervous System 
- CO2 Carbon Dioxide  
- COX-2 Cyclooxygenase-2 
- cpm counts per minute 
- CREB cAMP Response Element Binding protein 
- CTD kinases Carboxy-Terminal Domain kinases 
- c-Src Cellular homologue of v-Src 
- DAB 3,3’-Diaminobenzidine 
- DBD DNA-Binding Domain   
- DCC Dextran-Coated Charcoal 
- DCIS Ductal Carcinoma In Situ 
- DHEA Dehydroepiandrosterone 
- DMEM Dulbecco’s Modified Eagle’s Medium 
- DMSO Dimethyl Sulphoxide 
- DN Dominant Negative 
- DNA Deoxyribonucleic Acid 
- dsDNA double-stranded DNA 
- dNTPs deoxynucleotides Triphosphate 
- DTT Dithiothreitol  
- DVL Dishevelled  
- DYRK Dual-specificity Tyrosine-phosphorylated and Regulated Kinase 
- ECL Enhanced Chemiluminescence 
- EDTA Ethylen diaminetetraacetic Acid  
- EGF Epidermal Growth Factor 
- EGFR Epidermal Growth Factor Receptor 
- eIF2B eukaryotic Initiation Factor 2B 
- ER Estrogen Receptor 
- ERα Estrogen Receptor alpha 
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- ERβ Estrogen Receptor beta 
- ErbB EGFR family  
- ERE Estrogen Response Element 
- ERK Extracellular signal-Related Kinase  
- ER- ERα negative 
- ER+ ERα positive 
- E2 17β-Estradiol 
- FCS Foetal Calf Serum 
- FGFR Fibroblast Growth Factor Receptor 
- Fos nuclear DNA binding protein (product of the c-Fos proto-oncogene) 
- FRAT Frequently Rearranged in Advanced T-cell lymphomas  
- FSH Follicle Stimulating Hormone 
- Fwd primer Forward primer 
- Fyn member of the Src tyrosine kinase family 
- GAPDH Glyceraldehyde-3-Phosphate Dehydrogenase 
- GF Growth Factor 
- GFP Green Fluorescence Protein 
- GMCC Protein kinases group including GSK, MAPK, Cdk and CTD kinases. 
- GMP Guanosine Monophosphate 
- GnRH Gonadotrophin Releasing Hormone 
- GS Glycogen Synthase 
- GSK Glycogen Synthase Kinase 
- GSK-3 Glycogen Synthase Kinase-3 
- GSK-3α Glycogen Synthase Kinase-3alpha 
- GSK-3β Glycogen Synthase Kinase-3beta 
- GST Glutathione-S-Transferase 
- h hour 
- H & E Hematoxylin and Eosin 
- HCl Hydrochloric acid 
- HEPES  4-(2-Hydroxyethyl)-1-Piperazineethanesulfonic acid  
- HEPES/KOH HEPES/Potassium hydroxide 
- HER2 Human epidermal growth factor receptor 2 or ErbB2 
- HRP Horseradish Peroxidase 
- HRT Hormone Replacement Therapy  
- HSF-1  Heat Shock Factor-1 
- IDC  Invasive Ductal Carcinoma 
- IGF-1 Insulin-Like Growth Factor-1  
- IGFR Insulin Growth Factor Receptor 
- IgG Immunoglobulin G 
- IHC Immunohistochemistry 
- ILC Invasive Lobular Carcinoma 
- IL-6 Interleukin-6 
- IRS-1 Insulin Receptor Substrate-1  
- JNK c-Jun N-terminal kinase  
- Jun nuclear DNA binding protein (product of the c-Jun proto-oncogene) 
- KCl Potassium Chloride 
- kDa kilo Dalton 
- l litre 
- LacZ bacterial gene encoding the β-galactosidase 
- LAR Luciferase Assay Reagent 
- LB Luria Broth Bertani (culture medium for bacteria) 
- LBD Ligand Binding Domain  
- LCIS  Lobular Carcinoma In Situ 
- LEF Lymphoid-Enhancer Factor 
- LH Luteinising Hormone 
- LHRH Luteinising Hormone-Releasing Hormone  
- LiCl Lithium Chloride 
- Luc Luciferase 
- Lys (K) Lysine, amino acid 
- m milli 
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- M Molar 
- MAP Microtubule Associated Protein 
- MAPKAP-K1 MAPK-Activated Protein Kinase 1 or p90Rsk 
- MAPK Mitogen-Activated Protein Kinase 
- MCF-7  human breast carcinoma cell line, ER+ 
- MDA MB 231 human breast carcinoma cell line, ER- 
- MELN MCF-7 cells stably transfected with ERE-luciferase reporter plasmid 
- MEK MAPK/ERK kinase  
- Mg2+ Magnesium 
- MgCl2 Magnesium Chloride 
- MG132 Proteasome inhibitor 
- MgSO4 Magnesium sulfate 
- µ micro 
- min minutes 
- miR micro RNA 
- MMTV Mouse Mammary Tumor Virus 
- MnCl2 Manganese Chloride 
- mRNA messenger RNA 
- mTOR mammalian Target Of Rapamycin 
- Myc protein inducing cell growth and encoded by the c-Myc proto-oncogene 
- NaAc Sodium Acetate 
- NaCl Sodium Chloride 
- Na2CO3 Sodium Carbonate 
- NaF Sodium Fluoride 
- Na2HPO4 Di-sodium-hydrogen-phosphate 
- NaH2PO4 Sodium dihydrogen phosphate  
- NaN3 Sodium azide 
- NaOH Sodium hydroxide 
- Na3VO4 Sodium orthovanadate 
- NCAM Neural Cell-Adhesion Protein  
- NCI National Cancer Institute (USA) 
- NFAT  Nuclear Factor of Activating T cells 
- NFκB Nuclear Factor kappa B 
- NGF Nerve Growth Factor  
- NIH National Institutes of Health (USA)  
- NLS Nuclear Localization Signal 
- nm nanometres  
- O.D. Optical Density 
- ONPG 2-Nitrophenyl-β-D-Galactopyranoside 
- OPK group of Other Protein Kinases  
- OSM Oncostatin M 
- O/N Overnight 
- PAGE Polyacrylamide Gel Electrophoresis  
- PBS Phosphate Buffered Saline 
- PCR Polymerase Chain Reaction 
- PDGFR Platelet-Derived Growth Factor Receptor 
- PDK1 3-Phosphoinositide-Dependent Protein Kinase-1  
- PFA Paraformaldehyde 
- PGE2 Prostaglandin E2 
- PKA Protein Kinase A 
- PKB Protein Kinase B or Akt 
- PKC Protein Kinase C 
- PKCδ PKC delta 
- PI3K Phosphatidylinositol 3-Kinase 
- PIK3CA Gene encoding the PI3K Catalytic subunit (p110 Alpha) 
- PMSF Phenylmethylsulphonyl Fluoride 
- PR Progesterone Receptor 
- pS2 estrogen-responsive gene (TIFF1 or Trefoil Factor 1) 
- PTK Protein Tyrosine Kinase 
- PVDF Polyvinylidenfluoride 
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- p38 MAPK Mitogen Activated Protein Kinase p38 
- rcf Relative Centrifugal Force 
- RDδ Regulatory Domain of PKCδ 
- Rev primer Reverse Primer  
- RNA Ribonucleic acid 
- RNAi RNA interference 
- RNase Ribonuclease 
- RPA / p34 Replication Protein A or Human Single-Stranded DNA-Binding protein (HSSB) 
- rpm revolutions per minute 
- RPMI Roswell Park Memorial Institute cell culture medium 
- Rsk Ribosomal S6 Kinase or MAPKAP-K1 
- RT Room Temperature 
- RTK Receptor Tyrosine Kinase 
- RT-PCR Reverse Transcriptase- Polymerase Chain Reaction 
- SB2 GSK-3β inhibitor SB216763 (from Glaxo-Smith-Kline)  
- SB4 GSK-3β inhibitor SB415286 (from Glaxo-Smith-Kline)  
- SBR Scarff-Bloom-Richardson (tumor grading) 
- SDS Sodium Dodecyl Sulfate 
- sec seconds 
- SEM Standard Error of the Mean 
- Ser (S) Serine, amino acid 
- SERD Selective Estrogen Receptor Destabilisator 
- SERM Selective Estrogen Receptor Modulator 
- shRNA short hairpin RNA 
- Shc Src-homology adaptor complex 
- siRNA small interfering RNA 
- SNPs Single-Nucleotide Polymorphisms  
- SOC bacterial culture media 
- Sp-1 Specificity Protein 1 
- SYBR SYBR green (DNA intercalating dye) 
- TAE Tris Acetate EDTA buffer 
- Taq Thermus Aquaticus  
- TBS Tris-buffered saline 
- TBS/T TBS/Tween 20 
- TCF T-cell factor family of transcription factors or LEF  
- TE Tris-EDTA buffer 
- TEMED N, N, N’, N’-Tetramethyl ethylenediamine 
- TFIIH associated kinase complex 
- T47D human breast carcinoma cell line, ER+ 
- Thr (T) Threonine, amino acid 
- Tm melting Temperature 
- TNFα Tumor Necrosis Factor alpha 
- TNM Tumor-Nodes-Metastasis (cancer staging) 
- TPA 12-O-Tetradecanoylphorbol-13-Acetate 
- Tris trishydroxymethylaminomethane 
- Tyr (Y) Tyrosine, amino acid 
- U Unit of the enzyme activity 
- UV Ultraviolet 
- VEGFR Vascular Epithelial Growth Factor Receptor 
- v-Src Oncoprotein encoded by Rous sarcoma virus 
- v/v volume per volume 
- Wnt vertabrates secreted glycoprotein equivalent to the Wingless in drosophila 
- WT Wild Type 
- w/v weight per volume 
- ZAK1 Dictyostelium protein kinase 
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